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Cardiovascular disease (CVD) is the leading cause of death worldwide in adult men and 
women. Atherosclerotic cardiovascular disease (ASCVD) has been highlighted as the main 
cause of death among CVDs, due to development and progression of plaques resulting in 
major adverse cardiovascular events (MACE). The multifactorial processes resulting in the 
generation of plaques have been established, and anti-atherogenic effects of 17β-estradiol 
(E2) shown. Yet, a greater prevalence and mortality was recorded in some postmenopausal 
women using hormone replacement therapy (HRT). Recent evidence has shown the adverse 
or lack of effect of E2 treatment in ASCVD models depending on timing post menopause. 
The occurrence of MACE is correlated with complex, high-risk plaques, but the direct effects 
of E2 on plaque progression and development are yet to be elucidated. Key signalling factors 
that modulate vascular cell proliferation and inflammation underlie plaque advancement, 
including the nodal multifunctional calcium/calmodulin dependent protein kinase II 
(CaMKII). There is a sex-related difference in the activation profile of CaMKII in cardiac 
pathologies, yet its role in plaque progression, which leads to ASCVD, is unknown. Therefore 
this thesis set out to address the potential mechanisms driving the E2-induced advancement of 
atherosclerotic plaques using the murine model of atherosclerosis, Apolipoprotein E- deficient 
(ApoE-/-) mice. The association of CaMKII with E2-induced effects and the specific role of 
CaMKII in the pathogenesis of atherosclerosis were investigated with a focus on plaque 
calcification. 
 
To determine the effect of exogenous E2 on plaque advancement, female ApoE-/- mice with 
intermediate (25 weeks) and advanced (45 weeks) plaques were treated twice a week for 8 
weeks with subcutaneous injections of E2. E2 treatment caused a significant increase in 
calcification of intermediate plaques with no effect on plaque size. This increase in 
calcification was associated with a significant decrease in total CaMKII expression within 
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intermediate plaques, with no effect on phosphorylated CaMKII (pCaMKII), an indicator of 
CaMKII activity. E2 treatment had no effect on plaque size, calcification or CaMKII 
expression and phosphorylation in ApoE-/- mice with advanced plaques.  
 
To investigate the role of CaMKII in the typical progression of intermediate plaques, 25 
week-old female ApoE-/- mice were treated with intraperitoneal injections of KN-93, a potent 
CaMKII inhibitor. CaMKII inhibition resulted in an observed decrease in calcification, with 
no effect on plaque size. This was associated with no significant changes in pCaMKII and the 
calcification marker, osteocalcin. 
 
Finally, the role of CaMKII in the progression of early plaques was investigated in 20 week-
old male and female ApoE-/- mice. Plaques in female ApoE-/- mice were more progressed than 
those observed in male ApoE-/- mice and there was no evidence of calcification in male ApoE-
/- mice. CaMKII inhibition in female ApoE-/- mice showed a trend towards decreased 
calcification with no effect on plaque size, pCaMKII or the calcification markers osteocalcin 
and RUNX2. CaMKII inhibition in male mice showed a trend towards increased plaque 
formation with no effect on the protein parameters measured. 
 
The findings from this thesis identify CaMKII as an instigator in the advancement of 
atherosclerotic plaques through increased calcification. Additionally, this thesis establishes 
the differential, CaMKII-mediated effects of E2 on plaques dependent on stage of 
progression. This thesis provides novel evidence for a possible mechanism through which E2 
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CHAPTER 1: INTRODUCTION 
1.1. Cardiovascular Disease and Atherosclerosis  
Cardiovascular disease (CVD) is the leading cause of death worldwide in adult men and 
women (WHO, 2014). There are a number of factors that influence the risk of CVD such as 
genetics, sex, lifestyle and age. CVD is defined as a disease affecting either or both the 
cardiac and the vascular system. Thus the health of the vasculature plays a major role in 
determining the risk of a major adverse cardiovascular event (MACE). Vascular aging is 
coupled with the development and progression of lesions within the vessels, a condition 
known as atherosclerosis. Atherosclerotic plaque progression has emerged as a critical 
independent risk factor in determining whether a MACE will occur (Yusuf et al., 2004). 
Therefore, atherosclerotic cardiovascular disease (ASCVD) has been described as the main 
cause of death among CVDs (Roy, 2014). Historically ASCVD has been considered ‘a man’s 
disease’ (Mosca et al., 2011). This was due to the then higher prevalence and mortality seen 
in men compared to age-matched women. However, as life expectancy has increased, 
epidemiological studies show that an equal prevalence of ASCVD exists in post-menopausal 
women relative to age-matched men (Go et al., 2013) and there is a greater mortality rate 
from ASCVD in postmenopausal women (Go et al., 2013; Mikkola et al., 2013). Yet, current 
therapies used in ASCVD have been developed primarily on research from male experimental 
models and patients (Dhruva et al., 2011).  Even with these therapies ASCVD is still the 
number one cause of death worldwide. This thesis addresses the potential mechanisms driving 
the advancement of atherosclerotic plaques, focussing on plaque calcification, specifically in 
female arteries. The pathogenesis of plaque formation will be highlighted and the different 
cell-types and stimulating factors involved. In lieu of a number of inflammatory stimuli and 
osteogenic regulators, the thesis will focus on the role played by endothelial cells (EC) of the 
intimal layer, smooth muscle cells (VSMC) of the medial layer and macrophages of the 
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immune system. Specifically, the function of the female sex hormone, 17β-estradiol (E2), and 
the calcium signalling molecule, calcium/calmodulin dependent protein kinase II (CaMKII), 
in enhancing or inhibiting atherogenesis will be discussed.  
 
1.2. Pathogenesis of Atherosclerosis 
Theoretically, vascular aging ought to be asymptomatic, posing a problem only in individuals 
with pre-existing cardiovascular (CV) conditions. However, autopsy studies show that 
atherosclerotic lesions are formed from childhood and present as lipid deposits along the 
endothelial wall (Ross, 1993; Berenson et al., 1998). This process occurs in all individuals 
and is not always associated with any clinical presentations (Berenson et al., 1998; Virmani et 
al., 2000). The speed of growth and severity of the lesions then depends on the previously 
mentioned factors of genetics, age and lifestyle (Berenson et al., 1998; Hartiala et al., 2012).  
 
Atherosclerosis is a progressive, multifactorial, inflammatory disease (Ross, 1999) 
characterised by plaque formation along medium-large sized arteries (Ross & Glomset, 1976; 
Ross, 1999; Lu & Daugherty, 2013). There is a staged progression from the initial lipid 
deposits to intermediate fibrous plaques (Ross & Glomset, 1976) and finally to either full 
stenosis or an unstable necrotic/calcified complicated lesion, which is subject to rupture or 
erosion and precedes a MACE, such as stroke or myocardial infarction (Stary, 2000; Virmani 
et al., 2000). 
1.2.1. The Healthy Artery 
Healthy arteries are made up of three layers of different cell types with specific functions and 
characteristics necessary for vascular homeostasis (Fig. 1-1). The outermost layer (tunica 
externa), the adventitia, consists of the least organized collection of various cell types, which 
make up the vascular wall (Hurairah & Ferro, 2004).  
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The medial layer (tunica media) is separated from the adventitia by the external elastic lamina 
and is a multi-layer of VSMCs. These function primarily as the mechanical tools of the vessel 
(Dobrin, 1978). VSMCs are phenotypically diverse and are highly plastic (Lacolley et al., 
2012). In response to vasoactive factors, VSMCs contract and relax to modulate vascular 
tone. They undergo physiological phenotypic modulation, in developmental angiogenesis and 
in response to injury (Owens et al., 2004; Alexander & Owens, 2012). The normally 
quiescent differentiated cells switch from a contractile phenotype to a proliferative or 
synthetic form, resulting in protein synthesis, hyperplasia and cell-migration (Lundberg & 
Crow, 1999).  
 
The medial layer is separated from the intimal layer (tunica intima) by the internal elastic 
lamina (Stary et al., 1992). This layer, which lines the vessel lumen, is a monolayer of ECs 
(Fig. 1-1). ECs are multifunctional metabolically active cells that detect systemic changes by 
receiving humoral and endocrine type factors transported through the plasma (Pober et al., 
2009). In addition to secreting vasoactive products that regulate the activity of VSMCs 
thereby modulating vasal tone, and providing a portal for exchange between substances in 
blood and tissues, ECs maintain quiescence of inflammatory cells (Kuhlencordt et al., 2004) 
and participate in internal immune surveillance (Choi et al., 2004; Pober et al., 2009).  
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Figure 1-1 Structure of an artery wall. The inner layer, the intima is a monolayer of 
endothelial cells which line the lumen of the artery and are separated from the middle 
layer by the IEL. The middle layer, the media, a multi-layer organization of smooth 
muscle cells, is separated from the outer layer, the adventita, by the EEL. IEL- 
internal elastic lamina; EEL- external elastic lamina 
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1.2.2. Atherogenesis-plaque formation 
Plaque formation, within arteries is initiated via two possible cellular mechanisms, the 
initiating factors being dependent on the individual (Falk, 2006; Mannarino & Pirro, 2008). 
The first mechanism is initiated by elevated blood levels of cholesterol, either due to lifestyle 
or genetic predisposition seen in individuals with familial hypercholesterolemia (Brown & 
Goldstein, 1986; Hartiala et al., 2012). Low-density lipoprotein (LDL), the most abundant 
cholesterol-carrying lipoprotein in humans (Brown & Goldstein, 1986), is retained in the 
intima where it is oxidized, resulting in endothelial dysfunction (Mannarino & Pirro, 2008). 
In the absence of risk factors, the second mechanism is dependent on the vulnerability of the 
endothelial wall, including its permeability and susceptibility to injury (Falk, 2006), which 
can facilitate the retention of lipids. It is now understood that both initiation mechanisms 
occur within athero-susceptible regions of the vasculature (Gimbrone & Garcia-Cardena, 
2013), which explains why plaques are present in some arteries, but absent or present to a 
lesser degree in others in the same patients (Velican, 1969; McGill et al., 2000).  
 
The initial oxidation of LDL (ox-LDL) is thought to occur due to cells of the vasculature 
sensing the trapped lipid and secreting products of oxidation (Navab et al., 1991; 
Parthasarathy et al., 2010). This mild oxidation has been shown to induce secretion of cell 
adhesion and chemotactic molecules resulting in the recruitment of monocytes (Gerrity, 1981; 
Quinn et al., 1987; Cushing et al., 1990; Achmad et al., 1997) and other cells of the immune 
system. These immune cells, once recruited, contribute to the further increase in the 
inflammatory response through secretion of cytokines and reactive oxygen species (ROS) 
(Berliner et al., 1995). The phagocytosis of ox-LDL by differentiated monocytes results in 
foam cell formation (Gerrity, 1981; Ross, 1999; Stary, 2000; Falk, 2006). Accumulation of 
these foam cells leads to the presence of the fatty streaks, also known as initial xanthoma 
(Yahagi et al., 2016). Lesions at this stage do not necessarily progress into full plaques and 
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have been shown to regress (McGill et al., 2000; Virmani et al., 2000). It is now understood 
that the resulting apoptosis of endothelial cells (Durand et al., 2004) and phenotypic 
modulation of VSMCs in response to the local inflammation and oxidative stress (Ross, 1986) 
result in formation of the progressive plaque (Libby, 2006; Yahagi et al., 2016). Further 
accumulation of extracellular lipids and the infiltration of macrophages then lead to the 
formation of cholesterol crystals, calcification and eventually a necrotic core (Fig. 1-2) (Lutter 
& Joner, 2016; Yahagi et al., 2016). Each stage of plaque progression is driven by 
inflammation (Ross, 1993; Berliner et al., 1995; Ross, 1999; Libby, 2002). Studies in 
apparently healthy older men have shown elevated levels of C-reactive protein (CRP) years 
before they presented with a MACE (Kuller et al., 1996; Ridker et al., 1997). CRP is a 
systemic marker of inflammation and has been shown to not only bind to ox-LDL (Miller et 
al., 2003), but also positively correlate in a grade-dependent manner to plaque size (Zhang et 
al., 1999). Overall, the atherogenic process is governed by the interplay between functions 
and secreted products of macrophages and VSMCs.  
 
The pathological phenotypic modulation of VSMCs resulting in proliferation, differentiation 
into osteoblast-like cells and secretion of extracellular matrix (ECM) components that enable 
migration (Pauly et al., 1994), occurs in atherosclerosis (Ross, 1986; Chen et al., 1997; Louis 
& Zahradka, 2010; Chistiakov et al., 2015). It has been shown that these ECM components 
contribute to the trafficking of macrophages and other immune cells (Nakashima et al., 2007; 
Otsuka et al., 2015). Finally, the presence of calcium mineral deposition, necrotic core, due to 
inefficient clearance of apoptotic cell bodies (Tabas, 2010), is indicative of an advanced 





Figure 1-2 Human atherosclerotic plaque categorization. Illustration of 
morphologies of human coronary plaques from initial xanthoma to fibroatheroma 
(established plaque). Calcification is observed in plaques with acute thrombi, in which 
rupture is possible. Lesions- plaques. Adapted with permission from Nature/Springer/ 
Palgrave, Yahagi et al. (2016). 
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1.2.3. Plaque calcification 
Atherosclerotic plaque severity is dependent on two factors: first, the size of the plaque and 
second, the composition of the plaque. The size of the plaque, i.e. how much of the lumen is 
obstructed, is determined by the speed of lipid accumulation (Stary, 2000). In the absence of 
lumen obstruction, a mixed plaque with complex composition of various cell types has a 
greater risk of causing a MACE due to rupture (van der Wal & Becker, 1999). Autopsy 
studies from deaths caused by a MACE show evidence of ruptured or eroded plaques (Falk, 
1989; Davies, 1992; Burke et al., 2001a). These “vulnerable” or “high risk” plaques (Virmani 
et al., 2006; Fleg et al., 2012) are characteristically made up of thin fibrous caps, macrophage 
infiltration, calcification and apoptosis (Virmani et al., 2006; Fleg et al., 2012). In the 
classification of atherosclerotic plaques the presence of calcified deposits is indicative of a 
more severe plaque (Stary, 2000). This correlates with findings from the Framingham Study, 
in which the presence of plaque calcification was associated with an increased risk of CV 
death in individuals below the age of 65 (Witteman et al., 1990).  
 
However, some controversy exists concerning whether calcification is indicative of instability 
(Huang et al., 2001; Lin et al., 2006; Otsuka et al., 2013). Rupture occurs in areas of high 
fibrous cap stress, but not necessarily regions with the highest stress, as the heterogeneity of 
the underlying tissue is a second factor (Lee, 2000; Huang et al., 2001). Calcification 
contributes to both increasing the heterogeneity of plaque tissue and compressive stiffness of 
lesion (Lee, 2000). In some extensively calcified plaques an overall decrease in fibrous cap 
stress has been measured (Lee, 2000) resulting in increased stability (Wu et al., 2014). Yet 
epidemiological studies show the strong association between calcification markers and 
severity of ASCVD (Budoff et al., 2010; Coylewright et al., 2011; Yang et al., 2017). 
Calcification is present in all ruptured plaques investigated post-mortem (Virmani et al., 
2003). Regardless of its role, specifically in rupture, plaque calcification is indicative of 
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severe ASCVD, with no established treatment to date for calcified plaques (Liu et al., 2015). 
The currently available therapeutic interventions for ASCVD are dependent on the severity of 
disease. In the case of an already occluded vessel, therapy consists of coronary angioplasty, 
where a stent or balloon is introduced to “open-up” the lumen. Prior to vessel occlusion, i.e. 
before angioplasty is required, the most common prophylactic measure is to decrease lipid 
levels through the use of statins. Statins are competitive inhibitors of the rate-limiting 
enzyme, HMG-CoA reductase, for cholesterol synthesis (Tobert, 2003). The consequential 
decrease in hepatic cellular cholesterol levels results in an up-regulation of the LDL- receptor, 
promoting plasma LDL clearance and decreasing plasma lipid levels. Since their discovery, 
the adoption of statins has led to a significant reduction in mortality from ASCVD (Baigent et 
al., 2005; Brugts et al., 2009). Due to their mode of action, statins are generally prescribed in 
either cases of hyperlipidemia (Johansen et al., 2014) or in older patients (Wallach Kildemoes 
et al., 2012; Johansen et al., 2014; O’Keeffe et al., 2016), possibly due to the age-associated 
progression of atherosclerosis. In these patients, statins slow down the physical growth of 
plaques. However, the effects on plaque composition particularly calcification are either 
neutral (Bittencourt & Cerci, 2015) or adverse (Arad et al., 2005; Saremi et al., 2012). 
 
The process of vascular calcification involves the production and deposition of apatite and 
hydroxyapatite (Demer et al., 1994; Proudfoot & Shanahan, 2001). These mineral deposits 
occur around nucleation sites, which in the vasculature are matrix vesicles (Demer & Tintut, 
2008) and possibly oxidized lipids (Proudfoot & Shanahan, 2001). It is now accepted that the 
process of plaque calcification occurs through mechanisms synonymous with bone 
mineralization. Bone-like structures and chondrocyte-like cells have long since been 
identified in calcified plaques (Levy et al., 1979; Levy et al., 1986; Virchow, 1989). This has 
been associated with the presence of bone-morphogenic genes and gene products detected in 
calcified plaques (Boström et al., 1993; Dhore et al., 2001; Bobryshev et al., 2008). There is 
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some controversy concerning the origin of cells contributing to this deposition of calcium 
minerals. Bobryshev et al. (2008) were first to show the presence of osteoblast-like cells in 
human atherosclerotic plaques. In vitro studies have elucidated potential mechanisms 
involved in initiating the calcification process. Goettsch et al. (2011) showed the osteoblast-
like differentiation of VSMCs following incubation with ox-LDL. Sun et al. (2012) showed 
that VSMC-specific deletion of the osteogenic transcription factor, runt-related transcription 
factor 2 (RUNX2), inhibited oxidative stress-induced calcification of the VSMCs. More 
recently, Kapustin et al. (2015) reported that the calcium-dependent secretion of exosomes by 
VSMCs resulted in vascular calcification. Others have suggested the paracrine signalling of 
ECs (Shin et al., 2004) and macrophages (Liu et al., 2007; Ikeda et al., 2012) initiate 
osteoblast-like differentiation of VSMCs. Ikeda et al. (2012) showed the treatment of VSMCs 
with macrophage conditioned medium accelerated osteoblast-like differentiation of VSMCs, 
while others suggest the possibility of macrophages to potentiate the calcification process 
(New et al., 2013; Fu et al., 2016). 
   
Different subsets of macrophages with varying functional roles have been identified within 
plaques (Chinetti-Gbaguidi et al., 2015). These potentiate plaque growth and evolution by the 
continued secretion of pro-inflammatory cytokines and other factors like metalloproteinases, 
which degrade the extracellular matrix  (ECM) (Galis et al., 1995; Aikawa et al., 1998). A set 
of these heterogeneous plaque-macrophages has been shown to secrete matrix vesicles, 
providing a nucleation site for mineral deposition (New et al., 2013). In addition to their 
secretory function, macrophages have been shown to differentiate into osteoclast-like cells. 
Rogers et al. (2017) recently presented a working model for the role of these cells in plaque 
calcification. As reported, the incomplete differentiation of macrophage-derived osteoclast-
like cells results in low calcium resorption potential. This, when coupled with an additional 
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subset of macrophages, actively secreting calcific vesicles, may further drive the 
mineralization process (Rogers et al., 2017). 
 
Some research groups have shown the ability of VSMCs to switch into macrophage-like 
(Andreeva et al., 1997; Rong et al., 2003) cells. Others have highlighted the ability of 
macrophages to express smooth muscle cell markers (Martin et al., 2009; Stewart et al., 
2009), suggesting a similar phenotypic switch occurring in the macrophages. Martin et al. 
(2009) showed the thrombin-induced differentiation of peripheral blood mononuclear cells to 
contractile smooth muscle colonies (Martin et al., 2009). Regardless of origin, with the strong 
paracrine interaction within the vasculature, these cells are responding to the same local 
environmental changes and probably, together, contribute to the complication of plaque 
calcification and severity of ASCVD.  
 
1.3. Animal Models of Atherosclerosis 
Historic knowledge of atherosclerotic plaque formation, advancement and associated risk 
factors in humans has been provided post-mortem, from autopsies of individuals who died 
from non-CV related deaths (Restrepo & Tracy, 1975; Solberg & Strong, 1983; McGill, 1988; 
Wissler, 1991). Advances in technology have enabled real-time imaging and measurements of 
vascular dynamics, including the extent of lumen occlusion and some information on the 
morphology of plaques in at-risk individuals. However, a current limitation in the study of 
ASCVD is the difficulty in monitoring and assessing the direct effects of pharmacological 
agents to changes in plaque morphology; hence the advantages of preclinical animal models.  
 
The first preclinical model of atherosclerosis was in rabbits fed animal protein and a high fat 
diet (HFD). Ignatowski in 1908 observed formation of plaques in the aorta of these rabbits, 
but it was not until 1913 that the specific role of lipids in atherogenesis was discovered 
 12	
(Dock, 1958; Anitschkow, 1983). Since then, atherosclerotic research has made use of 
multiple large and small animal models, through HFDs tailored for each species (Dock, 
1958).  A major challenge in using animal models for study of atherosclerosis is that, due to 
the complexity of the disease, there are various systems to consider in assessing similarity to 
humans. The advantages and disadvantages of the different available animal models have 
been documented and reviewed extensively (see Fuster et al. (2012); Getz and Reardon 
(2012); Emini Veseli et al. (2017)). The hemodynamic and vascular anatomy of large animal 
models such as pigs and nonhuman primates make them an attractive preclinical model. 
However, the logistics in maintenance and in particular, costs of feeding and amount of 
pharmacological agent required for duration of a study, is a major disadvantage (Daugherty et 
al., 2017). Murine models have more commonly been used particularly due to low 
maintenance cost and high reproducibility (Getz & Reardon, 2012; Kapourchali et al., 2014). 
 
1.3.1. Murine models of atherosclerosis 
The two most commonly used murine models are the Apolipoprotein E-deficient (ApoE-/-) 
and low-density lipoprotein receptor-deficient (LDLR-/-) mice. The primary benefit of these 
transgenic mice models is their ability to spontaneously develop atherosclerotic plaques in the 
absence of a HFD. This feature is key because it has been shown in certain gene 
manipulations or treatments that the HFD differentially alters the atherosclerotic phenotype 
when evaluating the same experimental conditions in mice on standard-chow diet (Dansky et 
al., 1997; Getz & Reardon, 2012). Wild-type mice are naturally resistant to atherosclerosis. 
This is because of their very different lipid profile compared to humans. The predominant 
cholesterol carrier in mice is high-density lipoprotein (HDL) (Camus et al., 1983), described 
as the “good” cholesterol due to its athero-protective roles in humans in the reverse 
cholesterol transport and in preventing LDL oxidation. On the other hand, LDL is the main 
cholesterol carrier in humans. As a product of very low-density lipoproteins (vLDL), LDL is 
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considered “bad’ due to its size and ability to accumulate within vessel walls. The function of 
the LDLR is to enable uptake of LDL from the plasma into liver cells for catabolism, thereby 
decreasing circulating plasma lipid levels (Brown & Goldstein, 1976). Individuals with 
mutations in the LDLR develop severe hypercholesterolemia and die prematurely of ASCVD 
(Brown & Goldstein, 1984). Although the LDLR-/- mice provide an animal model for a 
human disease, they do not show similar increases in plasma lipid levels and only develop 
small plaques from 6 months of age whilst on a standard-chow diet (Ishibashi et al., 1994a; 
Merat et al., 2000). Most studies using this model tend to initiate plaque progression by 
placing mice on a HFD or inducing an additional mutation in another lipoprotein (Powell-
Braxton et al., 1998). Generally, the plaques that develop in these LDLR-/- mice on HFD 
remain at the initial xanthoma stage and rarely exhibit complex morphological features of 
advanced plaques as in humans (Daugherty et al., 2017). 
 
1.3.2. ApoE-/- mice 
The ApoE-/- mice model is the most extensively used animal model of unstable atherosclerosis 
(Getz & Reardon, 2012). This is due to the diet-independent development of plaques that 
advance in complexity of morphological features with age and time, comparable to plaques 
observed in humans (Rosenfeld et al., 2000). ApoE is a plasma protein found on a number of 
lipoproteins, and acts as a ligand for the LDLR (Yamamoto & Ryan, 2007). When on LDL, 
ApoE facilitates LDL uptake from plasma into the liver enabling catabolism (Mahley, 1988; 
Weisgraber, 1994). HDL functions to extract cholesterol from lipid-rich regions in peripheral 
tissues for transport to the liver. Once filled with cholesterol, HDL particles have a strong 
affinity for ApoE, which enables the plasma and peripheral excretion of cholesterol into the 
liver (Mahley, 1988). Patients with genetic mutations in their ApoE gene develop 
hyperlipoproteinemia, which results in the development of premature atherosclerosis (Mahley 
et al., 1999). Similarly, disruption of the ApoE gene in mice (Piedrahita et al., 1992; Plump et 
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al., 1992) leads to the generation of a similar hypercholesterolemia and more severe 
atherosclerosis on standard-chow diet (Zhang et al., 1992), relative to the LDLR-/- mice, due 
to the disruption of HDL-ApoE lipid-regulation axis.   
 
The model of atherosclerosis used in this thesis is the ApoE-/- mouse model, which has been 
characterized in terms of lesion development and progression on standard-chow diet 
(Nakashima et al., 1994; Reddick et al., 1994; Getz, 2000; Rosenfeld et al., 2000). The 
formation of lesions in the ApoE-/- mice has been documented to be site-dependent (Fig. 1-3) 
and progressive with the age of the animal, similar to humans (Nakashima et al., 1994; 
Reddick et al., 1994). As a result, at different ages in the ApoE-/- mice, it is possible to get an 
experimental snapshot of the different stages of plaque growth (Nakashima et al., 1994; 
Rosenfeld et al., 2000; Stary, 2000; Lhoták et al., 2016). 
 
Initial xanthomas are observed in these mice on standard-chow diet between 10-16 weeks of 
age and progress as the mice age (Nakashima et al., 1994; Reddick et al., 1994). Intermediate 
plaques appear from 25 weeks (Lhoták et al., 2016) whilst from 42 weeks, advanced plaques 
begin to appear (Rosenfeld et al., 2000). Plaque features such as calcification occur 
reproducibly between 45 and 75 weeks of age in these mice (Rattazzi et al., 2005). Different 
ages of mice were used in this thesis to correlate with the different stages of plaque growth; 




Figure 1-3 Predilection sites for plaque development in the arterial tree of ApoE-
/- mice. Schematic of murine arterial tree, arrows include labels of arteries. Yellow 
highlights indicate predilection sites of plaque formation; these tend to be regions, 
which experience turbulent flow. AoRt- aortic root, AA- Aortic arch, IA- innominate 
artery, RScA- right subclavian artery, RCCA- right common carotid artery, LCCA- 
left common carotid artery, LScA- left subclavian artery, DA- descending artery. 
Adapted with labels from Emini Veseli et al. (2017). 
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1.4. Estrogens in ASCVD 
Further complicating the assessment of ASCVD risk and treatment is the well-recognized 
disparity in disease progression between men and women. There is a documented 10-year lag 
in ASCVD in premenopausal women compared to age-matched men (Dubey et al., 2005). 
This delay in incidence of ASCVD in women is prime evidence for the premenopausal 
protection by estrogens and has been supported by a number of experimental reports (Adams 
et al., 1990; Bourassa et al., 1996; Elhage et al., 1997; Tse et al., 1999). 
 
1.4.1. Estrogens in vascular physiology 
Estrogens are the main female sex hormones. They are synthesised locally in reproductive and 
non-reproductive tissues (such as brain, bones, heart and liver) however their effects appear to 
be ubiquitous throughout the body (Cui et al., 2013). Of the three estrogens: estrone, 17β-
estradiol (E2) and estriol, the most potent is E2, which acts in a sex-independent but tissue-
specific manner (Wend et al., 2012; Cui et al., 2013). The cardio-protective effects of E2 have 
been extensively reported in humans (McGrath et al., 1998; Yeboah et al., 2008; Gardner et 
al., 2010) and in experimental settings (Li et al., 1999; Villablanca et al., 2009). Like other 
steroid hormones, E2 exerts its effects via the canonical genomic pathway, initiated by 
binding to cytoplasmic estrogen receptors (ER), ERα and ERβ (Guiochon-Mantel et al., 
1991). Upon binding to E2 they translocate to the nucleus, where they function as 
transcription factors, inducing the expression of genes encoding estrogen response elements 
(ERE) (Klinge, 2001). In this way, E2 modulates gene expression, protein synthesis and 
prevents pathological growth in vascular injury (Bakir et al., 2000). There is an additional 
non-genomic E2-mediated pathway through action on plasma membrane bound ER α and β 
(mERs) and the newly characterised G-protein coupled estrogen receptor (GpER) (Maggiolini 
& Picard, 2010). Through its various receptors, E2 contributes to vascular homeostasis 
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(Mendelsohn & Karas, 1999) by regulating specific processes in the different cells of the 
vasculature. In VSMCs, E2 increases the conductance of calcium- and voltage-activated 
potassium channels (White et al., 2002) contributing to vessel relaxation. Both GpER and 
mERs contribute to nitric oxide (NO) availability in ECs through downstream signalling 
mechanisms involving adenylyl cyclase (Maggiolini & Picard, 2010) and PI3K/Akt-
dependent eNOS activation (Simoncini et al., 2003). In this way, E2 regulates endothelium-
dependent relaxation (Caulin-Glaser et al., 1997; Lantin-Hermoso et al., 1997). Of the three 
ERs, ERα was first to be identified (Green et al., 1986; Mangelsdorf et al., 1995; Mosselman 
et al., 1996) and has been shown to mediate most of the E2 vascular effects (Meyer & Barton, 
2009; Arnal et al., 2010). Thus the thesis focuses on the expression of ERα. 
 
1.4.2. Anti-atherogenic effects of E2 
Coupled with the observational evidence on premenopausal cardio-protection are 
postmenopausal studies with reports on the beneficial effect of hormone replacement 
therapies (HRT). Randomized clinical trials and cross-sectional studies have shown the 
decrease in atherosclerosis progression (Hodis et al., 2001; Christian et al., 2002; Salpeter et 
al., 2004; Schierbeck et al., 2012), and specifically arterial calcification (Manson et al., 2007) 
or calcium scores (Gudmundsson et al., 2017), in women assigned to estrogen than placebo. 
Hodis et al. (2001) showed in a cohort of postmenopausal women, without pre-existing CVD, 
who took E2 for 2 years, a slower rate of subclinical atherosclerotic progression, relative to 
those on placebo. Subclinical atherosclerosis was defined in that study by the rate of change 
in intimal-medial thickness of the right carotid artery (Hodis et al., 2001). Schierbeck et al. 
(2012), investigating the long-term effect (10 years) of HRT in recently postmenopausal 
women, reported a significant reduction in risk of ASCVD. In a retrospective study of 
randomized trials of longer than 6 months duration, Salpeter et al. (2004) reported reduced 
total mortality by HRT in trials in which participants had a mean age of less than 60 years. 
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Autopsy studies on pre- and post-menopausal women who did and did not take HRT, showed 
a negative association between coronary artery plaque calcification and estrogen status 
(Christian et al., 2002).  
 
Studies in young animal models have facilitated the understanding of potential mechanisms 
through which estrogens, in particular E2, may provide this cardiovascular protection. A 
decrease in atherosclerotic lesion and plasma cholesterol levels has been shown in 
ovariectomized ApoE-/- mice treated with E2 (Hodgin et al., 2001). This atheroprotective 
effect of E2 was absent in ApoE-/- mice deficient of the estrogen receptor- (ER) α. A similar 
retardation in atherosclerotic plaque growth was reported in male ApoE-/- mice treated with 
E2 (Bourassa et al., 1996). Enhanced cholesterol efflux mediated by E2 has been confirmed 
in ox-LDL treated murine VSMCs (Wang et al., 2014), suggesting a possible atheroprotective 
mechanism. Excessive proliferation that occurs in pathological VSMC modulation was 
observed in the increased vascular medial area following carotid artery injury in ER α and β 
double knockout mice (Karas et al., 2001). This E2-mediated regulation of physiological 
VSMC phenotypic adaption has also been shown in vitro (Espinosa et al., 1996; Akishita et 
al., 1997; Li et al., 1999; Watanabe et al., 2003). Akishita et al. (1997) showed the inhibition 
of proliferation and migration, and therefore pathological intimal thickening, in male and 
female rat VSMCs by E2 in a dose-dependent manner. In particular, the inhibition of VSMC 
proliferation has been shown to occur in the overexpression of ERα and β in a dose-dependent 
manner in both rat and human aortic VSMCs (Watanabe et al., 2003). 
 
Similar reports have been documented of direct atheroprotective action of E2 in ECs. In 
response to inflammatory stimuli, ECs express cell adhesion molecules such as VCAM-1 and 
ICAM-1. This response by ECs has been suggested to be a key trigger in the formation of the 
initial xanthoma. In human umbilical vein endothelial cells, which endogenously express ER, 
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Caulin-Glaser et al. (1996) showed the strong inhibition of Interleukin-1-mediated VCAM-1 
and ICAM-1 induction by E2. A similar effect was noted in the reduction of CRP-mediated 
inflammatory response in human aortic ECs (Cossette et al., 2013). Apoptotic cell death, a 
result of increased ROS and inflammation, is a key component in plaque progression. E2 has 
been shown to attenuate TNF-α induced apoptosis in ECs and promote cell growth (Ling et 
al., 2006). Likewise following E2 treatment in ovariectomized rats, oxidative stress induced 
EC apoptosis was attenuated (Sudoh et al., 2001). 
 
1.4.3. Atherogenic effects of E2 
Whilst there is a lot of evidence for the atheroprotective effects of E2 in young females, it is 
important to highlight the discrepant findings of ASCVD risk amelioration in postmenopausal 
women. In the postmenopausal population, there is a surge in the risk of ASCVD and 
prevalence of atherosclerosis (Dubey et al., 2005). Based on the previously documented 
observed and experimental evidence of the beneficial E2-mediated effects on atherosclerosis, 
the hypothesis was that HRT would decrease the risk and prevalence of ASCVD. A trial 
investigating the use of estrogens after ischaemic stroke as a secondary prevention of 
cerebrovascular disease, found a higher mortality rate in women who received the E2 
treatment (Viscoli et al., 2001). A similar observation was made in another trial that 
investigated the advantages of E2 in slowing down the progression of coronary artery 
atherosclerosis (Herrington et al., 2000). Gabriel et al. (2005), in a retrospective study 
specifically investigating HRT trials designed for the primary treatment and prevention of 
ASCVD in postmenopausal women, concluded that the initiation of HRT for CV benefits 
should not be made. This study included women with or without previous history of ASCVD. 
Others have recommended that HRTs are more effective in maintaining vascular health but 
harmful in those at risk of ASCVD (Maas et al., 2003). 
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A review of these contradicting clinical trials produced the “timing hypothesis” (Dubey et al., 
2005; Hodis et al., 2012). First postulated by Dubey et al. (2005), it is the idea that the 
“timing of HRT initiation will determine whether HRT will protect against CVD”. This 
possibility has been shown in ovariectomized monkeys (Sophonsritsuk et al., 2013). 
Treatment one month after ovariectomy saw the inhibition of immune cell accumulation, 
which was not observed if treatment was started 54 months later. In ovariectomized ApoE-/- 
mice plaque size was shown to be greater in mice receiving late E2 therapy, 45 days after 
ovariectomy (Cann et al., 2008). In other cases, no beneficial or adverse effects of E2 have 
been noted. Daily subcutaneous E2 release in male ApoE-/- mice showed no difference in 
lesion size relative to placebo group as mice aged (Rosenfeld et al., 2002b). While recently 
McRobb et al. (2017) showed an increase in plaque calcification in male and female ApoE-/- 
mice treated with E2. These studies highlight the complexity of E2-mediated mechanisms 
within the vasculature, particularly in the context of atherosclerotic disease. 
 
These conflicting reports raise the question of how E2, having provided cardiovascular 
protection for so long in an individual, suddenly “switches” to no longer being protective and 
possibly detrimental. The literature suggests that following the postmenopausal decrease in 
endogenous E2 concentrations, a subsequent increase due to HRT potentially results in an 
aggravation of the already present atherosclerotic condition. This phenomenon could be due 
to the interplay and cross talk between pro- and anti-atherogenic mechanisms. Consequently, 
potentially pro-atherogenic signalling cascades inhibited by the constant presence of E2, may 
become active in the interim of E2 loss or decrease. In the administration of HRT, E2 may 
indirectly enhance these cascades, leading to detrimental effects.  
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1.5. Calcium/calmodulin Dependent Protein Kinase II (CaMKII) 
One possible regulator of these atherogenic mechanisms is the multifunctional enzyme 
CaMKII. CaMKII is a known mediator of calcium (Ca2+) signalling in different organs. The 
dual role of CaMKII in vascular health and disease has increasingly becoming apparent 
(Toussaint et al., 2016; Ebenebe et al., 2017). CaMKII is expressed in both VSMCs and 
macrophages and is already known in the heart to modulate apoptosis (Zhang et al., 2005; 
Yang et al., 2006; Erickson et al., 2008) and inflammation in cardiac pathologies (Zhang et 
al., 2003; Ling et al., 2009; Sag et al., 2009). It may exist as a common sensor linking 
environmental changes to downstream modulation pathways. The structure of the kinase is 
key to its function and will be discussed first before its role in vascular physiology and, 
potentially, disease are addressed. 
 
1.5.1. CaMKII structure 
CaMKII is a serine/threonine kinase that was initially isolated from neuronal tissue (Bennett 
et al., 1983) and is now known to be involved in synaptic transmission and long-term 
potentiation (Braun & Schulman, 1995; Lisman et al., 2002). Subsequent research has shown 
the ubiquitous expression of the kinase in peripheral tissues (Colbran et al., 1989; Tobimatsu 
& Fujisawa, 1989). 
 
CaMKII exists as a holoenzyme made up of 6-12 monomers (Braun & Schulman, 1995). Each 
monomer consists of an N-terminal catalytic domain, a regulatory domain and a C-terminal 
association domain (Fig. 1-4) (Braun & Schulman, 1995). The kinase is encoded by several 
genes, giving rise to at least four isoforms (α, β, δ and γ) and a number of splice variants. 
CaMKII is expressed in almost every tissue type, with cells of the cardiovascular system 
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predominantly expressing the δ and γ isoforms (Tobimatsu & Fujisawa, 1989; Edman & 
Schulman, 1994). 
 
1.5.2. CaMKII function/activation 
At rest, the kinase is maintained in an inactive state due to interaction between the regulatory 
and catalytic domains (Maier & Bers, 2002). The monomers are linked via the association 
domain. In the presence of calcium, where the calcium/calmodulin complex (Ca2+/CaM) is 
formed, Ca2+/CaM binds to the regulatory domain causing its dissociation from the catalytic 
domain (Fig. 1-4) (Maier & Bers, 2002). This frees the kinase to act on a variety of target 
proteins. The intersubunit phosphorylation of the regulatory domain at Threonine-287 
(Threonine-286 in the α-isoform), a process known as auto-phosphorylation, occurs during 
sustained calcium transients, in the presence of ATP (Lou et al., 1986; Lai et al., 1987; Braun 
& Schulman, 1995). Typically the dissociation of Ca2+/CaM allows the re-association of the 
regulatory and catalytic domains, auto-inhibiting the catalytic activity.  However, auto-
phosphorylation of the kinase results in a constitutively active (Meyer et al., 1992), 
Ca2+/CaM–independent enzyme (Lou et al., 1986; Schworer et al., 1986; Lai et al., 1987), a 
key feature of the CaMKII structure/function relationship.  
 
In addition to auto-phosphorylation, there are other post-translational modifications (PTM) of 
the regulatory domain that result in Ca2+/CaM-independence. In hyperglycemic conditions, 
CaMKII is O-GlcNAcylated at Serine-279, a covalent modification that contributes to cardiac 
pathology in diabetes (Erickson et al., 2013). In elevated oxidative stress, CaMKII is oxidized 
at a pair of methionine residues (281/282; isoform dependent) (Erickson et al., 2008). More 
recently, modification by S-nitrosylation has been shown in the neuronal and cardiac isoforms 
of CaMKII (Coultrap & Bayer, 2014; Erickson et al., 2015). CaMKII inhibition was observed 
after S-nitrosylation of the inactive kinase at Cysteine-273, through reduction in Ca2+/CaM 
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binding affinity. Following activation by Ca2+/CaM, S-nitrosylation at Cysteine-290 stabilizes 
its activity in a Ca2+/CaM- independent manner (Erickson et al., 2015). In this way, 
depending on the local environment, CaMKII has the ability to sense upstream signals and 





Figure 1-4 CaMKII as a monomer and decamer in various activation states. In normal 
conditions the close association between the catalytic and regulatory domains keeps the 
kinase in an inactive state (top left). With the rise of intracellular calcium and the formation of 
the calcium/calmodulin  (Ca2+/CaM) complex, CaMKII is activated (top right). Finally, in 
exposure to either reactive oxygen/nitrile species or high glucose conditions CaMKII 
undergoes post-translational modification (PTM), so is left in an autonomously active state 

















1.5.3. CaMKII in Vascular Physiology 
CaMKII activity is associated with physiological function of the vasculature. Activation of 
CaMKII has been shown to increase following sustained contractions of aortic strips (Kim 
2000). Rokolya and Singer (2000) observed in carotid arteries the dose-dependent decrease in 
contractile force, following treatment with the CaMKII inhibitor KN-93. Vessel relaxation in 
these arteries was also significantly attenuated following KN-93 incubation. In addition to this 
effect on overall vascular function a number of studies have recognized the role of CaMKII in 
the physiological phenotypic modulation of VSMC. Mercure et al. (2008) observed the acute 
activation of CaMKII in a scratch wound assay 30 seconds post-injury. This migration and 
proliferation were attenuated following incubation with a CaMKII- siRNA and a kinase-
negative CaMKII (House et al., 2007; Mercure et al., 2008). Similarly, platelet-derived 
growth factor (PDGF)-induced migration of VSMCs was associated with CaMKII activation 
(Pauly et al., 1995; Bilato et al., 1997). PDGF is an essential factor in embryonic 
development (Betsholtz, 2004).   
 
It has now been established that the α1 and β2 subunits of the L-type Ca2+ channel (LTCC), 
Cav1.2, both expressed in VSMCs, are targets of CaMKII (Striessnig et al., 2014). The 
voltage-gated LTCC are initiators of VSMC contraction by enabling extracellular Ca2+-influx. 
Phosphorylation of this channel has been shown to increase channel open probability (Lee et 
al., 2006; Blaich et al., 2010) resulting in an increase in Ca2+ current (ICa). In cardiac tissue, 
this regulation by CaMKII is paramount in physiological responses to exercise (Ross et al., 
1995; Xu et al., 2010). Prasad et al. (2013) documented the inhibition of LTCC in VSMCs of 
mesenteric arteries, in VSMC-specific-CaMKII-inhibited (SM-CaMKIIN) transgenic mice. 
The group showed a decrease in the sarcoplasmic reticulum (SR) Ca2+ content and 
phospholamban (PLN) phosphorylation in the SM-CaMKIIN mice. Ca2+- uptake into the SR 
is driven primarily by the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) pump 
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and enables vessel relaxation. SERCA, ubiquitously expressed in both VSMCs and ECs 
(Lipskaia et al., 2014), is negatively regulated by PLN. The phosphorylation of PLN, by 
CaMKII, dissociates the protein from SERCA increasing Ca2+- reuptake. 
 
CaMKII is also expressed in ECs and has been shown to modulate nitric oxide (NO) 
synthesis, through regulation of endothelial nitric oxide synthase (eNOS) (Fleming et al., 
2001). Under physiological shear stress and humoral signaling eNOS is activated by 
phosphorylation (Corson et al., 1996; Wang et al., 2004), resulting in NO synthesis and 
vasorelaxation. In response to humoral agents, histamine and bradykinin, CaMKII has been 
shown to phosphorylate eNOS, thereby increasing its activity (Fleming et al., 2001), 
facilitating endothelium-dependent relaxation.  
 
1.5.4. CaMKII in immune health 
The activation of the immune system is an essential component of whole body physiology. 
Macrophages are phagocytic cells of the immune system, present in all tissues in the body 
(Gordon & Pluddemann, 2017). They function to engulf pathogenic substances (Elhelu, 1983) 
and thus maintain the host defense system (Gordon & Pluddemann, 2017).  In response to 
injury, macrophages secrete inflammatory chemokines and cytokines, recruiting other 
immune cells, making up the host defense response (Bosurgi et al., 2017). CaMKII is 
expressed in macrophages and has been shown to contribute to macrophage activation and 
chemo-attractant signaling (Pereira et al., 2008; Zhou et al., 2014). In atherosclerotic disease 
the survival of macrophages is significant in impeding plaque progression as it prevents 
formation of necrotic core (Sakakura et al., 2013). Tano et al. (2012) observed that 
macrophage survival required activation of CaMKII. The group showed in bone-derived 
macrophages the inhibition of CaMKII resulted in increased apoptosis (2011; 2012). Similarly 
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Scott et al. (2013) observed a decrease in marker of macrophage maturation in artery lysates 
isolated from the CaMKII-/- mice.  
 
Together, these studies highlight the physiological role of CaMKII in contributing to vascular 
homeostasis and a similar role in the pro-survival and maturation of macrophages to 
maintaining vascular and immune health. However an equal number of reports documenting 
the involvement of CaMKII in vascular pathologies also exist.  
 
1.5.5. CaMKII in vascular disease 
In different models of hypertension CaMKII inhibition decreased mean arterial pressure 
(Prasad et al., 2015), interlobular artery necrosis (Muthalif et al., 2002) and normalized 
mesenteric vasoreactivity (Yousif et al., 2008). These pathological actions have been 
suggested to occur mainly through the post-translationally modified forms of CaMKII, 
resulting in autonomous activity.  
 
Vascular ischemic/reperfusion injury on the mesenteric artery showed an increase in both 
phosphorylated CaMKII (pCaMKII) and oxidized CaMKII (ox-CaMKII), which correlated 
with decreased vascular function (Lu et al., 2015). In oxidative-resistant CaMKII knock-in 
rodent models, a decrease in reactive oxygen species production was documented (Scott et al., 
2013; Zhu et al., 2014), coupled with deceased VSMC apoptosis following pro-inflammatory 
agonist treatment (Zhu et al., 2014). Reactive oxygen and nitrogen species (ROS and RNS), 
in low concentrations, play a significant role in vascular physiology (Trebak et al., 2010). 
Increasing concentrations, however, are indicative of pathologies as they then propagate a 
number of pathological mechanisms. These studies suggest that the PTM of CaMKII not only 
is a result of excessive ROS but also may regulate production. Oxido-reductase enzymes such 
as NADPH-oxidases (NOX) are major sources of ROS within the vasculature (Trebak et al., 
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2010). In bovine aortic ECs, phosphorylation of NOX5 by CaMKII caused an increased ROS 
production (Pandey et al., 2011), which was attenuated following inhibition by KN-93 or 
siRNA.  
 
In the same study showing a decrease in macrophage maturation markers in CaMKII-/- mice, 
decreased apoptosis was observed in cholesterol-loaded peritoneal macrophages isolated from 
the CaMKII-/- mice (Timmins et al., 2009). Recently, in necrotic and unstable atherosclerotic 
plaques, CaMKII activity has been shown to be up-regulated in macrophages (Doran et al., 
2017; Maione et al., 2017). Necrotic core formation within advanced plaques is a result of 
increased inflammation caused by inefficient efferocytosis of apoptosed macrophages and cell 
debris (Tabas, 2010). Doran et al. (2017) showed in advanced plaques the co-localization of 
pCaMKII to macrophages within the plaques. The study also showed in CaMKII-/- 
macrophages a significant decrease in efferocytosis. 
 
1.6. Summary  
The apparent dual role of CaMKII in the vasculature, presented in the preceding section 
(Section 1.5), coupled with the contradictory response to E2 treatments in human and animal 
models of ASCVD suggest a possibility that CaMKII could be mediating the alternating 
positive and negative action of E2. Recently it has been discovered that the PTMs of CaMKII 
are sex-specific. Bell et al. (2015) observed that in female hearts basal levels of pCaMKII are 
significantly lower than in male hearts. Similarly, Ma et al. (2009) observed an up-regulation 
in pCaMKII in hearts of ovariectomized rats, which correlated with a greater insult injury in 
ischemic/reperfusion setting. Levels of pCaMKII and ischemic insult were decreased 
following E2 treatment, and in inhibition of CaMKII by KN-93. This study concluded a 
cardio-protective mechanism conferred by estrogen through suppression of CaMKII activity. 
However, Bell et al. (2015) observed that when female cardiomyocytes were subjected to 
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arrhythmogenic challenges the up-regulation of pCaMKII was associated with decreased 
arrhythmias. Together, these studies highlight the potential mediation of E2 effects by 
CaMKII does exist in the heart, whether this is beneficial or adverse is yet to be established. 
To my knowledge there is currently no study investigating whether a similar biphasic 
regulation exists within the vasculature, specifically in the context of atherosclerotic plaque 
progression. Considering the role of CaMKII in regulating the different components of plaque 
progression, which contribute to the etiology of the disease, there is also no study that has 
investigated the direct effect of CaMKII in different stages of plaque progression. Likewise, 
with the discrepancy in the role played by E2 on ASCVD, there has been no study looking at 
the effect of E2 on the staged progression of plaques in the female ApoE-/- mice. 
 
1.7. Aims and Hypotheses 
Given these current gaps in knowledge, the aim of this thesis was to investigate the role of 
CaMKII in the pathogenesis of atherosclerotic plaque advancement and the effect of 17β-
estradiol (E2) using Apolipoprotein E- deficient  (ApoE-/-) mice, a murine model of 
atherosclerosis. After treating these mice with exogenous E2, I characterized the effect on 
plaque progression, starting treatment at different stages of plaque development (Chapter 3). I 
then investigated whether the E2-induced effects were associated with changes in CaMKII 
expression and activity. I also investigated the effect of chronic CaMKII inhibition, with KN-
93, on plaque progression, using calcification as a measure of severity in mice with 
intermediate (Chapter 4) and less established plaques (Chapter 5).  
 
I first hypothesized that in arteries with established plaques, E2 treatment will accelerate 
plaque progression through either an increase in plaque size or composition change or both. 





The second hypothesis was that CaMKII inhibition in vessels with established plaques will 
impede the advancement of the plaques within these vessels, indicated by changes in plaque 
composition and possibly size. 
 
 
My final hypothesis was CaMKII inhibition of vessels in early plaques would cause plaque 




CHAPTER 2: GENERAL METHODS AND MATERIALS 
2.1. Animals 
All animals in this study were adult ApoE- deficient (ApoE-/-) mice (C57BL/6 background). 
Founder animals were obtained from the Animal Resources Centre (Perth, Australia). The 
mice were housed and colony maintained in the Hercus Taieri Resource Unit (Dunedin, New 
Zealand) under conditions of 12-hours light and dark cycle at 21°C with standard-chow diet 
(Teklad Diet, Wisconsin, USA) and water available ad libitum. All experimental protocols 
were approved by the University of Otago Animal Ethics Committee (Dunedin, New 
Zealand) and were performed in accordance with the protocol guidelines. Sex and age (± 1 
week) of animals used will be specified in each individual chapter. The treatment plan for the 




Figure 2-1 Age-associated progression of plaques in ApoE-/- mice. Purple arrow indicates increased plaque progression in 
ApoE-/- mice with age. Mice at highlighted ages were included in this thesis; the corresponding chapters and pharmacological 
treatments are listed above.  
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2.2. Genotype 
A sample of mice from the cohort used in this thesis was tested to confirm the ApoE-/- 
genotype. When mice were 3-4 weeks old staff at Hercus Taieri Resource Unit collected tail-
tips or ear notches.  
 
2.2.1 DNA extraction 
DNA was extracted from each tip/notch using the prepGEM DNA extraction kit (ZyGEM, 
NZ), according to manufacturer’s protocol. Tissue (2mm) was added to 89µL of sterile DNA-
free water, 10µL extraction buffer (supplied in kit) and 1µL prepGEM enzyme. The mix was 
incubated at 75°C for 15min and 95°C for 5min to de-activate the enzyme; extract was stored 
at -20°C until analyses.  
 
2.2.2 PCR genotyping 
Mice were genotyped to confirm their ApoE-/- background using a Thermo Scientific Phusion 
High–Fidelity PCR kit. The wild-type (WT) ApoE allele was amplified using primers 180 
(5’- GCC TAG CCG AGG GAG AGC CG- 3’) and 181 (5’- TGT GAC TTG GGA GCT 
CTG CAG C- 3’) and detected as a 155bp band. The knockout (KO) allele was amplified 
using primers 180 and 182 (5’- GCC GCC CCG ACT GCA TCT- 3’) and detected as a 245bp 
allele (Gonzalez-Navarro et al., 2010). Heterozygous samples contained double bands (Fig. 2-
2). The cycling conditions of all amplifications are indicated in Table 2.1. Amplicons were 
separated on a 1% agarose gel in TAE buffer (40mM Tris, 1mM EDTA, 1.74M glacial acetic 






Figure 2-2 Representative image of agarose gel showing ApoE genotypes. ApoE status of 
mice was assessed by PCR and visualized on an agarose gel. The upper band is indicative of 
an ApoE knockout (ApoE-/-); lower band is a wild-type mouse, while the double band is 












Initial Denaturation 98°C 1min 1 
 
Denaturation 98°C 10sec 
35  Annealing 68°C 15sec 
 
Extension 72°C 20sec 
 
Final Extension 72°C 10min 1 
 
Hold 4°C ∞ 1 
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2.3. Tissue Collection 
All mice in this study were terminally anaesthetised using carbon dioxide (CO2) delivered in a 
CO2 chamber at the Hercus Taieri Resource Unit (flow rate- 8.5L/min) for 4min after last 
respiratory effort and euthanized by cardiac exsanguination. Mice were pinned in a supine 
position to the dissection board; a pfannenstiel incision was made 90° to torso and extended to 
both ends. The ventral skinfold was pinned back to expose diaphragm and ribs. Cutting 
through the diaphragm and laterally through ribs enabled access to the heart, 0.5-1mL of 
blood was collected from the right atrium using a 25G needle and 1mL syringe and stored at 
room temperature (RT), to allow coagulation. Serum was obtained by centrifugation 
(Centrifuge 5430R, Eppendorf, Hamburg, Germany) at 12000xg for 15min at 4°C and stored 
at -20°C for further analyses if required.  The heart and arterial tree were perfused with 20mL 
of warmed (~40°C) heparinized phosphate buffered saline (PBS)- 40U/mL (Hospira, Victoria, 
Australia), for 1min to remove blood. The tissues were fixed by perfusion with 60mL of 4% 
paraformaldehyde (PFA)- pH 7.3 (Merck Millipore) at a rate of 10mL/min; gastrointestinal 
organs and lungs were excised to gain access to the arterial tree (Fig. 2-3). The innominate 
artery and aortic sinus were dissected and stored in 4% PFA at room temperature overnight 
and subsequently transferred to 70% ethanol until further processing. The aortic arch, 










Figure 2-3 Aortic tree of ApoE-/- mouse. (A) Representative image of excised heart and aortic tree with labelled arteries. 0.5x magnification; 
scale bar- 100µm (B) Schematic showing orientation of embedded innominate artery; arteries were sectioned (broken lines) from AA-end till 
bifurcation. AA- Aortic arch; AoRt- Aortic root; DA- Descending artery; IA- Innominate artery; LCCA- Left common carotid artery; LScA- Left 



















2.4. Histological Processing 
All samples were processed by the Histology Service Unit (HSU), University of Otago 
(Dunedin, Otago) in an automated tissue processor (Thermo-Fisher). The protocol used by the 
service unit is detailed as follows: The innominate arteries were washed 6 x 20-30min in 
100% ethanol. This was followed by 3 x 30-40min incubations in wax at 60°C and finally 3 x 
20-30min xylene incubations at RT. Following processing, samples were embedded into a 
paraffin wax block and subsequently sectioned to a thickness of 4µm every 10µm (± 2µm). 
Each section was collected on an individual slide. The aortic sinus samples were processed in 
a similar manner as the innominate artery samples, but with incubation times of 1-1.5 hours, 
due to the larger tissue size. HSU staff embedded and sectioned only samples for Chapter 3, 
and sectioned some samples from Chapter 5.  
 
2.4.1. Morphological analyses 
2.4.1.A Haematoxylin and Eosin 
Every 5th section of the innominate arteries was stained using Haematoxylin and Eosin 
(H&E). H&E stain is a universal widely used method for the general detection of cellular 
structures within tissues (Elliott, 2012). Haematoxylin stains nucleic acid blue/black, while 
eosin stains basic tissue elements in different shades of pink (Fig. 2-4).  The protocol used for 
all samples in this thesis was modified from Gamble (2008). Sections were re-hydrated in 3 x 
2min xylene, 2 x 2min 100% ethanol, 1 x 2min 95% ethanol, and 1 x 1min 75% ethanol and 
then into tap water. Sections were incubated in Gill’s haematoxylin for 4min, followed by 
2min rinse in Scott’s tap water and normal tap water. Following a 30sec counterstain in eosin, 
sections were dehydrated by 3 x 30sec washes of 100% ethanol and 4 x 2min xylene 
incubations, before the final Distyrene, plasticizer and xylene (DPX) mount and covering with 
a coverslip. Innominate sections were included in analyses from the appearance of a complete 
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circumferential vessel to evidence of bifurcation into subclavian and carotid arteries (Fig. 2-
3B). 
 
2.4.1.B Alizarin Red S 
Subsequent 6th sections of the innominate arteries were stained with Alizarin Red S (AzR-S)- 
pH 4.2 to visualize calcification (Fig. 2-5). AzR-S is widely used as a calcium reagent. The 
compound forms a complex with calcium in a chelation process, producing an orange-red 
lake-dye precipitate (Dahl, 1952; McGee-Russell, 1958). The protocol used for all AzR-S 
staining in this thesis was obtained from Churukian (2008). Sections were re-hydrated as 
described in 2.4.1.A and halted at 95% ethanol, after which they were left to air dry. Once 
completely dry sections were incubated in AzR-S for 5min and rinsed briefly with distilled 
water. Sections were counterstained for 1min in 0.05% fast-green solution (in 0.2% acetic 
acid) followed by 3 brief rinses in distilled water. Sections were dehydrated, as described in 
2.4.1.A. before the final mount in DPX and covering with a coverslip. 
 
2.5. Data Analysis 
All sections were imaged, by the candidate, using a Motic BA310 light microscope (Xiamen, 
China) and digitally captured using a Moticam 580 digital camera. H&E and AzR-S stained 
sections were imaged at 10x magnification and immunohistochemistry (IHC) sections at 10x 
and 40x magnifications. Sections were analysed using ImageJ software (NIH, Bethesda, 
USA). Sections were randomized to conceal treatment groups. A scale was set using a 
micrometre, converting pixels to mm; this was applied to all images. The mean plaque area 
across each group was determined from H&E stained sections, the number of sections 
included in analyses will be specified in each chapter. Vessel wall thickness was used as a 
measure of plaque size; this was determined by tracing the entire vessel perimeter (Fig. 2-4). 
This value was then used to determine either the total or mean plaque area per mouse 
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(measurement used will be specified within each chapter), and subsequently mean plaque area 




Figure 2-4 Representative image of H&E stained section of the innominate artery. H&E 
stained sections were used to determine plaque size. Dark blue dots are nuclei, different hues 
of purple/pink are different cells that make-up the plaques. Total vessel wall thickness, used 
as a measure of plaque size, was determined by tracing along the outside and inside (lumen 
side) of the section, indicated by yellow trace. Images were calibrated using a micrometre. 
H&E- Haematoxylin and Eosin. 10x magnification; scale-bar-100µm. 
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Figure 2-5 Representative image of AzR-S stained section of the innominate artery. 
AzR-S stained sections were used to visualise calcified regions, indicated by the red stain 
(arrow). These regions of red were measured using the freehand tool in ImageJ. All images 





Intermediate sections (4µm) between those stained with H&E and the preceding AzR-S 
stained section, for example sections 7-9, between section 6 (AzR-S stained) and section 10 
(H&E stained), were used for IHC analyses using EXPOSE IHC kit (Abcam) adapted from 
the manufacturer’s protocol. Briefly, slides were re-hydrated as described in 2.4.1.A. The 
tissue sections were outlined on slides using a wax pen and incubated in hydrogen peroxide 
for 10min to block endogenous peroxidase activity. The sections were washed 2 x 4min with 
Tris-buffered saline supplemented with 1% Tween (TBS-T; 50mM Tris, 150mM NaCl, 
pH7.6). Next, antigen-retrieval was performed by heating the sections in 10mM citrate buffer 
at 95°C for 20min and then cooling them in a bath of tap water for 30min to an hour. Once 
cool enough to handle, non-specific protein binding was inhibited by incubation in EXPOSE 
Protein Block (Abcam/ for 10min; sections were rinsed with TBS-T (4min)). The sections 
were then incubated in primary antibody (specific antibodies and dilutions used are indicated 
in relevant chapters) overnight at 4°C, in a moisture chamber. Negative controls were absent 
of primary antibody and incubated in TBS-T (Appendix I). Sections were blotted dry with a 
paper towel and rinsed 3 x 4min in TBS-T prior to 15- 20min incubation with EXPOSE HRP-
conjugate (Abcam) at RT. Before and after incubation with freshly made 30µL (1 drop) 3,3`-
Diaminobenzidine (DAB) Chromagen and 1.5mL (50 drops) DAB substrate for 1-10min, 
sections were washed 4 x 4min in TBS-T and 1 x 4min in distilled water. Finally, the sections 
were counterstained in haematoxylin: either 10sec in Gill’s or 2mins in Mayer’s, dehydrated 
as in 2.4.1.A mounted in DPX and covered with a coverslip. Both Gill’s and Mayer’s 
haematoxylin are progressive acidic counterstains which differ only in haematoxylin dye 
concentration and preservative used (Kiernan, 1999). As a result, duration of incubation 
differs and is haematoxylin dependent. 
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2.6.1. IHC analysis 
Sections stained for relative protein expression were captured as described in section 2.5 and 
analysed using ImageJ software with the IHC Toolbox plug-in (Shu et al., 2013). 40 images 
of sections from all mice in the study, irrespective of treatment groups were used to create 
calibration files for analyses. Two different calibration files were created for each 
haematoxylin counterstain. Images were analysed, according to the counterstain used on the 
section, with the corresponding calibration file. Based on calibration, equivalent thresholds 
were set by the IHC Toolbox plugin for each image analysed. To determine staining intensity, 
the rectangle tool was used to draw a “region of interest (ROI)” box measuring 0.25 x 
0.25mm, for plaque regions (Fig. 2-6B) and 0.17 x 0.17mm for ‘VSMC’ region (Fig. 2-6A), 
any exceptions to these measurements will be specified in appropriate chapters. Using the 
“Analyse particles” function in ImageJ, the area and mean grey intensity was measured for 
each positively (brown-DAB) stained particle within the ROI. The integrated density (area x 
mean grey intensity) of each stained particle, within each ROI was calculated and totalled for 
that ROI. For all sections from ApoE-/- mice, two randomly selected regions were analysed 
within the plaque and two within VSMC regions, to encompass as much of the section as 
possible. The VSMC region consisted of areas of the vessel wall where there was no overt 
disease present, this included endothelial cells of the intima and smooth muscle cells of the 
media. This region is referred to throughout the thesis as ‘non-diseased VSMC’ region or 
VSMC region. For sections from WT mice, two VSMC regions were analysed per protein of 
interest. In co-localization experiments the ROIs of each anatomical region of protein B were 
selected relative to ROIs selected for protein A. Both ROIs per anatomical region were 
averaged per mouse; this was done independently for each protein of interest and for 4 mice 
per treatment group. The mean integrated density values from these 4 mice were determined 




























Figure 2-6 Representative images of immunohistochemistry measurement. Original 
images with region of interest (ROI) box (left panel) on ‘non-diseased VSMC’ region 
(A) and plaque region (B). Images after DAB threshold has been set (right panel) and 
particles within ROI highlighted and measured. VSMC- vascular smooth muscle cell. 
40x magnification; scale bar-100µm. 
 46	
2.7. Western Blot  
The aortic arch and descending artery of each mouse were pooled together in these 
experiments. These samples were fixed with PFA during dissection; subsequently, they were 
homogenized using a Qproteome FFPE Tissue Kit (Qiagen) according to manufacturer’s 
protocol. 94µL of extraction buffer (supplied in the kit) and 6µL of β-mercaptoethanol (Merck 
Millipore) were added to each sample. Phosphatase inhibitors PhosSTOP (10µL; Sigma-
Aldrich) and cOmplete (4µL; Roche) were added to prevent de-phosphorylation of proteins 
during extraction. The mixture was incubated on ice for 5min, mixed by vortex and incubated 
at 100°C for 20min. Tubes were sealed with a collection clip and further incubated at 80°C for 
2hours with agitation at 750rpm. Following rapid cooling at 4°C for 1min, samples were 
centrifuged at 14000xg for 15min at 4°C. Total protein concentration was determined using 
the Bradford method (BioRad); bovine serum albumin was used as a protein standard. Protein 
homogenates were snap-frozen in liquid nitrogen and stored at -80°C till further analysis. 
40µg of protein homogenates were boiled in sample buffer (62.5mM Tris, 10% Glycerol, 2% 
SDS, 100mM DTT and 0.01% Bromophenol blue) at 95°C for 5min, prior to separation on 8-
10% SDS polyacrylamide gels. Proteins were separated at 120V for 90-100min. Resolved 
proteins were transferred onto polyvinylidene difluoride (PVDF) membranes (BioRad) at 
100V for 100min. Membranes were blocked with 5% milk in TBS-T at RT for 30min, 
followed by a 5min rinse in TBS-T. Membranes were cut and incubated in primary antibody 
solutions either overnight at 4°C or at RT for 1.5- 4 hours (Table 2.2), followed by secondary 
antibody incubation at RT for 1- 1.5 hours. Between antibody incubations and after the 
secondary antibody incubation, membranes were rinsed 4 x 5min in TBS-T. Following a final 
rinse in TBS, membranes were incubated at RT for 5min in freshly prepared West Pico ECL 
solution (Thermo-Fisher) and visualized using SynGene Imaging System (Cambridge, UK). 
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Blots were analysed using ImageJ software. Target proteins and housekeeping protein 
(GAPDH) were analysed separately. Lane 1 of each gel was set as the reference lane. 
Densitometry values obtained for each target protein were normalized to GAPDH. A 
reference sample was loaded on each gel to enable normalization between blots.  
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Table 2.2. Antibodies used in Western Blot experiments 







































All antibodies were diluted in Tris-buffered saline with tween. Antibody dilution for Total CaMKII was determined from optimization experiments.  
GAPDH- Glyceraldehyde 3-phosphate dehydrogenase, Ms- Mouse, Rb- Rabbit, RT- Room temperature, HRP- horseradish peroxidase.  
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2.8. Optimization 
For all immunological experiments (WB and IHC) the primary antibody concentrations were 
determined from optimization experiments, before study samples were tested. 
 
2.8.1 Optimization of western blot 
Briefly, western blot experiments were carried out as described (section 2.7) first using the 
aortic arch and descending artery as separate samples, then pooling both aortic arch and 
descending artery together to determine appropriate protein yield. The antibody 
concentrations for pCaMKII, GAPDH and all secondary antibodies were used based on pre-
established lab protocols, as was the initial concentration used for total CaMKII (stock 
0.41mg/mL, dilutions- 1:3000, 1:1000). The final dilution used for all blots was 1:1000 
(Table 2.1) 
 
2.8.2 Optimization of immunohistochemistry 
For each protein target the initial antibody concentrations used were based on manufacturer’s 
recommendations.  
Total CaMKII (stock 0.41mg/mL): 1:1000, 1:500, 1:250, 1:100 
RUNX2 (stock 200µg/mL): 1:500, 1:250 and 1:100 
ERα (stock 1µg/µL): 1:500, 1:250, and 1:100  




2.9. Statistical Analyses 
Data were processed in Excel 2010 (Microsoft) and analysed in Prism (GraphPad version 7). 
Data values are represented as mean ± standard error of the mean (S.E.M.). The statistical 
tests used will be specified in each chapter. A p value of <0.05 was considered to be 
statistically significant.  
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CHAPTER 3: EXOGENOUS E2 EFFECTS ON 
INTERMEDIATE AND ADVANCED PLAQUES 
3.1. Introduction 
The timing hypothesis for hormone replacement therapy (HRT) suggests that the outcome of 
HRT is dependent on the timing of therapy initiation (Dubey et al., 2005). This hypothesis 
was postulated following review of contradictory reports on the cardiovascular benefits in 
randomized control trials of HRT (Dubey et al., 2005; Hodis et al., 2012). In subsequent years 
there have been a handful of experimental studies documenting the capability of exogenous 
17β-estradiol (E2) treatment to have adverse effects depending on when administered 
(Chapter 1).  
 
A limitation in the preclinical study of E2 effects after menopause is the lack of a truly 
representative menopausal model. The majority of studies make use of ovariectomized 
animals; this was particularly the case in studies documenting the anti-atherogenic effects of 
E2 (Bourassa et al., 1996; Elhage et al., 1997; Sudoh et al., 2001). However, 
ovariectomization has been shown to cause significant increases in serum lipid levels (Oliver 
& Boyd, 1959; Boese et al., 2017), and E2 is known to have direct effects on plasma lipid 
profile. Through inhibition of low-density lipoprotein (LDL) production and oxidation (Rifici 
& Khachadurian, 1992; Sack et al., 1994), coupled with its action on the LDL-receptor and 
therefore enhancing LDL uptake and clearance, E2 can inhibit plaque formation (Bourassa et 
al., 1996). In the context of plaque advancement by calcification, hyperlipidaemia is 
associated with plaque calcification (Schmidt et al., 1996). Specifically, modified LDL, 
through increased apoptosis, has been shown to stimulate vascular smooth muscle (VSMC) 
calcification (Proudfoot et al., 2000; Proudfoot et al., 2002). Thus, the observed anti-
atherogenic effects of E2 after ovariectomy may be due to its direct lipid regulating function. 
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 The capacity for E2 to have adverse effects becomes clear when considering these changes 
post-ovariectomy. The preclinical studies investigating the timing effects of E2 administration 
using ovariectomized mice observed a lack of effect if E2 therapy was not administered 
immediately (Cann et al., 2008; Sophonsritsuk et al., 2013). Other groups using gonadal-
intact but aged mice observed either no effect on plaque advancement (Rosenfeld et al., 
2002b) or significant increase in plaque calcification (McRobb et al., 2017). Atherosclerotic 
plaques progress as the individual gets older. This means that, in addition to the decrease in 
E2, the postmenopausal women in these trials would have some level of ASCVD, albeit 
possibly asymptomatic. There is a possibility that as plaques progressed in an age-
dependent/lifestyle manner, E2 would have provided ASCVD protection pre-menopause 
through the various mechanisms described in Chapter 1. Pro-atherogenic mechanisms 
involved in plaque advancement may have escalated in the interim between the decrease in E2 
levels and the administration of treatment. Holm et al. (1999) showed that for high-fat fed 
ovariectomized rabbits with deendothelialized aorta the E2 treatment caused significantly 
greater vessel-wall cholesterol accumulation (plaque formation) relative to placebo. This 
effect was not observed in healthy arteries. Endothelial cell apoptosis is a known stage in 
plaque progression (Durand et al., 2004). So, in the case of post-menopausal women, 
depending on the health of their arteries i.e. the stage of plaque advancement, E2 treatment 
may have very different effects.  
 
As discussed in Chapter 1 plaque calcification is indicative of disease severity (Stary, 2000) 
and is associated with increased major adverse cardiovascular events (MACE). The 
mechanisms involved in plaque calcification are similar to bone-mineralization (Dhore et al., 
2001; Bobryshev et al., 2008), which has been shown to be regulated by the calcium-
signalling molecule CaMKII (Shin et al., 2011; Choi et al., 2013). In vitro studies have 
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established the inhibition of osteoblast-like differentiation of VSMCs and therefore 
calcification by E2 (Rzewuska-Lech et al., 2005). Yet osteoblast differentiation is associated 
with increased activation of CaMKII (Choi et al., 2013). The only known interaction between 
E2 and CaMKII in the cardiovascular system was documented in the heart. E2 conferred a 
basal inhibition of CaMKII activity (Ma et al., 2009; Bell et al., 2015), which was then 
seemingly reversed in disease (Bell et al., 2015). CaMKII has been reported to have a dual 
role in the vasculature (Toussaint et al., 2016; Ebenebe et al., 2017), and its role in plaque 
progression is still being explored (Doran et al., 2017; Maione et al., 2017). The paucity of 
data on the effects of E2 in plaque development and CaMKII activity in the vasculature leaves 
a critical hole in our understanding of vascular pathology. The goal of this chapter is to 
contribute to the field by investigating the effect of E2 on established atherosclerotic plaques, 
using the ApoE-/- mouse model of atherosclerosis.  
 
Therefore, the aims of this chapter were as follows:  
 
1.) To determine the effect of E2 treatment on atherosclerotic plaques at different stages of 
development. I hypothesized that E2 treatment will decrease atherosclerotic burden by 
decrease in calcification in intermediate plaques but also cause an increase in more advanced 
plaques. 
 
2.) To investigate whether E2 induced effects on atherosclerotic plaques, at different stages of 
growth, are associated with changes in expression or activation of CaMKII. For this aim I 




Adult female ApoE-/- mice (C57BL/6) aged 25 or 45 weeks were used in this study. These 
ages were selected because or previous publications indicating that plaques in the ApoE-/- 
mice are the intermediate stage at 25 weeks (Nakashima et al., 1994; Lhoták et al., 2016) and 
advanced plaques are present from 42 weeks (Rosenfeld et al., 2000). Thus in this chapter, 
data from animals that began treatment at 25 weeks and their age-matched wild-type controls 
will be referred to as intermediate vessels/ the intermediate group. The animals that began 
treatment at 45 weeks and their age-matched wild-type controls will be referred to as having 
advanced vessels/ the advanced group. The animals were housed at Hercus Taieri Resource 
Unit under a 12-hour light/dark cycle and had access to a normal chow diet ad libitum. Age-
matched female wild type C57Bl/6 (WT) mice were included in the study to provide control 
samples for protein expression and localization experiments. All experimental protocols were 
approved by the University of Otago Animal Ethics Committee. At the end of treatment, the 
average age of the intermediate group was 36 weeks and the mean weight was 27g; the 
average age of the advanced group was 54 weeks and mean weight was 29g.  
 
3.2.2. Experimental Design 
Female ApoE-/- mice (C57Bl/6) with intermediate and advanced plaques were randomly 
assigned to one of two treatment groups: vehicle treated (V-T) or E2 treated. Mice were 
treated with subcutaneous injections biweekly for 8 weeks (Fig. 3-1) and then sacrificed by 
cardiac exsanguination (Chapter 2). E2 group received 3µg/g of 17β-estradiol (Cal-biochem) 
dissolved in 100% ethanol. Final drug delivery used corn oil (Sigma-Aldrich) for a vehicle 
and final E2 concentration was 0.9µg/µL; V-T mice received 10% ethanol in corn oil as 
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control. WT mice were sacrificed, and tissues harvested once mice got to the average age of 
either the intermediate or advanced group. 
 
3.2.3. Tissue Processing 
Tissue extraction and processing were carried out as described in Chapter 2. The innominate 
artery was isolated and processed for histological and immunohistochemical (IHC) analyses. 
4µm sections were collected in 10µm intervals, arteries were sectioned through to the end of 
tissue block. Every 5th section was stained with Haematoxylin & Eosin (H&E); the 
succeeding 6th section was stained with Alizarin red (AzR-S). Interval sections were used for 
IHC analysis using the protocol described in Chapter 2. Antibody concentrations used are 
shown in Table 3.1. A subset of histology samples were collected and processed by the 
Histology Service Unit (University of Otago). The aortic arch and descending artery were 






Figure 3-1 Treatment schedule of mice in Chapter 3. Female ApoE-/- mice from birth were left to age to either 25 weeks (wks) or 45 wks, 
from then they received subcutaneous injections twice a week for 8 weeks of E2 or vehicle (corn-oil). After the final injection mice were 
euthanized, the heart and arterial tree were excised.  
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Table 3.1. Immunohistochemistry Antibodies-Chapter 3 
  
Primary antibody Company/Cat. No. Concentration-4°C overnight Species Secondary antibody (Company/Cat. No.) 
     
Total CaMKII Thermo/PA5-22168 0.1µg/µL Rabbit EXPOSE HRP-conjugate (Abcam/ab80436) 
     
Phosphorylated CaMKII  Abcam/ab32678 1:100 (Stock concentration not supplied) Rabbit 
EXPOSE HRP-conjugate 
(Abcam/ab80436) 
     
Estrogen Receptor-α Abcam/ab75635 0.1µg/µL Rabbit EXPOSE HRP-conjugate (Abcam/ab80436) 
 
All antibodies were made up in tris-buffered saline with tween. Antibody concentrations were determined from optimization experiments. 
HRP- horseradish peroxidase.  
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3.2.4. Data Analyses 
All sections were imaged by light microscopy (Motic BA310, Moticam 580, Hong Kong, 
China) using 10x objective in H&E and AR stained sections and 40x objective in antibody-
stained sections. Sections were analysed using ImageJ software. Sections were analysed in a 
random order, so the identity and treatment of the mouse represented in each section was 
unknown throughout analyses.  
 
H&E stained sections were used to determine plaque size. Only mice with a minimum of five 
sections were included for analysis. For each mouse, consecutive sections were included in 
analyses beginning from the appearance of a circumferential vessel to the end of the tissue 
block or the appearance of bifurcation (whichever came earlier). Because the number of 
sections included in analyses varied per mouse, the mean plaque size was calculated across 
sections per mouse. This value for each animal was used to calculate the mean plaque area of 
each group. 
 
AzR-S stained sections were used to determine calcified regions within plaques. All sections 
were included in the quantification of mean calcified regions, beginning from the appearance 
of a circumferential vessel to either the end of the tissue block or the appearance of 
bifurcation (whichever came earlier). The mean area of calcified regions per mouse was used 
to calculate the mean area of calcification within each group.  
 
Protein expression and localization were determined using IHC antibody-probed sections. 
Consecutive sections stained for CaMKII, ERα and phosphorylated CaMKII (pCaMKII) were 
analysed at the same time. Protein expression analyses were performed using IHC Toolbox 
plugin (Shu et al., 2013), ImageJ Software (described in Chapter 2). Arterial sections in which 
there were no overt signs of atherosclerotic disease present were referred to as the ‘non-
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diseased VSMC region’ or at times ‘VSMC region’. For both regions only DAB staining in 
medial and intimal layers was quantified.  
 
3.2.5. WB Analyses 
Tissue levels of total CaMKII and pCaMKII were determined by WB experiments. 
Preliminary data showed that individual homogenization of the descending artery or aortic 
arch resulted in very low protein yield. Consequently both vessels were pooled per animal; 
these homogenates from the combined tissues were used in experiments (Chapter 2, Section 
2.7). Membranes were first probed with pCaMKII antibody, stripped and then probed again 
with the total CaMKII antibody. All membranes were probed for GAPDH to ensure an equal 
load of protein across samples. Antibody concentrations are listed in Table 2.2 (Chapter 2).  
 
Relative quantification of proteins were analysed using ImageJ. Densitometry values obtained 
for each target protein were normalized to GAPDH. A reference sample was loaded on each 
gel to enable between gel normalization. 
 
3.2.6. Statistical Analyses 
Data values are presented as mean ± standard error of the mean (S.E.M.). Shapiro-Wilk 
normality test was used to ensure normality of data. Parametric data sets were analysed using 
unpaired t-test and Mann-Whitney test for non-parametric data. Data were assembled using 
Excel 2010 (Microsoft), and analyses were performed using Prism (GraphPad version 7); 




3.3.1. Effect of E2 treatment on plaque size  
All ApoE-/- aortic blood vessels showed presence of atherosclerotic plaques with regions of 
lipid infiltration. Cholesterol crystals and mineral deposits were observed in all mice in this 
study (Fig. 3-2). Plaques in vessels from the advanced age group of mice were noticeably 
larger and more complex than those from the intermediate-aged group, thereby confirming the 
expected trajectory of plaque infiltration in this model of atherosclerosis. In ApoE-/- mice with 
intermediate or advanced plaques, there was no effect of E2 treatment on mean plaque area 































Figure 3-2 Effect of E2 treatment on plaque growth in intermediate and advanced plaques in the innominate 
artery of ApoE-/- mice. Representative images of H&E stained sections from the innominate artery of vehicle- and 
E2- treated ApoE-/- mice with intermediate and advanced plaques. Dark purple regions indicative of mineral 
deposition, regions of lipid infiltration and cholesterol crystals are annotated. L denotes vessel lumen. Double arrows 
point to chondrocyte-like cells. A minimum of five successive sections (4µm), were used to determine mean plaque 























Figure 3-3 Effect of E2 treatment on mean plaque area of intermediate and advanced 
plaques in the innominate artery of ApoE-/- mice.  (A) Mean plaque area in the innominate 
artery of vehicle- and E2- treated ApoE-/- mice with intermediate plaques, data comparison 
was made using unpaired t-test, p=0.96. (B) Mean plaque area in the innominate artery of 
vehicle- and E2- treated ApoE-/- mice with advanced plaques, data comparison was made 





































3.3.2. Effect of E2 treatment on plaque calcification  
Plaque calcification, associated with increased risk of CVD (Davies, 1992), is known to 
increase atherosclerotic burden (Burke et al., 2001b). To test the hypothesis that E2 treatment 
will alter plaque burden depending on stage of plaque progression, I examined the effect of 
E2 on the level of calcification in intermediate and advanced plaques, evidence by red 
precipitate in AzR-S stained sections (Fig. 3-4). In E2-treated ApoE-/- mice with intermediate 
plaques there was a significant increase in mean area of calcification when compared to V-T 
group (Fig. 3-5A, p=0.01). There was no effect of E2 treatment on plaque calcification in 
ApoE-/- mice with advanced plaques (Fig. 3-5B). This observation suggests that in arteries 
with intermediate plaques, E2 treatment is causing an acceleration of plaque advancement, by 
accelerating processes that lead to calcification, a known end-point in plaque progression 
(Hutcheson et al., 2017). 
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Figure 3-4 Effect of E2 treatment on calcification in intermediate and advanced plaques 
in the innominate artery. Representative images of AzR-S stained sections of the 
innominate artery of vehicle and E2 treated ApoE-/- mice with intermediate and advanced 
plaques. L denotes vessel lumen. Calcified regions are stained red and indicated by arrow. All 
sections with evidence of calcification from the appearance of full circumferential vessel were 
used to determine the mean calcified region within each artery; these were then coalesced to 














Figure 3-5 Effect of E2 treatment on calcification in intermediate and advanced plaques 
in the innominate artery of ApoE-/- mice. (A) Mean area of calcification within intermediate 
plaques in the innominate artery of vehicle- and E2- treated ApoE-/- mice. Data comparison 
was made using unpaired t-test, *p= 0.01. (B) Mean area of calcification within advanced 
plaques in the innominate artery of vehicle- and E2- treated ApoE-/- mice. Data comparison 










































3.3.3. CaMKII expression and phosphorylation in ApoE-/- vessels 
Having observed the E2-induced acceleration of intermediate plaques, by calcification, I next 
set out to determine whether CaMKII, a known calcium signal transductor, mediated this 
effect. To appropriately interpret potential effects of E2 treatment, I first examined if CaMKII 
expression and activity in vessels of age-matched WT mice are altered in ApoE-/- mice. 
 
The relative expression of CaMKII was 65% greater in intermediate WT mice compared to 
age-matched ApoE-/- mice (Fig. 3-36A) this did not reach statistical significance (p=0.05). 
Relative CaMKII expression in advanced ApoE-/- vessels was double the expression in age-
matched WT (Fig. 3-6B); this too did not reach statistical significance (p=0.15).  
 
CaMKII becomes phosphorylated when activated; this is broadly used as an indirect measure 
of kinase activity (Colbran, 1992). In WB analyses the ratio of phosphorylated CaMKII 
(pCaMKII) to total CaMKII gives an indication of how much of the kinase present in the 
sample is active. There was no effect of ApoE-/- on relative pCaMKII levels in the 
intermediate group (Fig. 3-7A); likewise in the advanced group there was no effect of ApoE-/- 


































Figure 3-6 Relative CaMKII expression in ApoE-/- mice with intermediate and 
advanced plaques and their age-matched wild-type C57Bl/6 mice (WT). (A) 
Representative immunoblots (i) and densitometry measurements (ii) of total CaMKII 
expression in descending artery and aortic arch of ApoE-/- mice with intermediate 
plaques and age-matched WT. Data comparison was made using unpaired t-test, 
p=0.05. (B) Representative immunoblots (i) and densitometry measurements (ii) of total 
CaMKII expression in descending artery and aortic arch of ApoE-/- mice with advanced 
plaques and age-matched WT. Data comparison was made using unpaired t-test, 
p=0.15. GAPDH was used as loading control. Each data point was referenced to mean 
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Figure 3-7 Relative pCaMKII expression in ApoE-/- mice with intermediate and 
advanced plaques and their age-matched wild-type C57Bl/6 mice (WT).  
(A) Representative immunoblots (i) and densitometry measurements (ii) of pCaMKII 
expression in descending artery and aortic arch of ApoE-/- mice with intermediate 
plaques and age-matched WT. Data comparison was made using Mann Whitney test, 
p=0.31. (B) Representative immunoblots (i) and densitometry measurements (ii) of 
pCaMKII expression in descending artery and aortic arch of ApoE-/- mice with 
advanced plaques and age-matched WT. Data comparison was made using unpaired t-
test, p=0.05. GAPDH was used as loading control. Each data point was referenced to 














































































3.3.4. CaMKII expression and phosphorylation in E2-treated ApoE-/- vessels 
Having observed no significant difference in CaMKII expression and phosphorylation, 
between WT and ApoE-/- mice, I investigated the effect of E2 treatment on these parameters 
in ApoE-/- vessels.  
 
There was no effect of E2 treatment on relative CaMKII expression in ApoE-/- mice with 
intermediate plaques (Fig. 3-8A). In ApoE-/- mice with advanced plaques, although the 
relative expression of CaMKII was decreased by 36% in the E2-treated group, after statistical 
comparison, there was no effect of E2 treatment on CaMKII expression ApoE-/- mice 
advanced plaques  (Fig. 3-8B). 
 
E2 treatment of ApoE-/- vessels with intermediate plaques resulted in a 27% increase in 
relative pCaMKII levels (Fig. 3-9A); this change did not reach statistical significance (p= 
0.34). In vessels with advanced plaques E2 treatment had no effect on pCaMKII levels (Fig. 
3-9B).  
 
In these WB experiments, none of the differences in total or phosphorylated CaMKII 
achieved statistical significance. However, my observations were consistent with trends 
towards modulation of CaMKII levels. As discussed in Chapter 1, the different cells of the 
vasculature contribute in different ways to the pathology of atherogenesis and plaque 
development. It has been shown that CaMKII is expressed within these different cells of the 
vasculature performing cell-specific roles (Pandey et al., 2011; Prasad et al., 2015), 
highlighting a potential for CaMKII-mediated cell-specific contributions to plaque 
progression. Additionally, plaque regions consist of variety of cell types including immune 
cells, which also express CaMKII (Tano et al., 2012; Scott et al., 2013). Therefore, I 
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investigated whether these modulations in CaMKII levels could be clarified using 

































Figure 3-8 Relative CaMKII expression in vehicle and E2-treated ApoE-/- mice 
with intermediate and advanced plaques. (A) Representative immunoblots (i) and 
densitometry measurements (ii) of total CaMKII expression in descending artery and 
aortic arch of vehicle and E2- treated ApoE-/- mice with intermediate plaques. Data 
comparison was made using unpaired t-test, p=0.84. (B) Representative immunoblots (i) 
and densitometry measurements (ii) of total CaMKII expression in descending artery 
and aortic arch of vehicle and E2- treated ApoE-/- mice with advanced plaques. Data 
comparison was made using unpaired t-test, p=0.4 GAPDH was used as loading control. 
Each data point was referenced to mean of vehicle-treated group and collectively 





































































































Figure 3-9 Relative pCaMKII expression in vehicle and E2-treated ApoE-/- mice with 
intermediate and advanced plaques. (A) Representative immunoblots (i) and 
densitometry measurements (ii) of pCaMKII expression in descending artery and aortic 
arch of vehicle and E2- treated ApoE-/- mice with intermediate plaques. Data comparison 
was made using unpaired t-test, p=0.72. (B) Representative immunoblots (i) and 
densitometry measurements (ii) of pCaMKII expression in descending artery and aortic 
arch of vehicle and E2- treated ApoE-/- mice with advanced plaques. Data comparison was 
made using unpaired t-test, p=0.96. GAPDH was used as loading control. pCaMKII value 
for each mouse was normalized to total CaMKII value and collectively data are presented 







































































3.3.5. Regional expression of ERα and CaMKII expression and phosphorylation in 
ApoE-/- vessels (IHC) 
To further investigate whether CaMKII expression and phosphorylation within the vessel wall 
differed between WT and ApoE-/- mice, I analysed protein expression within regions of vessel 
wall in the ApoE-/- innominate arteries where there was no overt presence of plaque and 
compared these data to WT. This was to establish whether the ApoE-/- mutation altered 
CaMKII expression or phosphorylation in regions without plaques. I also investigated the 
expression of the estrogen receptor, ERα, which has been implicated as a mediator of the anti-
atherogenic effects of E2 (Hodgin et al., 2001). These regions are referred to as ‘non-diseased 
VSMC’.  
 
CaMKII immunoreactivity was present in all layers of the artery cross-section. Nuclei and 
cytoplasmic DAB staining were observed in both WT and ApoE-/- with intermediate (Fig. 3-
10) and advanced (Fig. 3-11) age groups. pCaMKII-DAB staining pattern was localized to 
nuclei of cells lining the lumen (presumably endothelial cells) in both intermediate and 
advanced vessels. There was little to no observed immunoreactivity of pCaMKII in the 
cytoplasm or nuclei of smooth muscle cells in the medial layer (Fig. 3-13, Fig. 3-14). In both 
intermediate and advanced vessels, there was no effect of ApoE-/- in CaMKII expression (Fig. 
3-12) or phosphorylation (Fig. 3-15) within ‘non-diseased VSMC’ regions.   
  
ERα immunoreactivity was widespread, DAB staining was observed within the nuclei of cells 
lining the lumen (presumably endothelial cells) and nuclei of the smooth muscle cells in 
medial layer. ERα-DAB staining was also observed in the cytoplasm of the smooth muscle 
cells (Figs. 3-16 and 3-17). There was no effect of ApoE-/- on ERα expression within ‘non-
diseased VSMC’ regions in both intermediate and advanced vessels (Fig. 3-18).  
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Figure 3-10 CaMKII expression in ‘non-diseased VSMC’ regions of the innominate 
artery of ApoE-/- mice with intermediate plaques and age-matched wild-type C57Bl/6 
mice (WT). Representative images showing positive DAB staining (brown) of total 
CaMKII in ‘non-diseased VSMC’ regions of 4µm sections from the innominate artery of 
ApoE-/- mice with intermediate plaques (B) compared to age matched WT (A). Sections 
were counterstained with Gill’s haematoxylin. Images in left panel (i) were taken at 10x 
magnification; box indicates image in the right panel (ii) taken at 40x magnification, these 
were used for analyses. Scale bar- 100µm 
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Figure 3-11 CaMKII expression in ‘non-diseased VSMC’ regions of the innominate 
artery of ApoE-/- mice with advanced plaques and age-matched wild-type C57Bl/6 
mice (WT). Representative images showing positive DAB staining (brown) of total 
CaMKII in ‘non-diseased VSMC’ regions of 4µm sections from the innominate artery of 
ApoE-/- mice with advanced plaques (B) compared to age matched WT (A). Sections were 
counterstained with Gill’s haematoxylin. Images in left panel (i) were taken at 10x 
magnification; box indicates image in the right panel (ii) taken at 40x magnification, these 












Figure 3-12 Relative CaMKII expression in ‘non-diseased VSMC’ regions of the 
innominate artery of age-matched wild-type C57Bl/6 mice (WT) and ApoE-/- mice 
with intermediate and advanced plaques. (A) Mean DAB staining intensity of total 
CaMKII within ‘non-diseased VSMC’ regions of ApoE-/- mice with intermediate 
plaques and age-matched WT mice. Data comparison was made using unpaired t-test, 
p=0.56. (B) Mean DAB staining intensity of total CaMKII within ‘non-diseased 
VSMC’ regions of ApoE-/- with advanced plaques and age-matched WT mice. Data 
comparison was made using unpaired t-test, p=0.55. Each data point was referenced to 





















































































Figure 3-13 pCaMKII expression in ‘non-diseased VSMC’ regions of the 
innominate artery of ApoE-/- mice with intermediate and age-matched wild-type 
C57Bl/6 mice (WT). Representative images showing positive DAB staining (brown) of 
pCaMKII in ‘non-diseased VSMC’ regions of 4µm sections from the innominate artery 
of ApoE-/- mice with intermediate plaques (B) compared with age matched WT (A). 
Sections were counterstained with Gill’s haematoxylin. Images in left panel (i) were 
taken at 10x magnification; box indicates image in the right panel (ii) taken at 40x 
magnification, these were used for analyses. Scale bar- 100µm. 
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Figure 3-14 pCaMKII expression in ‘non-diseased VSMC’ regions of the innominate 
artery of ApoE-/- mice with advanced and age-matched wild-type C57Bl/6 mice (WT). 
Representative images showing positive DAB staining (brown) of pCaMKII in ‘non-
diseased VSMC’ regions of 4µm sections from the innominate artery of ApoE-/- mice with 
advanced plaques (B) compared with age matched WT (A). Sections were counterstained 
with Gill’s haematoxylin. Images in left panel (i) were taken at 10x magnification; box 
indicates image in the right panel (ii) taken at 40x magnification, these were used for 











Figure 3-15 Relative pCaMKII expression in ‘non-diseased VSMC’ regions of the 
innominate artery of age-matched wild-type C57Bl/6 mice (WT) and ApoE-/- mice 
with intermediate and advanced plaques. (A) Mean DAB staining intensity of total 
CaMKII within ‘non-diseased VSMC’ regions of ApoE-/- mice with intermediate 
plaques and age-matched WT mice. Data comparison was made using Mann-Whitney 
test, p=0.63. (B) Mean DAB staining intensity of total CaMKII within ‘non-diseased 
VSMC’ regions of ApoE-/- with advanced plaques and age-matched WT mice. Data 
comparison was made using unpaired t-test, p=0.05. Each data point was referenced to 

















































































Figure 3-16 ERα expression in ‘non-diseased VSMC’ regions of the innominate 
artery of ApoE-/- mice with intermediate plaques and age-matched wild-type 
C57Bl/6 mice (WT). Representative images showing positive DAB staining (brown) 
of ERα in ‘non-diseased VSMC’ regions of 4µm sections from the innominate artery 
of ApoE-/- mice with intermediate plaques (B) and age-matched WT (A). Sections 
were counterstained with Gill’s haematoxylin. Images in left panel (i) were taken at 
10x magnification; box indicates image in the right panel (ii) taken at 40x 
magnification, these were used for analyses. Scale bar- 100µm 
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Figure 3-17 ERα expression in ‘non-diseased VSMC’ regions of the innominate 
artery of ApoE-/- mice with advanced plaques and age-matched wild-type C57Bl/6 
mice (WT). Representative images showing positive DAB staining (brown) of ERα in 
‘non-diseased VSMC’ regions of 4µm sections from the innominate artery of ApoE-/- 
mice with advanced plaques (B) and age-matched WT (A). Sections were 
counterstained with Mayer’s haematoxylin. Images in left panel (i) were taken at 10x 
magnification; box indicates image in the right panel (ii) taken at 40x magnification, 











Figure 3-18 Relative ERα expression in ‘non-diseased VSMC’ regions of the 
innominate artery of age-matched wild-type C57Bl/6 mice (WT) and ApoE-/- mice 
with intermediate and advanced plaques. (A) Mean DAB staining intensity of ERα 
within ‘non-diseased VSMC’ regions of intermediate ApoE-/- and WT innominate 
arteries. Data were compared using unpaired t-test, p=0.58. (B) Mean DAB staining 
intensity of ERα within ‘non-diseased VSMC’ regions of advanced ApoE-/- and age-
matched WT innominate arteries. Data were compared using unpaired t-test, p=0.12. 































































3.3.6. Effect of E2 treatment on ERα expression and CaMKII expression and 
phosphorylation 
Within the ApoE-/- group, in the same ‘non-diseased VSMC’ regions I investigated the effect 
of E2 treatment on CaMKII expression and phosphorylation and ERα.  
 
CaMKII immunoreactivity pattern was unchanged by E2 treatment in ‘non-diseased VSMC’ 
region of intermediate (Fig. 3-19) and advanced (Fig. 3-20) ApoE-/- mice. E2 treatment had no 
effect on CaMKII expression (Fig. 3-21) in the ‘non-diseased VSMC’ region of both 
intermediate and advanced ApoE-/- mice. Similarly, pCaMKII immunoreactivity pattern was 
unchanged by E2 treatment in these ‘non-diseased VSMC’ regions of intermediate (Fig. 3-22) 
and advanced (Fig. 3-23) ApoE-/- mice. E2 treatment had no effect on the relative 
phosphorylation (Fig. 3-24) of CaMKII in ‘non-diseased VSMC’ region of ApoE-/- mice with 
intermediate and advanced plaques. 
 
ERα immunoreactivity pattern was unchanged by E2 treatment in ‘non-diseased VSMC’ 
region of both intermediate (Fig. 3-25) and advanced (Fig. 3-26) ApoE-/- mice. There was no 
effect of E2 treatment on the relative expression of ERα in ‘non-diseased VSMC’ region of 
ApoE-/- mice with intermediate and advanced plaques (Fig. 3-27). 
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Figure 3-19 CaMKII expression in ‘non-diseased VSMC’ regions of the innominate 
artery of vehicle- and E2- treated ApoE-/- mice with intermediate plaques. 
Representative images showing positive DAB staining (brown) of total CaMKII 
expression in ‘non-diseased VSMC’ region of 4µm sections from the innominate artery 
of vehicle- and E2- treated ApoE-/- mice with intermediate plaques. Sections were 
counterstained with Gill’s haematoxylin. Top row images were taken at 10x 
magnification, box indicates 40x image in bottom panel; 40x images were used for 











Figure 3-20 CaMKII expression in ‘non-diseased VSMC’ regions of the innominate 
artery of vehicle- and E2- treated ApoE-/- mice with advanced plaques. Representative 
images showing positive DAB staining (brown) of total CaMKII expression in ‘non-
diseased VSMC’ region of 4µm sections from the innominate artery of vehicle- and E2- 
treated ApoE-/- mice with advanced plaques. Sections were counterstained with Mayer’s 
haematoxylin. Top row images were taken at 10x magnification, box indicates 40x image 













Figure 3-21 Relative CaMKII expression in ‘non-diseased VSMC’ regions of the 
innominate artery of vehicle- and E2- treated ApoE-/- mice with intermediate (A) 
and advanced (B) plaques. (A) Mean DAB staining intensity of CaMKII expression in 
‘non-diseased VSMC’ regions of innominate artery of vehicle- and E2- treated ApoE-/- 
mice with intermediate plaques. Data comparison was made using Mann-Whitney test, 
p=0.42. (B) Mean DAB staining intensity of CaMKII expression in ‘non-diseased 
VSMC’ regions of innominate artery of vehicle- and E2- treated mice with advanced 
plaques. Data comparison was made using unpaired t-test, p=0.99. Each data point was 








































































Figure 3-22 pCaMKII expression in ‘non-diseased VSMC’ regions of the innominate 
artery of vehicle- and E2- treated ApoE-/- mice with intermediate plaques. 
Representative images showing positive brown (DAB) staining of pCaMKII expression in 
‘non-diseased VSMC’ regions of vehicle- and E2-treated ApoE-/- mice with intermediate 
plaques. Sections were counterstained with Mayer’s haematoxylin. Top row images were 
taken at 10x magnification, box indicates 40x image in bottom panel; 40x images were 









Figure 3-23 pCaMKII expression in ‘non-diseased VSMC’ regions of the innominate 
artery of vehicle- and E2- treated ApoE-/- mice with advanced plaques. Representative 
images showing positive brown (DAB) staining of pCaMKII expression in ‘non-diseased 
VSMC’ regions of vehicle- and E2-treated ApoE-/- mice with advanced plaques. Sections 
were counterstained with Mayer’s haematoxylin. Top row images were taken at 10x 













Figure 3-24 Relative pCaMKII expression in ‘non-diseased VSMC’ region of the 
innominate artery of vehicle and E2-treated ApoE-/- mice with intermediate and 
advanced plaques. (A) Mean DAB staining intensity of pCaMKII within ‘non-diseased 
VSMC’ regions of vehicle and E2 treated ApoE-/- mice with intermediate plaques. Data 
comparison was made using unpaired t-test, p=0.11. (B) Mean DAB staining intensity of 
pCaMKII within ‘non-diseased VSMC’ regions of vehicle and E2- treated ApoE-/- mice with 
advanced plaques. Data comparison was made using unpaired t-test, p=0.97. Each data point 













































































Figure 3-25 ERα expression in ‘non-diseased VSMC’ regions of the innominate artery 
of vehicle- and E2-treated ApoE-/- mice with intermediate plaques. Representative 
images showing positive DAB staining (brown) of ERα expression within ‘non-diseased 
VSMC’ regions of 4µm sections from the innominate artery of vehicle- and E2-treated 
ApoE-/- mice with intermediate plaques. Sections were counterstained with Gill’s 
haematoxylin. Top row images were taken at 10x magnification, box indicates 40x image in 
bottom panel; 40x images were used for analyses. Scale bar-100µm. 
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Figure 3-26 ERα expression in VSMC regions of innominate artery of vehicle- and 
E2-treated ApoE-/- mice with advanced plaques. Representative images showing 
positive DAB staining (brown) of ERα expression in VSMC regions of 4µm sections from 
the innominate artery of vehicle- and E2-treated ApoE-/- mice with advanced plaques. 
Sections were counterstained with Gill’s haematoxylin. Top row images were taken at 10x 
magnification, box indicates 40x image in bottom panel; 40x images were used for 













Figure 3-27 Relative ERα expression in ‘non-diseased VSMC’ regions of 
innominate artery of vehicle- and E2 treated ApoE-/- mice with intermediate and 
advanced plaques. (A) Mean DAB staining intensity of ERα within ‘non-diseased 
VSMC’ regions of intermediate vehicle- and E2- treated ApoE-/- mice. Data were 
compared using Mann-Whitney test, p=0.42. (B) Mean DAB staining intensity of ERα 
within ‘non-diseased VSMC’ regions of advanced vehicle- and E2- treated ApoE-/- 
mice. Data were compared using unpaired t-test, p=0.62. Each data point was 



























































3.3.7. Effect of E2 treatment on CaMKII expression within intermediate plaques 
To further investigate the hypothesis that E2-induced effects would be associated with 
changes in CaMKII expression I examined the effect of E2 treatment on CaMKII expression 
within diseased plaque regions in the same artery-sections examined in 3.3.6. 
Immunoreactivity pattern of CaMKII within intermediate plaques consisted of nuclei 
localization, in addition to lipid-rich regions and cholesterol crystals annotated in Fig. 3-28A.  
 
CaMKII-DAB staining intensity was noticeably stronger in plaque regions of V-T ApoE-/- 
mice relative to plaques from the E2-treated group (Fig. 3-28A). Once quantified, the relative 
expression of CaMKII within intermediate plaques of E2 treated ApoE-/- mice was 
significantly reduced by 48% compared to the expression within plaques from the vehicle-













Figure 3-28 Relative CaMKII expression within intermediate plaques of vehicle- 
and E2-treated ApoE-/- innominate arteries. (A) Representative images showing 
positive DAB staining (brown) of CaMKII expression within intermediate plaques of 
vehicle- and E2-treated ApoE-/- mice. Sections were counterstained with Mayer’s 
haematoxylin. L denotes vessel lumen. Arrows point to regions of lipid infiltration and 
cholesterol crystals. Image 40x magnification. Inset shows full image of vessel section, 
10x magnification; scale bar- 100µm. (B) Mean DAB staining intensity of CaMKII 
expression in intermediate plaques of 4µm sections of vehicle- and E2- treated ApoE-/- 
mice. Each data point was referenced to mean of vehicle-treated and collectively 



































3.3.8. Effect of E2 treatment on CaMKII expression within advanced plaques 
Immunoreactivity pattern of CaMKII in advanced plaques was similar between the two 
treatment groups (Fig. 3-29A). DAB staining was noticed mainly in cells lining the lumen 
side of the plaque (presumably fibrous cap), lipid-rich regions around cholesterol crystals and 
regions outlining and within mineral deposits.  
   
The relative expression of CaMKII in advanced plaques of E2-treated ApoE-/- mice was 
decreased by 57% compared to the V-T group; this did not reach statistical significance (Fig. 













Figure 3-29 Relative CaMKII expression within advanced plaques of vehicle- and E2-
treated ApoE-/- innominate arteries. (A) Representative images showing positive DAB 
staining (brown) of CaMKII expression within advanced plaques of vehicle- and E2-treated 
ApoE-/- mice. Sections were counterstained with Mayer’s haematoxylin. L denotes vessel 
lumen. Arrows point to regions of lipid infiltration and cholesterol crystals. Image 40x 
magnification. Inset shows full image of vessel section, 10x magnification; scale bar- 100µm. 
(B) Mean DAB staining intensity of CaMKII expression in advanced plaques of 4µm sections 
of vehicle- and E2- treated ApoE-/- mice. Each data point was referenced to mean of vehicle-


































3.3.9. Effect of E2 treatment on levels of pCaMKII within intermediate plaques 
To continue testing the hypothesis that E2-treated ApoE-/- mice with intermediate plaques had 
calcification associated with changes in CaMKII activity, pCaMKII levels, used as a measure 
of kinase activity, was assessed within diseased plaque regions.   
 
The immunoreactivity pattern of pCaMKII appeared to mirror that of total CaMKII (Fig. 3-
28A) but to a lesser extent, in that the DAB staining intensity observed was markedly 
decreased (Fig. 3-30A). Staining was localized to nuclei of cells lining the lumen (presumably 
fibrous cap) and certain nuclei within the plaque regions. No pattern of nuclei staining within 
the plaque could be determined. pCaMKII-DAB staining was noticeably absent from the 
cytoplasm of smooth muscle cells and majority of lipid-rich regions surrounding cholesterol 
crystals.  
 
In comparing treatment groups, relative expression of pCaMKII within intermediate plaques 
of E2-treated ApoE-/- mice was decreased by 35% compared to V-T plaques; this difference 













Figure 3-30 Relative pCaMKII expression within intermediate plaques of vehicle 
and E2 treated ApoE-/- innominate arteries. (A) Representative images showing 
positive DAB staining (brown) of pCaMKII expression in intermediate plaques of 
vehicle- and E2- treated ApoE-/- mice. Sections were counterstained with Mayer’s 
haematoxylin. L denotes vessel lumen. Arrows point to regions of lipid infiltration and 
cholesterol crystals. Image 40x magnification. Inset shows full image of vessel section, 
10x magnification; scale bar- 100µm. (B) Mean DAB staining intensity of pCaMKII in 
plaque region of 4µm sections from vehicle- and E2- treated ApoE-/- mice. Each data 
point was referenced to mean of vehicle-treated and collectively presented as mean ± 


































3.3.10. Effect of E2 treatment on levels of pCaMKII within advanced plaques 
Within advanced plaques pCaMKII immunoreactivity pattern was distinctively faint, absent 
from majority of the vessel section (Fig. 3-31A), compared to that of total CaMKII (Fig. 3-
29). DAB staining was localized to edges of regions mineral deposits nuclei of cells lining the 
lumen and certain nuclei within the plaque. No visible pattern of nuclei staining within the 
plaque could be determined.  
 
There was no noticeable effect of E2 treatment in the relative expression of pCaMKII within 
advanced plaques. It should be noted, however that the E2-treated group consisted of a sample 















Figure 3-31 Relative pCaMKII expression within advanced plaques of vehicle- and 
E2 treated ApoE-/- vessels. (A) Representative images showing positive DAB staining 
(brown) of pCaMKII expression in advanced plaques of vehicle- and E2-treated ApoE-/- 
mice. Sections were counterstained with Mayer’s haematoxylin. L denotes vessel 
lumen. Arrows point to regions of lipid infiltration and cholesterol crystals. Image 40x 
magnification. Inset shows full image of vessel section, 10x magnification; scale bar- 
100µm. (B) Mean DAB staining intensity of pCaMKII in plaque region of 4µm sections 


































3.3.11. Effect of E2 treatment on ERα expression within intermediate plaques  
Next I investigated whether the expression pattern of ERα within diseased region of the vessel 
i.e. in the plaque region was altered by E2 treatment. The immunoreactivity of ERα in 
intermediate plaques, regardless of treatment appeared to be highly nuclear specific. DAB 
staining was observed in lipid-rich regions, indicated in Fig. 3-32A. 
 
 The relative expression of ERα in intermediate plaques of E2-treated ApoE-/- mice was 
decreased by 26% relative to V-T intermediate plaques; this difference was not statistically 














Figure 3-32 Relative ERα expression within intermediate plaques of vehicle and E2 
treated ApoE-/- innominate arteries. (A) Representative images showing positive DAB 
staining (brown) of ERα expression in intermediate plaques of vehicle- and E2- treated 
ApoE-/- mice. Sections were counterstained with Gill’s haematoxylin. L denotes vessel 
lumen. Arrows point to regions of lipid infiltration and cholesterol crystals. Image 40x 
magnification. Inset shows full image of vessel section, 10x magnification; scale bar- 
100µm. (B) Mean DAB staining intensity of ERα in intermediate plaques of 4µm 
sections from vehicle- and E2- treated ApoE-/- mice. Each data point was referenced to 
mean of vehicle-treated and collectively presented as mean ± S.E.M. Data were 






























3.3.12. Effect of E2 treatment on ERα expression within advanced plaques 
Figure 3-33 shows ERα immunoreactivity in advanced plaques. DAB staining pattern was 
nuclear-specific, irrespective of treatment (Fig. 3-33A). Staining was noticeably absent from 
the cytoplasm of smooth muscle cells and appeared lower in E2-treated plaques.  
 
Once quantified, the relative expression of ERα in advanced plaques of E2-treated ApoE-/- 
mice was 51% lower than expression in V-T treated mice; this difference however did not 














Figure 3-33 Relative ERα expression within advanced plaques of vehicle and E2 
treated ApoE-/- innominate arteries. (A) Representative images showing positive DAB 
staining (brown) of ERα expression in advanced plaques of vehicle- and E2- treated 
ApoE-/- mice. Sections were counterstained with Gill’s haematoxylin. L denotes vessel 
lumen. Arrows indicate positive nuclei and lipid staining. Image 40x magnification. Inset 
shows full image of vessel section, 10x magnification; scale bar- 100µm. (B) Mean DAB 
staining intensity of ERα in plaque region of 4µm sections from vehicle- and E2- treated 
ApoE-/- mice. Each data point was referenced to mean of vehicle-treated and collectively 































The experiments conducted in this chapter set out to determine whether, at different stages of 
plaque growth, exogenous E2 treatment alters the severity of plaque advancement. It was also 
investigated whether any E2-induced alterations in plaque severity occurred via a CaMKII-
mediated mechanism. Sections were studied from the innominate artery of ApoE-/- mice with 
intermediate stage plaques and mice with more advanced plaques, as a result of age. The 
innominate artery is a site of predilection for plaque formation in the ApoE-/- mouse, possibly 
due to its exposure to turbulent flow, and therefore is a key location for the study of plaque 
development and progression (Nakashima et al., 1994; Reddick et al., 1994).  Indeed, 
findings in the present study showed that advanced plaques were larger and had a greater 
degree of calcification than intermediate plaques at the end of treatments.  This served as a 
confirmation of the expected age-related plaque progression in this murine model of 
atherosclerosis.   
 
Data from this chapter shows for the first time that the stage of plaque progression determines 
the effect of E2 administration. I established for the first time that 8 weeks of chronic 
administration of E2 in ovary-intact female ApoE-/- mice with intermediate plaques increased 
plaque advancement by increasing calcification with no effect on plaque size. In contrast, 
chronic administration of E2 in ovary-intact female ApoE-/- mice with advanced plaques had 
no effect on plaque calcification or plaque size. The protective effects of E2 on atherosclerotic 
burden have been well documented in animal (Hayashi et al., 1995) and human (McGrath et 
al., 1998; Yeboah et al., 2008) studies. There have only been a handful of studies observing 
some adverse effects, mainly in the context of menopause by ovariectomization (Cann et al., 
2008; Sophonsritsuk et al., 2013). With the emergence of conflicting reports on hormone 
replacement therapies (HRT) (Herrington et al., 2000; Schierbeck et al., 2012), current 
research is now focused on clarifying possible adverse effects of E2. Based on the American 
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Heart Association (AHA), atherosclerotic plaque classification system, the presence of 
calcified deposits within atherosclerotic plaques is indicative of disease progression and 
severity (Stary, 2000). There appears to be different opinions on whether this calcification 
precedes rupture, therefore making it indicative of plaque instability. Some groups have 
hypothesized that plaque calcification is indicative of healing, evidence that rupture may have 
occurred already (Otsuka et al., 2014). Regardless of the order of events in changes to 
composition, calcified plaques are associated with increased cardiovascular risk (Mauriello et 
al., 2013) and are known to be clinically relevant. Thus, my findings suggest a possible 
mechanism that would explain the increased adverse cardiovascular events observed in 
women in HRT group of hormone clinical trials.  
 
The data presented in this chapter are in contrast to a recent study where no difference in 
calcified area was noted in the innominate artery following E2 treatment of both male and 
female ApoE-/- mice (McRobb et al., 2017). At the end of that study, which also administered 
E2 for 8 weeks, the mice were more similar in age to the ApoE-/- mice with advanced plaques 
in my study. E2 had no effect on plaque size or calcification in vessels from ApoE-/- mice 
with advanced plaques in this chapter. Together, both this study and the report by McRobb et 
al. (2017) provide evidence to support the “timing hypothesis”. This hypothesis suggests that 
17β-estradiol treatment has the capability to have initial adverse cardiovascular effects but 
past a certain stage in atherosclerotic plaque progression, there is a lack of effect on the 
atherosclerotic burden. Whether these stages in plaque progression for the ApoE-/- mouse can 
be translated to a specific age in women is currently unknown. To my knowledge there is no 
published correlation of the maturational rate of ApoE-/- mice and specific stages in plaque 
development in adult humans.  
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In relating data from this study to the reports on adverse E2 effects post-menopause, a major 
limitation is the lack of an ideal preclinical menopausal murine model. Ovariectomized 
rodents have been widely used as a preclinical model of menopause (Diaz Brinton, 2012). 
However, E2 treatment following ovariectomy has been known to have significant effects on 
lipid levels and therefore their plaque size. E2 has been shown to have lipid-lowering 
mechanisms and can therefore have anti-atherogenic effects in that manner (Bourassa et al., 
1996). In order to differentiate from the lipid-lowering, anti-atherogenic effects of E2 and 
considering that most menopausal women tend to be ovary-intact, I chose to use ovary-intact 
mice. Rodents are known to undergo reproductive senescence, in which there is an age-related 
decrease in estrous cycling coupled with decreased levels of ovarian steroids (Diaz Brinton, 
2012), with some animals reaching full anestrous state.   
 
The youngest group of mice in this study were those in the intermediate group. Mice in this 
group were 25 weeks old at the start of the study. By the time of termination the mean age of 
the mice was 36 weeks, the age in which rodents are known to begin natural reproductive 
senescence (Van Kempen et al., 2011). Thus, the group with plaques at the intermediate stage 
could be representative of the early perimenopausal phase, while the group with more 
advanced plaques, late perimenopausal. Plasma E2 levels were not measured in mice in this 
chapter, highlighting a limitation of the study. One could argue that the endogenous levels of 
E2 were still high in the intermediate group, and that could be the reason for the observed 
adverse effect on plaque composition. However, this argument would conflict with data from 
Freudenberger et al. (2010). These authors specifically noted increased atherosclerotic burden 
in the group receiving low doses of E2, relative to an anti-atherogenic effect observed in the 
high-dose group. However, these reports, plus data from this study highlight a discrepancy 
within the field in the interpretation of preclinical E2-mediated effects. Freudenberger et al. 
(2010) address this in highlighting a high-dose issue in previous studies reporting anti-
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atherogenic effects. This suggests that the observed effect of E2 on plaque calcification in my 
study is not due to a high plasma level of E2.  
 
The closeness of the reproductive senescence in rodents to that of the perimenopausal 
transition in human is yet to be fully established. One potential study that could address this 
issue would be to use 4-vinylycyclohexene diepoxide (VCD) as a model of menopause in 
ApoE-/- mice. VCD, an industrial chemical shown to cause small follicle depletion, induces 
menopause without loss of other ovarian hormones, as in ovariectomy (Mayer et al., 2004; 
Lohff et al., 2005). The hormone profile of VCD-treated mice has been reviewed (Brooks et 
al., 2016) and studied in the context of atherosclerosis using fat-fed LDL-receptor deficient 
(LDLR-/-) model (Mayer et al., 2005). As discussed in chapter 1, the ApoE-/- model is 
particularly useful due to the spontaneous development of plaques on a standard diet. The use 
of VCD in ApoE-/- at different stages of plaque development with/without E2 treatment will 
provide a background that best mimics the at-risk postmenopausal-atherosclerotic population.   
 
There is also the added question of which ER mediates these adverse effects. Other groups 
have shown the inhibition of E2’s atheroprotective effects in ERα knockout ApoE-/- mice 
(Hodgin et al., 2001). Hodgin et al. (2001) observed decreased lesion size in E2-treated 
ApoE-/- mice, which was abrogated in E2-treated ApoE/ERα-/- mice. Additionally, the in vitro 
silencing of ERα resulted in a down regulation of calcification markers and a decrease in 
calcium mineral deposition (McRobb et al., 2017), hence the reason for investigating the ERα 
in this chapter. The lack of association of E2-induced calcification on levels of ERα does 
suggest that this action of E2 may not be occurring through ERα. In the same report, Hodgin 
et al. (2001) noted there was an E2-mediated decrease in advanced plaque features in the 
ApoE/ERα-/-. Likewise McRobb et al. (2017), although observing ERα-mediated changes in 
vitro, saw no changes in expression levels of ERα in vivo, supporting the data obtained from 
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this chapter. Interestingly, the researchers document a down-regulation of ERβ in female 
ApoE-/- with E2-induced increased calcification (McRobb et al., 2017). Yet a positive 
correlation between ERβ and coronary calcification has previously been reported in both pre- 
and post- menopausal women (Christian et al., 2006). There appears to be an interaction 
between the various receptors, which may be mediating these adverse effects of E2. It has 
previously been reported that ERβ exerts an inhibitory effect on ERα-mediated gene 
expression (Matthews & Gustafsson, 2003). There is a possibility that the ERα/β ratio is 
altered in atherosclerosis, this imbalance may contribute to the adverse effects observed 
(Meyer & Barton, 2009). It would be of interest to further investigate how ERβ levels are 
altered in the E2-mediated increase in calcification in this Chapter. Additionally, whether an 
association exists with the expression levels of GpER and E2-mediated calcification, as not 
much is known of the clinical relevance of the GpER.  
 
In this chapter I also examined the link between E2 treatment, and CaMKII activation in 
atherosclerosis. CaMKII is a known mediator of calcium signalling events in the heart and in 
the vasculature (Maier & Bers, 2002; Prasad et al., 2013).  No significant effect of E2 
treatment was noted in CaMKII expression or phosphorylation, when considering the vessels 
as a whole using WB experiments. The WB technique makes use of vessel homogenates. 
However, as discussed in chapter 1, CaMKII is expressed in and has specific roles within the 
different cells of the vasculature and immune cells. Thus, the homogenization of the vessel 
presented an issue in that, any E2-induced alterations to regional-tissue CaMKII expression 
and phosphorylation would be undetectable. In using immunohistochemical techniques, the 
aim was to clarify these changes in CaMKII expression and phosphorylation. To my 
knowledge there have been no studies looking at the expression and activity of CaMKII in the 
vasculature of an atherosclerotic animal model. There was no significant effect of ApoE-/- in 
CaMKII expression or activity in vessel homogenates (WB data) and tissue localization (IHC) 
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in both intermediate and advanced vessels. There were, however, interesting trends observed 
in each data set. The negative trend observed in vessels with intermediate plaques compared 
to their age-matched WT was inverse to the positive trend observed in the comparison within 
the advanced group. Whether there are age-related changes in CaMKII expression in any 
organ system is unknown to me. It is known that ageing in humans (Fares & Howlett, 2010) 
and other species (Dibb et al., 2004; Santalla et al., 2014) can be associated with disturbances 
in calcium homeostasis in the myocardium. Therefore, a future topic to be explored is to 
establish the age-related changes in CaMKII levels within the vasculature and the effect on 
vascular function.  
 
A key finding from this chapter was that in intermediate plaques from the innominate artery 
of female ApoE-/- mice, which are accelerated through calcification by E2 treatment, total 
CaMKII expression is decreased. There is a possibility that E2-treated plaques would have a 
more acellular profile due to the increase in calcium mineral deposition in these intermediate 
plaques. This means that calcium deposits would have replaced the immune cells and smooth 
muscle cells, thereby decreasing viable cellular structures. This feature would then be 
reflected in the decreased CaMKII expression. This is highly likely as all the protein 
measured in the intermediate plaques showed a trend towards down regulation in the E2-
treated group. However, as down regulation of CaMKII was the only target to reach statistical 
significance, this implies an additional reason behind this change.  
 
The decrease in CaMKII expression could actually be a reflection of a significant increase in 
CaMKII activity. As a functional kinase, changes in the total protein expression usually occur 
to reflect opposite changes in kinase activity. pCaMKII is a broadly accepted indirect measure 
of kinase activity, because active CaMKII auto-phosphorylates adjacent subunits (Colbran, 
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1992). Thus, the increase or decrease in pCaMKII levels in response to an experimental 
condition is indicative of alterations in kinase activity.  
 
For intermediate plaques the levels of pCaMKII in the E2 group was not significantly 
different from levels in the V-T group, yet the total amount of CaMKII in the former was 
significantly deceased. This fact suggests that out of all the CaMKII present within these 
plaques, there would be more phosphorylated in the E2 group, relative to V-T. An additional 
consideration is that the other post-translational modifications of CaMKII (discussed in 
Chapter 1) can occur without an auto-phosphorylation event, but still result in a constitutively 
active kinase. The experiments carried out in this study were not designed to capture these 
other forms of CaMKII activity. Taken together, the data strongly suggest that the adverse 
effect of E2 treatment in these vessels with intermediate plaques may be occurring through a 
CaMKII-dependent mechanism.  
 
Considering the nature of the subcellular atherosclerotic plaque environment, which has 
increased reactive oxygen and reactive nitrogen species, there is a possibility that oxidized 
and/or nitrosylated CaMKII will be significantly increased. Thus, my use of phosphorylated 
CaMKII as a proxy for kinase activation may have underestimated the extent of CaMKII 
activation in the vessels. Further studies are required to dissect the potential effects of E2 
treatment on oxidized and nitrosylated CaMKII. 
 
A more immediate study is to determine the role of CaMKII and pCaMKII in the typical 
advancement of plaques. There is a possibility that the pathological signalling of the kinase 
results in advancement of intermediate plaques, which may be exacerbated by E2 treatment. 
This topic will be addressed in the following chapter.  
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CHAPTER 4: THE EFFECTS OF CaMKII INHIBITION ON 
ATHEROSCLEROTIC PLAQUE PROGRESSION IN 25 WEEK 
OLD ApoE-/- MICE 
4.1. Introduction 
Atherosclerotic plaque formation is progressive, beginning at childhood. However, most of 
the major adverse cardiovascular events (MACE) due to plaque formation occur later in life. 
Calcium/calmodulin dependent kinase II (CaMKII) has been implicated in a number of 
cellular processes that are altered during atherosclerotic plaque formation. In macrophages, 
CaMKII signaling has been shown to contribute to maturation (Scott et al., 2013), cytokine 
secretion/signaling (Weinreuter et al., 2014) and the inflammatory response (Pereira et al., 
2008). The engulfing of lipids by macrophages in the vessel wall results in the formation of 
foam cells, the initial xanthoma that sets the foundation for plaque development. The 
proliferation, migration and hypertrophy of vascular smooth muscle cells (VSMCs) contribute 
to the process of plaque formation and further accumulation of more macrophages gives rise 
to the physical growth in plaque size.  CaMKII is expressed in VSMCs and has been shown to 
be associated with these phenotypic modulations of VSMCs (Pfleiderer et al., 2004; Ginnan 
et al., 2013) resulting in neointima formation following injury (House et al., 2007; House & 
Singer, 2008). The accumulation of apoptotic debris, coupled with calcium mineral 
deposition, produces the necrotic, labile core. CaMKII is known to regulate osteoblast 
differentiation (Zayzafoon, 2006; Shin et al., 2011; Choi et al., 2013) and has been implicated 
in cholesterol-induced macrophage apoptosis (Timmins et al., 2009). Considering the 
contribution of CaMKII to these different processes and the contribution of these processes to 
the complexity of plaque progression, there is a possibility that CaMKII plays a key role in 
the atherogenic process.  
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The incidence and risk of a MACE is associated with the presence of calcification in plaques. 
Calcification is indicative of severity and advancement of plaque progression in human 
atherosclerosis (Stary, 2000) and in the ApoE-/- mouse model (Rattazzi et al., 2005). Data 
reported in Chapter 3 showed that the administration of 17β-estradiol (E2) in 25-week old 
ApoE-/- mice with established, intermediate plaques increased the extent of plaque 
calcification. In this same cohort of E2-treated ApoE-/- mice, there was a significant decrease 
in the expression of CaMKII within these plaques.  This was surprising as CaMKII is a 
calcium-signalling molecule, and therefore the expectation would be that an increase in 
calcium mineral deposition would be associated with an increase in CaMKII expression. The 
decrease in CaMKII expression in E2-treated intermediate mice may be due to over activity of 
the kinase. When activated, CaMKII undergoes auto-phosphorylation, leaving it in a 
constitutively active state until de-phosphorylation by phosphatases (Lai et al., 1986). 
Phosphorylated CaMKII (pCaMKII) is used as an indirect marker of kinase activity and has 
been shown to be upregulated in a number of physiological and pathological processes, for 
example in osteoblast differentiation (Zayzafoon, 2006; Eapen et al., 2013; Villa et al., 2017). 
 
The presence of bone-associated proteins within calcified plaques suggests that the 
mechanisms involved in bone formation and remodeling share similarities with those 
involved in vascular calcium mineral deposition (Levy et al., 1979; Gijsbers et al., 1990). 
Dhore et al. (2001) observed differential expression patterns of these osteogenic modulators 
in plaques at different stages of growth. The study suggested that the temporal-spatial 
activation of these proteins governs their contribution to plaque calcification. Bobryshev et al. 
(2008) confirmed the presence of osteoblast-like cells in plaques from endarterectomy 
patients. The group discovered the presence of core binding factor 1 (Cbfa1)/runt-related 
transcription factor 2 (RUNX2)-immunopositive cells, which were co-localized with 
osteocalcin (a bone associated protein).  The origin of these osteoblast-like cells, releasing 
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calcifying matrix-vesicles and osteogenic proteins are yet to be confirmed. Some reports 
suggest these osteoblast-like cells are de-differentiated VSMCs (Bobryshev et al., 2008) 
pathologically responding to the atherosclerotic environment. Other groups suggest the 
infiltrating macrophages are the source of these calcifying matrix-vesicles (New et al., 2013). 
 
Shin et al. (2011) showed the osteogenic differentiation of human mesenchymal stem cells 
occurs via a CaMKII-mediated pathway. Using a collagen-binding protein to stimulate 
differentiation, they observed inhibition of migration and mineralization of stem cells 
following CaMKII inhibition. Likewise, in myoblast cells, inhibition of CaMKII attenuates 
the expression of osterix, an osteoblast-specific transcription factor (Choi et al., 2013). Dentin 
phosphophoryn was shown to induce osteoblast-differentiation of mesenchymal cells through 
the action of pCaMKII (Eapen et al., 2013). In human bone-marrow cells, betaine-induced 
osteoblast differentiation of these cells (Villa et al., 2017) was associated with a significant 
increase in pCaMKII. These in vitro studies show a link between the potential mechanisms of 
plaque calcification and their regulation by CaMKII. However, to my knowledge, there has 
been no study investigating the influence of CaMKII in plaque progression and calcification 
in vivo, in a murine model of atherosclerosis. 
 
This chapter addressed the contribution of CaMKII to the typical progression of intermediate 
atherosclerotic plaques in the innominate artery of female ApoE-/- mice. 
 
Therefore the aims of this chapter were as follows:  
 
1.) Investigate the effect of KN-93, a potent CaMKII inhibitor, on plaque progression, 
indicated by size and calcification of plaques. I hypothesized that the inhibition of CaMKII in 
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these ApoE-/- mice would impede the progression of plaques, as measured by a decrease in 
calcification and plaque size. 
 
2.) Investigate the effect of KN-93 on the expression of the calcification marker, osteocalcin. I 




4.2.1. Experimental Design 
Adult female ApoE-/- (C57BL/6) mice aged 25 weeks were used in this study and randomly 
assigned to one of three treatment groups: KN-93 (10µmol/kg; APExBIO), KN-92 
(20µmol/kg; APExBIO) or DMSO (10%; Merck). Female mice were used in this study to 
maintain consistency with sex of mice used in the study detailed in Chapter 3. CaMKII 
activation is inhibited in a dose-dependent manner by KN-93. KN-93 is known to have off-
target effects, thus the biologically inactive analogue KN-92 (20µmol/kg) was used as a 
control. Both compounds are soluble only in DMSO, of which the safety dose for mice is 
10%; hence an additional group received DMSO with saline to control for any adverse effects 
of the solvent. All drug concentrations used were based on previous studies investigating 
cardiac effect of CaMKII inhibition by KN-93 (Zhang et al., 2005; Khoo et al., 2006; 
Kaurstad et al., 2012). 
 
The mice were treated with intraperitoneal injections on alternate days four times a week for 
32 days (Fig. 4.1) and euthanized by cardiac exsanguination (Chapter 2). When terminated, 
mice were 30 weeks old. Tissue extraction and processing were carried out as described in 
Chapter 2. Mice were weighed at the start of their treatment, at midpoint, and before 
termination. Average weights in both treatment groups were stable for the duration of study,  
 
4.2.2 Tissue Processing  
Histological and immunohistochemical (IHC) analyses in this chapter were performed on 
4µm sections collected from the innominate arteries at 10µm intervals. Antibodies and the 
concentrations used in this chapter are indicated in Table 4.1.  
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Figure 4-1 Treatment schedule of mice in Chapter 4. Female ApoE-/- mice from birth were left to age to 25 weeks (wks). Thereafter, animals 
were randomly allocated to 3 experimental groups (Vehicle DMSO, KN-92 or KN-93) to commence a regime of intraperitoneal injections every 
2nd day for 32 days. After the final injection mice were euthanized, the heart and arterial tree were excised. 
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Table 4.1. Immunohistochemistry Antibodies- Chapter 4 
 
Primary antibody Company/Cat. No. Concentration- 4°C overnight Species Secondary antibody (Company/Cat. No.) 
     
Total CaMKII Thermo/PA5-22168 0.1µg/µL Rabbit EXPOSE HRP-conjugate (Abcam/ab80436) 
     
Phosphorylated 
CaMKII  Abcam/ab32678 
1:100  
(Stock concentration not supplied) Rabbit 
EXPOSE HRP-conjugate 
(Abcam/ab80436) 
     
Osteocalcin Abcam/ab93876 10ng/µL Rabbit EXPOSE HRP-conjugate (Abcam/ab80436) 
 
All antibodies were made up in tris-buffered saline with tween. Antibody concentrations were determined from optimization experiments. 
HRP-horseradish peroxidase  
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4.2.3 Data Analyses 
All sections were imaged by light microscopy (Motic BA310, Moticam 580, Hong Kong, 
China) using 10x objective in Haematoxylin and Eosin (H&E) and Alizarin Red (AzR-S) 
stained sections and 40x objective in IHC-stained sections. Sections were analyzed using 
ImageJ software, and the individual analyzing the data was blinded to the identity and 
treatment of the mouse represented in each section.  
 
H&E stained sections were used to determine plaque area. Plaque area measurement consisted 
of tracing along the vessel wall from the external elastic lamina to the lumen in each section 
(Chapter 2). Seven consecutive H&E stained sections, from the appearance of a 
circumferential vessel, were used to determine plaque area for each mouse. This value was 
used to calculate the mean plaque area of each group. 
 
AzR-S stained sections were used to determine calcified regions within plaques. All sections 
from the appearance of a circumferential vessel to the end of the tissue block or the 
appearance of bifurcation (whichever came earlier) were included in the quantification of 
calcified regions. All mice were assessed for presence of calcification and included in 
analyses, regardless of eligibility for plaque area assessment. The total area of calcified 
regions per mouse was used to calculate the mean area of calcification within each group.  
  
Target protein levels were measured using mean DAB staining intensity of IHC sections 
probed with appropriate antibodies (detailed protocol in Chapter 2). Arterial sections in which 
there were no overt signs of atherosclerotic disease present were referred to as the ‘non-
diseased VSMC region’ or at times ‘VSMC region’.  
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4.2.4 Statistical Analyses  
Data values are presented as mean ± standard error of the mean (S.E.M.). Shapiro-Wilk 
normality test was used to ensure normality of data. Parametric data sets were analysed using 
one-way ANOVA and Tukey’s post-hoc test or Kruskal-Wallis test for non-parametric data 
sets. Data were processed using Excel 2010 (Microsoft), and analyses were done using Prism 




4.3.1. Effect of KN-93 treatment on plaque size in 25wk ApoE-/- mice 
After four weeks of treatment with the CaMKII inhibitor KN-93, its inactive analogue KN-92 
or solvent control DMSO, I measured the effects on plaque size in H&E stained sections from 
the innominate artery. There was no difference in mean area of plaques from mice treated 
with KN-93 compared with those treated with KN-92 or DMSO. Fig.4-2 includes 
representative images from each group. Mice in all three groups showed evidence of plaque 
formation within the innominate artery, with the exception of one mouse from the KN-93 
treated group. In this mouse, there was no evidence of any lipid deposition or foam-cell 
formation, which was surprising.  
 
When plaques were present, the morphology across the groups were observationally different. 
Plaques in mice treated with the CaMKII inhibitor KN-93 consisted mainly of regions of 
cholesterol crystals, VSMC proliferation and infiltration of lipids into VSMCs (Fig.4-2). 
There was evidence of mineral deposition, indicated by regions of darker purple in H&E 
stain, and chondrocyte-like cells in plaques from mice treated with DMSO or KN-92, in 
addition to the cholesterol crystals and lipid infiltrates (Fig.4-2).  
 122	
DMSO KN-92 KN-93 
   
 
Figure 4-2 Effect of CaMKII inhibition on plaque size in the innominate artery of 25WK ApoE-/- mice. Representative H&E stained 4µm 
sections of the innominate artery from ApoE-/- mice treated with DMSO (vehicle control), KN-92 (inactive analogue to KN-93) or KN-93 (potent 
CaMKII inhibitor). Mice were treated every 2nd day for 32 days with intraperitoneal injections. L denotes vessel lumen. Regions of mineral 
deposition, VSMC proliferation, lipid infiltration and cholesterol crystals are annotated. Single arrows point to lipid rich region cells, double 













4.3.2. Effect of KN-93 treatment on plaque calcification in 25wk ApoE-/- mice 
CaMKII is known to regulate key pathways involved in osteoblast differentiation, which are 
also responsible for calcium mineral deposition within plaques. Plaque calcification increases 
plaque burden and is indicative of severity, so I next examined the effect of CaMKII 
inhibition by KN-93 on the presence and extent of calcification within these mice.  
 
It was noted that the amount of calcified plaques in the KN-93 treated group was less than in 
both DMSO and KN-92 treated mice (Fig. 4-3). Two out of 8 mice treated with KN-93 
showed calcification in plaques from the innominate artery. While in the DMSO group 4 out 
of 6 mice and 4 out of 8 mice in the KN-92 group showed signs of plaque calcification.  
 
Of the mice that showed plaque calcification, the extent of these calcified regions was 
measured. The area of calcification in the KN-93 treated group was smaller than the other two 
groups (Fig. 4-3). No statistical comparison could be made because only 2 mice in the KN-93 
treated group showed plaque calcification. Nevertheless, these observations align with my 
hypothesis regarding a beneficial effect of CaMKII inhibition.  
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Figure 4-3 Effect of CaMKII inhibition on plaque calcification in the innominate artery of 25WK ApoE-/- mice. (A) Representative images 
of AzR-S stained 4µm sections of the innominate artery from ApoE-/- mice treated with DMSO, KN-92 or KN-93. L denotes vessel lumen. 
Calcified regions are stained red and indicated by arrow. 10x magnification; scale bar-100µm. (B) Quantification of calcification incidence in 

























4.3.3. Effect of KN-93 treatment on osteocalcin expression and CaMKII expression and 
phosphorylation in VSMC region of 25wk ApoE-/- vessels 
To address the second hypothesis that KN-93 treatment would significantly decrease the 
expression of osteocalcin (OCN), I examined OCN expression within regions of the vessel 
wall in which there was no overt presence of atherosclerotic disease. However, in order to 
establish the protein expression profile of these regions without the overt presence of a 
plaque, I first examined the expression and phosphorylation of CaMKII in ‘non-diseased 
VSMC’ regions.   
 
CaMKII immunoreactivity was widespread throughout the vessel section. DAB staining was 
observed in both nuclei and cytoplasm of smooth muscle cells in the medial layer (Fig. 4-4). 
There was no effect of KN-93 treatment on the relative expression of CaMKII in the ‘non-
diseased VSMC’ region of the innominate artery in ApoE-/- mice (Fig. 4-5). 
 
pCaMKII immunoreactivity within the ‘non-diseased VSMC’ region was localized to the 
nuclei of intimal cells lining the vessel lumen (presumably endothelial cells). DAB staining 
was noticeably absent from the cytoplasm of smooth muscle cells of the medial layer (Fig. 4-
6). There was no effect of KN-93 treatment on the relative expression of pCaMKII in the 
‘non-diseased VSMC’ region (Fig. 4-7). 
 
OCN immunoreactivity was localized to the nuclei of cells lining the lumen (presumably 
endothelial cells), DAB staining was observed within the cytoplasm of smooth muscle cells of 
the medial layer. There were no noticeable nuclei staining of cells in the medial layer (Fig. 4-
8). There was no significant effect of KN-93 treatment on the relative expression of OCN in 
the ‘non-diseased VSMC’ region (Fig. 4-9). 
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Figure 4-4 CaMKII expression in ‘non-diseased VSMC’ regions of the innominate 
artery of 25WK ApoE-/- mice. Representative images showing positive DAB staining 
(brown) of CaMKII in ‘non-diseased VSMC’ regions of 4µm sections from the innominate 
artery of 25WK ApoE-/- mice treated with DMSO (solvent control), KN-92 (inactive 
analogue) or KN-93 (CaMKII inhibitor). Sections were counterstained with Mayer’s 
haematoxylin. Images in the top panel were taken at 10x magnification, box indicates 40x 





Figure 4-5 Effect of CaMKII inhibition on relative CaMKII expression in ‘non-diseased 
VSMC’ regions of the innominate artery of 25WK ApoE-/- mice. Mean DAB staining 
intensity of total CaMKII within VSMC region of the innominate artery of DMSO, KN-92 
and KN-93 treated ApoE-/- mice. Each data point was referenced to mean DMSO and 
presented as mean ± S.E.M. Comparisons were made using one-way ANOVA and Tukey’s 










































   
 
 
Figure 4-6 pCaMKII expression in ‘non-diseased VSMC’ regions of the innominate 
artery of 25WK ApoE-/- mice. Representative images showing positive DAB staining 
(brown) of pCaMKII in ‘non-diseased VSMC’ regions of 4µm sections from the innominate 
artery of 25WK ApoE-/- mice treated with DMSO (solvent control), KN-92 (inactive 
analogue) and KN-93 (CaMKII inhibitor). Sections were counterstained with Mayer’s 
haematoxylin. Images in the top panel were taken at 10x magnification, box indicates 40x 






Figure 4-7 Effect of CaMKII inhibition on relative pCaMKII expression in ‘non-
diseased VSMC’ regions of the innominate artery of 25WK ApoE-/- mice. Mean DAB 
staining intensity of pCaMKII within VSMC regions of the innominate artery of 25WK 
ApoE-/- mice treated with DMSO, KN-92 and KN-93. Each data point was referenced to mean 
DMSO and presented as mean ± S.E.M. Comparisons were made using one-way ANOVA 









































   
 
 
Figure 4-8 OCN expression in ‘non-diseased VSMC’ regions of the innominate artery of 
25WK ApoE-/- mice. Representative images showing positive DAB staining (brown) of OCN 
in ‘non-diseased VSMC’ regions of 4µm sections from the innominate artery of 25WK ApoE-
/- mice treated with DMSO (solvent control), KN-92 (inactive analogue) and KN-93 (CaMKII 
inhibitor). Sections were counterstained with Mayer’s haematoxylin. Images in the top panel 
were taken at 10x magnification, box indicates 40x image in the bottom panel; 40x images 






Figure 4-9 Effect of CaMKII inhibition on relative OCN expression in ‘non-diseased 
VSMC’ regions of the innominate artery of 25WK ApoE-/- mice. Mean DAB staining 
intensity of osteocalcin within VSMC regions of the innominate artery of 25WK ApoE-/- mice 
treated with DMSO, KN-92 and KN-93. Each data point was referenced to mean DMSO and 
presented as mean ± S.E.M. Comparisons were made using one-way ANOVA and Tukey’s 





































4.3.4. Effect of KN-93 treatment on CaMKII expression within plaques of 25wk ApoE-/- 
mice 
Having observed no effect of KN-93 in the vessel regions in which there was no overt 
presence of plaques. I investigated the effect of KN-93 treatment on CaMKII expression 
within diseased plaque regions.  
 
The difference in cellular composition between the three groups (Fig. 4-2) was reflected in the 
DAB staining pattern of CaMKII. CaMKII immunoreactivity was widespread throughout 
plaque region. DAB staining was observed in lipid-filled cells and regions surrounding 
cholesterol crystals (annotated in Fig. 4-10). Nuclei-DAB staining was particularly noted in 
cells lining the plaque on the lumen-side (presumably fibrous cap) and chondrocyte-like cells 
within the plaque (Fig. 4-10). There was a noticeable absence of staining in nuclei of some 
smooth muscle-like cells within the plaque (blue dots in Fig. 4-10). No obvious difference 
was noticed in DAB staining intensity between the groups (Fig. 4-10).  
 
Although relative levels of CaMKII expression in plaques from KN-93 treated mice was 45% 
less than the DMSO group and 26% more than the KN-92 group. When compared as a group 
there was no effect of KN-93 treatment on CaMKII expression in plaques (Fig. 4-11).   
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Figure 4-10 CaMKII expression within plaques in the innominate artery of 25WK ApoE-/- mice. Representative images showing positive 
DAB staining (brown) of CaMKII expression in plaques of DMSO (solvent control), KN-92 (inactive analogue) and KN-93 (CaMKII inhibitor) 
treated vessels. Sections were counterstained with Mayer’s haematoxylin. L denotes vessel lumen. Single arrows indicate intimal staining 
(presumably fibrous cap). Curved arrows indicate lipid- rich regions and cholesterol crystals. Double arrows indicate chondrocyte-like cells. Blue 
dots are nuclei absent of CaMKII immunoreactivity. Image 40x magnification. Inset shows full image of vessel section, 10x magnification. Scale 






Figure 4-11 Effect of CaMKII inhibition on relative CaMKII expression within 
plaques in the innominate artery of 25WK ApoE-/- mice.  Mean DAB staining 
intensity of CaMKII expression in plaques from the innominate artery of DMSO, KN-92 
and KN-93 treated ApoE-/- mice. Data were normalized to mean DMSO and presented as 




































4.3.5. Effect of KN-93 treatment on CaMKII phosphorylation within plaques of 25wk 
ApoE-/- mice 
To further test the hypothesis that CaMKII inhibition with KN-93 treatment decreases plaque 
calcification and expression of the calcification marker, I examined the immunoreactivity 
pattern and intensity of pCaMKII within plaque regions. As explained in Chapter 3, pCaMKII 
is an indirect measure of kinase activity; therefore the next experiments were performed to 
determine whether changes in levels of pCaMKII reflected kinase inhibition by KN-93.  
 
pCaMKII immunoreactivity within the plaque was faintly present in nuclei of cells lining the 
plaque (presumably fibrous cap). DAB staining was noticeably absent from regions 
surrounding cholesterol crystals. This was apparent in all treatment groups (Fig. 4-12). There 
was a downward trend in the relative expression of pCaMKII within plaques across treatment 
groups (Fig. 4-13). Relative pCaMKII expression in plaques from KN-93 treated mice was 
decreased by 69% compared to the DMSO treated mice and 32% compared to the KN-92 
treated mice (Fig. 4-13). 
 
An interesting observation was the localization of pCaMKII immunoreactivity when 
compared to that of CaMKII. Figure 4-14 shows the absence of pCaMKII staining in these 
lipid-rich cholesterol crystals, which were positive for CaMKII. It was also interesting to note 
that for some plaques with cholesterol crystals and lipid-filled cells, pCaMKII staining was 
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Figure 4-12 pCaMKII expression within plaques in the innominate artery of 25WK ApoE-/- mice. Representative images showing positive 
DAB staining (brown) of pCaMKII in plaques of DMSO (solvent control), KN-92 (inactive analogue) and KN-93 (CaMKII inhibitor) treated 
vessels. Sections were counterstained with Mayer’s haematoxylin. L denotes vessel lumen. Single arrows indicate intimal staining (presumably 
fibrous cap). Curved arrows indicate lipid- rich regions and cholesterol crystals. Double arrows indicate chondrocyte-like cells. Blue dots are 
nuclei absent of pCaMKII immunoreactivity. Image 40x magnification; this image was analyzed. Inset shows full image of vessel section, 10x 







Figure 4-13 Effect of CaMKII inhibition on relative pCaMKII expression within plaques 
in the innominate artery of 25WK ApoE-/- mice. Mean DAB staining intensity of pCaMKII 
in plaques from the innominate artery of DMSO, KN-92 and KN-93 treated ApoE-/- mice. 
Data were normalized to mean DMSO and presented as mean ± S.E.M. Comparisons were 






































Figure 4-14 Consecutive sections of plaques in the innominate artery of an ApoE-/- mouse DAB-stained for total CaMKII and 
pCaMKII. Representative images of sections from the innominate artery stained with antibodies against total CaMKII (left panel) and 
pCaMKII (right panel). L denotes vessel lumen. Curved arrows indicated positively stained lipid-filled cells. Straight arrows indicate lipid-
filled cells absent of pCaMKII immunoreactivity. Image in 40x magnification; this image was analyzed. Inset shows full image of vessel 
section, 10x magnification. Scale bar- 100µm. 
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4.3.6. Effect of KN-93 treatment on osteocalcin within plaques of 25wk ApoE-/- mice 
Having observed a decrease in calcified plaques from mice treated with KN-93, I next 
investigated whether this would be reflected in a similar down-regulation of the bone-
associated protein OCN within plaque regions. As mentioned above (Section 4.1) CaMKII is 
a regulator of osteoblast differentiation (Zayzafoon, 2006) and bone-associated proteins are 
expressed by calcifying vascular cells (Bobryshev et al., 2008; Sun et al., 2012). Figure 4-15 
shows OCN immunoreactivity was distinctly present in nuclei of cells lining the plaque 
(presumably cells of the fibrous cap). DAB staining was observed in lipid-filled cells and 
lipid-rich regions surrounding cholesterol crystals. Interestingly, staining was markedly 
absent from the nuclei of certain cells, presumably hyperplasic smooth muscle cells within the 
plaque, but was present in others (blue dots in Fig. 4-15). 
 
There was a visible downward trend in the relative expression of OCN across the three 
groups. Relative expression of OCN in plaques from KN-93 treated mice was 37% lower than 
the relative expression in DMSO treated group and 13% lower than the relative expression in 
KN-92 treated group; this did not reach statistical significance (Fig. 4-16).  
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Figure 4-15 OCN expression within plaques in the innominate artery of 25WK ApoE-/- mice. Representative images showing positive DAB 
staining (brown) of osteocalcin in plaques of DMSO (solvent control), KN-92 (inactive analogue) and KN-93 (CaMKII inhibitor) treated vessels. 
Sections were counterstained with Mayer’s haematoxylin. L denotes vessel lumen. Single arrows indicate intimal staining (presumably fibrous 
cap). Curved arrows indicate lipid- rich regions and cholesterol crystals. Blue dots are nuclei absent of staining. Image 40x magnification; this 





Figure 4-16 Effect of CaMKII inhibition on relative OCN expression within plaques in 
the innominate artery of 25WK ApoE-/- mice. Mean DAB staining intensity of osteocalcin 
in plaques from the innominate artery of DMSO, KN-92 and KN-93 treated ApoE-/- mice. 
Data were normalized to mean DMSO and presented as mean ± S.E.M. Comparison was 






































The aim of this chapter was to investigate how CaMKII influenced the typical progression of 
atherosclerotic plaques in the innominate artery of female ApoE-/- mice.  Following chronic 
treatment with KN-93, a potent CaMKII inhibitor, I examined the effect this had on plaque 
size and calcification and on the expression of the calcification marker osteocalcin. In support 
of the hypothesis, the main finding from this chapter was the decrease in calcification in the 
group of mice treated with KN-93. The second major finding was that CaMKII inhibition 
with KN-93 did not decrease expression of the calcification marker osteocalcin, which refutes 
my hypothesis.  
 
Although within the plaques there was an observed downward trend in pCaMKII and OCN 
expression, which suggests a possible mechanism through which KN-93 may cause a 
decrease in calcification. It was surprising that CaMKII inhibition with KN-93 did not 
significantly decrease OCN expression. More surprising was that KN-93 treatment did not 
have any effect on the level of pCaMKII in ‘non-diseased VSMC’ region or result in a 
significant decrease of pCaMKII within plaques.  OCN is a bone- associated protein secreted 
by osteoblasts and contains calcium-binding γ-carboxyglutamic acid (Gla) residues (Lacombe 
& Ferron, 2015). Bone- associated proteins have long been found to be expressed in calcified 
atherosclerotic plaques (Levy et al., 1979; Levy et al., 1986; Bostrom et al., 1995; Dhore et 
al., 2001). OCN in particular has been shown to regulate the osteoblast-like differentiation of 
VSMCs (Idelevich et al., 2011). Endothelial progenitor cells (EPCs) of severely 
atherosclerotic patients were found to express high levels of OCN relative to EPCs from 
healthy individuals (Gössl et al., 2008). CaMKII is also known to contribute to bone-
formation processes and regulate osteoblast differentiation (Choi et al., 2013). The specific 
involvement of OCN in the vascular calcification process in vivo is still being determined. 
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The data presented here suggests that OCN expression may not be mediated by CaMKII and 
is possibly not directly involved with enhancing plaque calcification. 
 
KN-93 is a competitive inhibitor of the Ca2+/CaM binding site (Maier & Bers, 2007). 
Therefore it was expected that KN-93 treatment, via intraperitoneal injections, would prevent 
activation of the kinase. The lack of observed effect on levels of pCaMKII suggests a number 
of possibilities. The first is that the activation of CaMKII, which may be contributing to 
plaque progression, has already occurred. Due to the mode of action of KN-93, if the 
Ca2+/CaM complex was already bound and the kinase activated, there would be no observed 
effect at initiation of KN-93 treatment. However, this seems unlikely considering the 
observed decrease in calcification in the KN-93 treated group.  The measurement of pCaMKII 
as a marker of kinase activity is used because, in the presence of ATP, activated CaMKII 
auto-phosphorylates resulting in a constitutively active kinase (Colbran, 1992). However, as 
discussed in Chapter 1, the post-translational modification (PTM) of CaMKII by oxidation 
(ox-CaMKII) or nitrosylation (nitro-CaMKII) can also give rise to a constitutively active 
enzyme. The sites of these PTMs on the kinase are hidden when CaMKII is inactive. 
Activation by the Ca2+/CaM complex exposes the PTM sites, which results in autonomous 
activity. This can occur without an autophosphorylative event. Considering that the 
recruitment of immune cells and adaptation of vascular cells which result in plaque growth 
and formation is a result of increased reactive oxygen species (ROS) and possibly reactive 
nitrogen species (RNS), there is a possibility that these PTMs occur in CaMKII. If this is the 
case then the current study has not yet captured the effect of KN-93 treatment on CaMKII 
within the vessels. Future study requires measurement of ox-CaMKII and nitro-CaMKII, 
within these vessels or the inhibition of these other active forms of CaMKII.  The lack of an 
effect of KN-93 on pCaMKII associated with decreased calcification in this chapter is in 
support with the E2-induced lack of effect on pCaMKII associated with increased 
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calcification in Chapter 3. Both data strongly suggest that CaMKII-mediated plaque 
calcification may not be occurring through pCaMKII.  
 
Data from this study further supports the notion of a differential role for pCaMKII and other 
modified forms of CaMKII within the atherosclerotic plaque. Figure 4-14 showed the 
widespread lipid-rich immunoreactivity of CaMKII, which was distinct from the cell-specific 
immunoreactivity of pCaMKII. This suggests that the CaMKII expressed in different cells 
within the plaque is present in different activation states, possibly contributing to features of 
the plaque. Recently, Maione et al. (2017) observed the differential cell-specific expression of 
CaMKII in stable and unstable atherosclerotic plaques. The group noted that in stable plaques 
CaMKII expression was greatest in VSMCs whilst unstable plaques showed greater 
expression of CaMKII in macrophages. Interestingly, pCaMKII levels were greater in stable 
plaques than unstable.  This supports the possibility that the calcification in plaques in the 
present study is not occurring through the action of pCaMKII. 
 
Plaque calcification increases atherosclerotic burden and is associated with major adverse 
cardiovascular events, possibly due to rupture. The observed increase of CaMKII expression 
in VSMC-rich stable plaques by Maione et al. (2017) raises a number of questions relevant to 
the present study. Are the calcified-unstable plaques from my findings macrophage rich? Is 
the KN-93-induced decrease in calcification due to changes in plaque cell type? There was no 
effect of KN-93 on plaque size across the groups, but there was an observed difference in the 
composition of the plaques (Fig. 4-2). If CaMKII expression was greater in macrophages, yet 
pCaMKII was greater in stable plaques (Maione et al., 2017), this must either mean that the 
CaMKII active in macrophages is not phosphorylated; or the total amount of CaMKII in 
macrophages is significantly lower than in VSMCs hence the low pCaMKII levels measured 
in the unstable-macrophage rich plaques (Maione et al., 2017). Both are possible, yet my 
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study suggests the latter is not the case. Per mm2 of ROI, the expression level of all proteins 
investigated in the plaque region was significantly greater than in the ‘non-diseased VSMC’ 
region (Appendix II). An interesting further study would be to determine the macrophage 
profile of these plaques in response to KN-93 treatment, thereby addressing the questions 
highlighted above.  
 
The innominate artery is a predilection site of atherosclerotic plaque development, possibly 
due to the turbulent flow to which it is exposed. Features of advanced plaques have been well 
characterized at this site in the ApoE-/- mouse (Rosenfeld et al., 2000), and multiple groups 
have presented plaques in this region as an adequate model for the study of plaque disruption 
(Rosenfeld et al., 2002a; Williams et al., 2002; Rosenfeld et al., 2008). The mice used in this 
study were 30 weeks old at the time they were euthanized; it has been documented that from 
24 weeks the composition of plaques in the innominate artery are at the intermediate stage 
(Lhoták et al., 2016) and continue progression to become more advanced (Rosenfeld et al., 
2000; Meir & Leitersdorf, 2004). KN-93 treatment did impede some of these compositional 
changes as observed by the predominantly lipid-rich cholesterol crystals (Fig. 4-2) and 
decreased calcification (Fig. 4-3). Investigating fibrous cap thickness, intra-plaque 
hemorrhage or indicators of plaque disruption through use of more detailed stains, such as 
Movat-pentachrome stain, in KN-93 treated ApoE-/- mice would provide additional insight 
into the role of CaMKII in plaques.  
 
The observation of an absence of lipid deposition or foam cell formation in one mouse in the 
KN-93 treated group was extremely surprising and highly unusual. In the atherogenic process, 
lipid deposition is the obvious indicator of plaque presence; this is usually coupled with 
VSMC hypertrophy and proliferation resulting in intimal thickening. This observation raised 
the question of whether, in some mice, CaMKII inhibition may result in a regression of 
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plaques. In the ApoE-/- mouse model of atherosclerosis when plaques are at the intermediate 
stage and are advancing, this advancement can usually be characterized by age as the plaques 
generally exhibit similar features in composition and size (Nakashima et al. (1994); Reddick 
et al. (1994) and seen in Chapter 3). However it is possible that at the start of the atherogenic 
process, where plaques are not fully advanced, slight variation may exist in the extent of 
progression.  
 
The data from this chapter show for the first time in the innominate artery of female ApoE-/- 
mice that CaMKII inhibition with KN-93 caused marked changes to the composition of 
intermediate plaques and impeded plaque progression by decreasing calcification, 
observations that are in line with my hypothesis. The study was unable to determine the 
potential mechanism through which these CaMKII-mediated changes may be occurring, 
future studies required to address this will be discussed in Chapter 6.  
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CHAPTER 5: EFFECT OF CaMKII INHIBITION WITH KN-93 
IN 20 WEEK OLD ApoE-/-MICE 
5.1. Introduction 
Data in Chapter 4 show CaMKII inhibition with KN-93 treatment caused a decrease in plaque 
calcification and no effect on plaque size. However, I did make the surprising observation that 
a portion of the KN-93 treated ApoE-/- mice had vessels that were nearly absent of plaques. 
This absence of plaques was never observed in the control treated groups. This observation 
was inconsistent with previously reported data using the ApoE-/- model, which showed that 
plaques are visible in these mice between 10-16 weeks and, from 24 weeks, plaques start to 
advance with complex changes in cellular composition (Rosenfeld et al., 2008). Hence, I 
expected that plaques would be present in all ApoE-/- mice at the 30-week time point. My data 
show that KN-93 greatly reduced plaque progression, observed in morphological changes, 
and even yielded some mice without plaques, suggesting that inhibition of CaMKII may have 
had regressive effects on plaque growth.  However, this finding could not be confirmed 
without determining the uniformity of plaque advancement in the innominate artery prior to 
25-weeks of age, the point at which KN-93 treatment started in Chapter 4. 
 
The innominate artery, the base of the carotid artery, is an early predilection site for plaque 
formation (Nakashima et al., 1994). The advancement of plaques in the ApoE-/- mice has been 
well characterised at this site (Rosenfeld et al., 2000). Plaque progression within this artery 
has been shown to present an ideal model for the study of advanced complex plaques 
especially those on the verge of or healing from disruption (Rosenfeld et al., 2002a; Williams 
et al., 2002; Schwartz et al., 2007). However, the study of plaque progression prior to the 
intermediate/advanced stage in the innominate artery has not been extensively reported. 
Lhoták et al. (2016) recently confirmed the observation by Nakashima et al. (1994), that 
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around 25 weeks in ApoE-/- mice, plaques considered to be at the intermediate stage were 
observed. These intermediate plaques consisted of a large necrotic core (Lhoták et al., 2016) 
surrounded by a mixture of foam cells and spindle-shaped cells (Nakashima et al., 1994) and 
a cellular fibrous cap (Lhoták et al., 2016). These observations, however, were made in 
plaques developing at the aortic root, and frequency of occurrence in mice at this age has not 
been determined.   
 
Data from Chapter 4 show that compositional changes in plaques in the innominate artery, 
such as calcification, may have begun at some point during treatment (between 25 to 30 
weeks). It is also possible, however, that plaque compositional changes may have begun prior 
to treatment and therefore before 25 weeks. Whichever the case, understanding the 
uniformity, or lack of, in plaque composition and in changes such as calcification is critical in 
contextualizing my findings from previous chapters 
 
In order to appropriately interpret the observations made in Chapters 3 & 4, in which plaque 
calcification was altered in mice that began treatments at the intermediate stage (25 weeks), it 
is necessary to understand the progression of plaques leading up to this stage within the 
innominate artery in the ApoE-/- model, and thus, clarify the effects of CaMKII in plaque 
progression.  
 
Therefore, the aims of this chapter were as follows:  
 
1.) To investigate the progression of plaques in the innominate artery of 20wk ApoE-/- mice. I 
hypothesized that plaques should be present with 100% occurrence in the innominate artery of 
control-treated 20wk old ApoE-/- mice, at the time of euthanasia.  
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2.) To investigate the effect of CaMKII inhibition with KN-93 on plaque size in 20wk old 
ApoE-/- mice. I hypothesized that CaMKII inhibition would cause a decrease in plaque size in 
these younger mice. 
 
3.) To determine the extent of plaque calcification in 20wk old ApoE-/- mice following KN-92 
and KN-93 treatment. I hypothesized that there would be minimal calcification present in 
these vessels from both treatment groups, but whatever calcification present would be 
decreased in the KN-93 treated group.  
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5.2. Methods  
5.2.1. Experimental Design  
Adult male and female ApoE-/- (C57BL/6) mice aged 20 weeks were used in this study. After 
categorization according to sex, mice were randomly assigned to one of two treatment groups: 
CaMKII inhibitor- KN-93 (10µmol/kg; APExBIO) or inactive analogue- KN-92 (20µmol/kg; 
APExBIO).  
 
Mice were treated with intraperitoneal injections on alternate days four times a week for 40 
days with either KN-92 or KN-93 (Fig. 5-1) and sacrificed by cardiac exsanguination 
(Chapter 2). When terminated mice were 26 weeks old. Mice were weighed at the start of 
their treatment, at midpoint, and before termination. Average weights in both treatment 
groups were stable for the duration of study, at the end of the study weight of male mice was 
32g and female mice was 24g. Data presented in this chapter are from histological and IHC 
analyses of 4µm sections collected from the innominate arteries at 10µm intervals. 
 
5.2.2. Tissue Processing  
Tissue extraction and processing were carried out as described in Chapter 2. In this Chapter, 
three sections from the innominate artery were placed on one slide. Starting from the fifth 
section, sections placed in intervals of five (i.e. section 5, 10, 15, 20 etc.) were stained with 
Haematoxylin and Eosin (H&E) and used to determine plaque size. Corresponding sections 
starting from the sixth section, in the same pattern (section 6, 11, 16, 21 etc.) were stained 
with Alizarin Red (AzR-S) and used to assess calcification. Remaining sections between 6 
and 10 were placed in consecutive order and used for IHC analysis. A subset of samples were 
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collected and processed by the Histology Service Unit (University of Otago). Antibodies and 





Figure 5-1 Treatment schedule of mice in Chapter 5. Male and female ApoE-/- mice from birth were left to age to 20 weeks 
(wks), from then they received intraperitoneal injections every 2nd day for 40 days of either KN-92 (inactive analogue control) or 
KN-93 (potent CaMKII inhibitor). After the final injection mice were euthanized, the heart and arterial tree were excised. 
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Table 5.1. Immunohistochemistry Antibodies- Chapter 5 
 
Primary antibody Company/Cat. No. Concentration- 4°C overnight Species Secondary antibody (Company/Cat. No.) 
     
Osteocalcin Abcam/ab93876 10ng/µL Rabbit EXPOSE HRP-conjugate (Abcam/ab80436) 
     
RUNX2 (CBFA1) Abcam/ab23981 2.8ng/µL Rabbit EXPOSE HRP-conjugate (Abcam/ab80436) 
     
Phosphorylated CaMKII  Abcam/ab32678 1:100  (Stock concentration not supplied) Rabbit 
EXPOSE HRP-conjugate 
(Abcam/ab80436) 
     
 
All antibodies were made up in tris-buffered saline with tween. Antibody dilutions were determined from optimization experiments. 
HRP- horseradish peroxidase, RUNX2- runt-related transcription factor 2, CBFA1- core-binding factor alpha 1 
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5.2.3. Data Analyses 
All sections were imaged by light microscopy (Motic BA310, Moticam 580, Hong Kong, 
China) using 10x objective in H&E and AzR-S stained sections and 40x objective in 
antibody-stained sections. Sections were analyzed using ImageJ software. Arteries were 
collected, processed and sectioned in a random order, so in analyses, the identity and 
treatment of the mouse represented in each section was unknown. Data were collected and 
processed using Microsoft Excel 2010; all analyses were done using GraphPad Prism 7. 
 
Only mice with five consecutive H&E-stained sections beginning from the appearance of a 
full circumferential vessel were included in analyses of plaque size. These five sections were 
used to determine total plaque area within the innominate artery for each mouse. Plaque area 
measurement in this chapter consisted of tracing along the internal elastic lamina and around 
cells protruding into the lumen (Fig. 5-2).  This value for each animal was then used to 





Figure 5-2 Example of plaque morphological analysis in chapter 5. H&E stained sections 
were used to determine plaque area. This representative image was from a 20-week female 
ApoE-/- mouse treated with KN-92. Plaque measurement consisted of tracing along the 
internal elastic lamina and around cells protruding into the lumen (Black/Yellow trace). 
Images were calibrated using a micrometre. H&E- Haematoxylin and Eosin. Scale bar- 
100µm. 
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5.2.4. IHC Analyses 
Target protein levels were measured using mean DAB staining intensity of IHC sections 
probed with appropriate antibodies (detailed protocol in Chapter 2 -Section 2.6). Sections 
used for protein analyses in the IHC experiments were placed in triplicate on slides in 
consecutive order. Arterial sections in which there were no overt signs of atherosclerotic 
disease present were referred to as the ‘non-diseased VSMC region’ or at times ‘VSMC 
region’. IHC sets were picked in order to obtain three consecutive sections with both regions 




5.3.1. Effect of CaMKII inhibition on plaque size in 20wk ApoE-/- mice 
To address the first aim of this study, which was to investigate the uniformity of plaque 
progression in the ApoE-/- mice, I first assessed the extent of plaque progression looking at the 
KN-92 control-treated ApoE-/- mice. There was a clear difference observed in plaque 
formation between male and female ApoE-/- mice. In male mice there were a couple of 
arteries in which there was no apparent presence of plaque formation.  For this reason the data 
from male and female arteries will be reported separately.  
 
100% (5 out of 5) plaque formation was noted in KN-92 treated female ApoE-/- mice and 75% 
(6 out of 8) in the KN-93 group. Surprisingly, in the male mice there was plaque formation in 
71% (5 out of 7) of the KN-93 treated group and 29% (2 out of 7) in KN-92 group, this trend 
did not reach statistical significance (Fig. 5-3, p=0.06).  
 
The morphology of those plaques present consisted mainly of lipid-filled foam cells (Fig. 5-4. 
In the female vessels more of these lipid-filled foam cells were observed with evidence of 
hypertrophic smooth muscle cells and in some mice chondrocyte-like cells. In the male 
vessels, in addition to the lipid filled foam cells, there was evidence of lipid infiltration within 
the cells of the medial layer, without any noticeable hypertrophy (Fig. 5-4). The morphology 
of plaque in arteries studied in this chapter is very different from that observed in Chapter 4. 
   
Mean plaque area was ~6X larger in females compared to males (Fig. 5-5). There was no 
effect of KN-93 treatment in both female (Fig. 5-5A) and male (Fig. 5-5B) mice. However 
there were interesting, opposite trends. KN-93 tended to reduce plaque area (Fig. 5-5A) and 





Figure 5-3 Effect of CaMKII inhibition on frequency of observed plaques in the 
innominate artery of 20WK ApoE-/- mice. Percentage of arteries within each experimental 
group, in which there was an obvious plaque present in female mice treated with KN-92 (5 
out of 5) and KN-93 (6 out of 8) and male mice treated with KN-92 (2 out of 7) and KN-93 (5 
out of 7). Data were compared using the chi-square test, p=0.06. 
 











































Figure 5-4 Representative images of H&E stained sections from the innominate artery of 
KN-92 and KN-93 treated 20WK ApoE-/- mice. Dark blue dots represent cell nuclei, 
pink/purple staining cytoplasmic regions. L denotes vessel lumen. Straight arrows point to 
lipid-filled foam cells. Double arrows point to lipid infiltrated vascular smooth muscle cells. 
10x magnification. Five successive sections (4µm) were used to determine total plaque area in 













Figure 5-5 Effect of CaMKII inhibition on plaque size in 20WK old ApoE-/- mice. 
(A) Mean plaque area in innominate artery of female mice treated with KN-92 and KN-93. 
Data were compared using Mann-Whitney test, p=0.94. (B) Mean plaque area in innominate 
artery of male mice treated with KN-92 and KN-93. Data were compared using Mann-



































5.3.2. Effect of KN-93 treatment on plaque calcification in 20wk ApoE-/- mice 
Having observed in Chapter 4 that KN-93 treatment decreased plaque calcification in 25WK 
female ApoE-/- mice, I investigated the extent of calcification in 20WK ApoE-/- mice. In line 
with the second hypothesis, minimal plaque calcification was observed in these mice. Plaque 
calcification was only present in one female ApoE-/- mouse in the KN-92 treated group (1 out 
of 5) while no plaque calcification was observed in arteries of KN-93 treated female ApoE-/- 
mice (0 out of 8).  
 
Plaque calcification was absent in male ApoE-/- mice from both KN-92 and KN-93 treated 
groups. Representative images in Fig. 5-6 are the corresponding AzR-S stained sections from 
Fig. 5-4.  
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Figure 5-6 Representative images of AzR-S stained sections from the innominate artery 
of KN-92 and KN-93 treated 20WK ApoE-/- mice. Representative images of succeeding 
4µm sections of the innominate artery from Fig. 5-3 stained with AzR-S to detect presence of 
calcification. L denotes vessel lumen. Calcification was not observed in these sections. Scale 




5.3.3. Effect of KN-93 treatment on expression of calcification markers in VSMC region 
of 20wk ApoE-/- mice  
Although there was no evidence of plaque calcification in arteries studied in this chapter, 
there is a possibility that calcification markers are expressed before calcium mineral deposits 
are observed in plaques (Aikawa et al., 2007). Thus, I investigated the presence of two 
calcification markers, osteocalcin (OCN) and Runt-related transcription factor 2 (RUNX2) in 
these younger mice (20WK) and whether CaMKII inhibition by KN-93 altered their 
expression. As explained in Chapter 4 OCN is a bone-associated protein, expressed in 
atherosclerotic plaques and RUNX2 is a transcription factor essential for differentiation of 
cells down osteoblast lineage (Steitz et al., 2001). RUNX2 has been shown to regulate OCN 
expression (Steitz et al., 2001). As in Chapters 3 and 4, I first investigated expression in 
regions of vessel wall where there was no apparent presence of plaque formation. These ‘non-
diseased VSMC’ regions included endothelial cells of the intima and smooth muscle cells of 
the medial layer.  
 
IHC sections were picked for analyses in order to measure target protein expression within 
both plaque regions and ‘non-diseased VSMC’ region. As indicated in section 5.3.1 of this 
chapter, only 2 out of 7 male ApoE-/- mice studied had signs of discernable plaque formation, 
hence no statistical significance could be determined in any of the IHC experiments in the 
male group, changes in protein expression levels however, will be reported. 
 
OCN immunoreactivity in ‘non-diseased VSMC’ region was localized to the intimal and 
medial layer in both female (Fig. 5-7) and male (Fig. 5-8) ApoE-/- innominate arteries. DAB 
staining was present in nuclei of cells lining the lumen (presumably endothelial cells) and 
nuclei of cells in the outer-end of the external elastic lamina (adventitial layer). Within the 
medial layer staining was present in cytoplasm of the smooth muscle cells. There was no 
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obvious effect of KN-93 treatment on OCN expression pattern in the VSMC region in both 
sexes (Fig. 5-9).  
 
When quantified, the expression of OCN in KN-93 treated female ApoE-/- mice was 26% 
greater than in KN-92 treated mice. When groups were compared there was no effect of KN-
93 treatment on the expression of OCN in ‘non-diseased VSMC’ region of female ApoE-/- 
mice (Fig. 5-9A). 
 
Of the vessels analysed the expression of OCN in ‘non-diseased VSMC’ region of male 








Figure 5-7 OCN expression in ‘non-diseased VSMC’ regions of the innominate artery of 
female 20WK ApoE-/- mice. Representative images showing positive DAB staining (brown) 
of OCN expression in ‘non-diseased VSMC’ region of 4µm sections from the innominate 
artery of female KN-92 and KN-93 treated ApoE-/- mice. Sections were counterstained with 
Mayer’s haematoxylin. Top panel images were taken at 10x magnification, box indicates 40x 







Figure 5-8 OCN expression in ‘non-diseased VSMC’ regions of the innominate artery of 
male 20WK ApoE-/- mice. Representative images showing positive DAB staining (brown) of 
OCN expression in ‘non-diseased VSMC’ region of 4µm sections from the innominate artery 
of male KN-92 and KN-93 treated ApoE-/- mice. Sections were counterstained with Mayer’s 
haematoxylin. Top panel images were taken at 10x magnification, box indicates 40x image in 









Figure 5-9 OCN expression in ‘non-diseased VSMC’ regions of the innominate artery of 
KN-92 and KN-93 treated female (A) and male (B) 20WK ApoE-/- mice. (A) Mean DAB 
staining intensity of OCN expression in VSMC region of the innominate artery of KN-92 and 
KN-93 treated female ApoE-/- mice. Data comparison was made using unpaired t-test, p=0.46. 
Data are presented as mean ± S.E.M. (B) Mean DAB staining intensity of OCN expression in 
















































RUNX2 immunoreactivity in the ‘non-diseased VSMC’ region of the innominate artery 
appeared dispersed in all layers of the artery section. Strong DAB staining was noted 
particularly in cells lining the lumen (presumably endothelial cells); nuclei staining were 
localized to these cells. Within the medial layer, DAB staining was noted in cytoplasm of the 
smooth muscle cells, with nuclei staining in some cells. This was observed in both female 
(Fig. 5-10) and male (Fig. 5-11) arteries, there was no obvious effect of KN-93 treatment on 
DAB staining pattern.  
 
There was no effect of KN-93 treatment on the expression of RUNX2 in the ‘non-diseased 
VSMC’ region of female ApoE-/- arteries (Fig. 5-12A).  
 
In male ApoE-/- mice immunoreactivity of RUNX2 in the ‘non-diseased VSMC’ region of 
KN-93 treated arteries appeared lighter than in KN-92 treated arteries (Fig. 5-11). The 
expression of RUNX2 in ‘non-diseased VSMC’ region of arteries from KN-93 treated male 
mice was 59% lower than in arteries KN-92 treated mice. However due to the low sample size 







Figure 5-10 RUNX2 expression in ‘non-diseased VSMC’ regions of the innominate 
artery of female 20WK ApoE-/- mice. Representative images showing positive DAB 
staining (brown) of RUNX2 expression in VSMC region of 4µm sections from the 
innominate artery of female KN-92 and KN-93 treated ApoE-/- mice. Sections were 
counterstained with Mayer’s haematoxylin. Top panel images were taken at 10x 
magnification, box indicates 40x image in bottom panel; 40x images were used for analyses. 








Figure 5-11 RUNX2 expression in ‘non-diseased VSMC’ regions of the innominate 
artery of male 20WK ApoE-/- mice. Representative images showing positive DAB staining 
(brown) of RUNX2 expression in VSMC region of 4µm sections from the innominate artery 
of male KN-92 and KN-93 treated ApoE-/- mice. Sections were counterstained with Mayer’s 
haematoxylin. Top panel images were taken at 10x magnification, box indicates 40x image in 











Figure 5-12 RUNX2 expression in VSMC region of the innominate artery of KN-92 and 
KN-93 treated female (A) and male (B) 20WK ApoE-/- mice.  (A) Mean DAB staining 
intensity of RUNX2 expression within VSMC region of KN-92 and KN-93 treated female 
ApoE-/- mice. Data comparison was made using unpaired t-test, p=0.65. Data are presented as 
mean ± S.E.M. (B) Mean DAB staining intensity of RUNX2 expression in VSMC region of 










































5.3.4. Effect of KN-93 treatment on pCAMKII levels in VSMC region of 20wk ApoE-/- 
mice 
As explained in the previous chapters pCaMKII is broadly used as an indirect measure of 
activated CaMKII. The experiments in this section were carried out to assess the effect of 
KN-93 on the levels and expression pattern of phosphorylated CaMKII in innominate artery 
of 20WK old ApoE-/- mice.  
 
Immunoreactivity of pCaMKII was visibly lighter than that of both calcification markers. 
pCaMKII-DAB expression was noticed more in the nuclei of cells lining the lumen and cells 
in the adventitial region the vessel (Figs. 5-13 and 5-14).    
 
In female ApoE-/- mice there was faint evidence of cytoplasmic DAB staining in cells of the 
media, in both KN-92 and KN-93 treated arteries (Fig. 5-13). Although the expression of 
pCaMKII within these ‘non-diseased VSMC’ regions of female ApoE-/- mice was increased 
by 36% in the KN-93 group relative to KN-92, when both groups were compared, there was 
no effect of KN-93 treatment on mean staining intensity of pCaMKII (Fig. 5-15A). 
 
 Cytoplasmic pCaMKII immunoreactivity was noted in the cytoplasm of cells adjacent to the 
internal elastic lamina (Fig. 5-14) in male ApoE-/- arteries. In KN-93 treated male ApoE-/- 
arteries, expression of pCaMKII was decreased by 70% relative to the KN-92 treated group 
(Fig. 5-15B). Overall there was a positive trend in pCaMKII levels in these ‘non-diseased 








Figure 5-13 pCaMKII expression in ‘non-diseased VSMC’ regions of the innominate 
artery of female 20WK ApoE-/- mice. Representative images showing positive DAB 
staining (brown) of pCaMKII expression in VSMC region of 4µm sections from the 
innominate artery of female KN-92 and KN-93 treated ApoE-/- mice. Sections were 
counterstained with Mayer’s haematoxylin. Top panel images were taken at 10x 
magnification, box indicates 40x image in bottom panel; 40x images were used for analyses. 








Figure 5-14 pCaMKII expression in ‘non-diseased VSMC’ regions of the innominate 
artery of male 20WK ApoE-/- mice. Representative images showing positive DAB staining 
(brown) of pCaMKII expression in VSMC region of 4µm sections from the innominate artery 
of male KN-92 and KN-93 treated ApoE-/- mice. Sections were counterstained with Mayer’s 
haematoxylin. Top panel images were taken at 10x magnification, box indicates 40x image in 











Figure 5-15 pCaMKII expression in ‘non-diseased VSMC’ region of the innominate 
artery of KN-92 and KN-93 treated female (A) and male (B) 20WK ApoE-/- mice.  
(A) Mean DAB staining intensity of pCaMKII in VSMC region of female ApoE-/- mice 
treated with KN-93 and KN-92. Data comparison was made using unpaired t-test, p=0.39. 
Data are presented as mean ± S.E.M. (B) Mean DAB staining intensity of pCaMKII 
expression in VSMC region of the innominate artery of KN-92 and KN-93 treated male 











































5.3.5. Effect of KN-93 treatment on calcification markers within plaques of 20wk ApoE-/- 
mice 
Having observed no effect of OCN expression but decreased calcification in plaques from 
25WK old KN-93 treated ApoE-/- mice in Chapter 4, I next investigated whether KN-93 
treatment of 20WK old ApoE-/- mice would result in a more apparent decrease in OCN 
expression within plaques, prior to signs of calcium deposition. The plaques in the ApoE-/- 
mice studied in Chapters 3 and 4 were more developed and advanced than those studied in 
this chapter. The observation of these less developed plaques was that the ‘plaque region’ 
consisted mainly of lipid-rich foam cells and medial thickening with chondrocyte-like cells 
(Fig. 5-4). The smaller size of plaques in this chapter necessitated a decrease in ROI area so 
as to avoid including non-plaque regions in analyses (Section 5.2.4. in this chapter).  
 
OCN immunoreactivity was noticeably present in the edges of lipid-rich regions and the 
edges of cholesterol crystals. Nuclei staining were observed in cells within the lipid-rich 
regions in both female and male arteries (Figs. 5-16 and 5-17) and in chondrocyte-like cells in 
female arteries (Fig. 5-16).  
 
In female arteries, OCN-DAB staining was present in lipid-infiltrated smooth muscle cells of 
the medial layer; this was more evident in KN-93 treated group (Fig. 5-16A). The expression 
of OCN within plaques from KN-93 treated female ApoE-/- mice was 37% greater than in 
plaques of the KN-92 group; this was unexpected. But when groups were compared, there 
was no effect of KN-93 treatment on OCN expression in plaques of 20WK female mice (Fig. 
5-16B).  
 
In male ApoE-/- arteries the expression of OCN was 56% greater in KN-93 treated male 












Figure 5-16 OCN expression within plaques of 20WK female ApoE-/- mice.  
(A) Representative images showing positive DAB staining (brown) of OCN expression within 
plaques in KN-92 and KN-93 treated female ApoE-/- innominate arteries. Sections were 
counterstained with Mayer’s haematoxylin. L denotes vessel lumen. Straight arrows indicate 
cells lining the plaque. Curved arrows indicate lipid-rich regions. Double arrows indicate 
chondrocyte-like cells. Image 40x magnification. Inset shows full image of vessel section, 
10x magnification. Scale bar- 100µm. (B) Mean DAB staining intensity of OCN in plaques 
from the innominate artery of female KN-92 and KN-93 treated ApoE-/- mice. Data 


































Figure 5-17 OCN expression within plaques of 20WK male ApoE-/- mice.  
(A) Representative images showing positive DAB staining (brown) of OCN expression within 
plaques in KN-92 and KN-93 treated male ApoE-/- innominate arteries. Sections were 
counterstained with Mayer’s haematoxylin. L denotes vessel lumen. Straight arrows indicate 
cells lining the lumen. Curved arrows point to lipid-rich regions. Image 40x magnification. 
Inset shows full image of vessel section, 10x magnification. Scale bar- 100µm. (B) Mean 
DAB staining intensity of OCN in plaques from the innominate artery of male KN-92 and 
























RUNX2 immunoreactivity was distinctly nuclei specific in lipid-filled cells within plaques 
and cells lining the plaque (Figs. 5-18A and 5-19A). Staining appeared to precipitate within 
these lipid-rich regions.  DAB staining was noticeably absent from the nuclei of smooth 
muscle cells in the medial layer but present in cytoplasm (Figs. 5-18A and 5-19A)  
 
When quantified, expression of RUNX2 within plaques of KN-93 treated female ApoE-/- mice 
was 46% lower than in KN-92 treated group; this difference did not reach statistical 
significance (Fig. 5-18B, p=0.06). 
  
In plaques from KN-93 treated male ApoE-/- mice, the expression of RUNX2 was 36% greater 












Figure 5-18 RUNX2 expression within plaques of 20WK female ApoE-/- mice.  
(A) Representative images showing positive DAB staining (brown) of RUNX2 expression 
within plaques in KN-92 and KN-93 treated female ApoE-/- innominate arteries. Sections 
were counterstained with Mayer’s haematoxylin. L denotes vessel lumen. Straight arrows 
indicate cells lining the plaque. Curved arrows point to lipid-rich regions and double arrows 
point to chondrocyte-like cells. Image 40x magnification. Inset shows full image of vessel 
section, 10x magnification. Scale bar- 100µm. (B) Mean DAB staining intensity of RUNX2 in 
plaques from innominate artery of female KN-92 and KN-93 treated ApoE-/- mice. Data 

































Figure 5-19 RUNX2 expression within plaques of 20WK male ApoE-/- mice.  
(A) Representative images showing positive DAB staining (brown) of RUNX2 expression 
within plaques in KN-92 and KN-93 treated male ApoE-/- innominate arteries. Sections were 
counterstained with Mayer’s haematoxylin. L denotes vessel lumen. Straight arrows indicate 
cells lining the lumen. Curved arrows point to lipid-rich regions. Image 40x magnification. 
Inset shows full image of vessel section, 10x magnification. Scale bar- 100µm. (B) Mean 
DAB staining intensity of RUNX2 in plaques from innominate artery of male KN-92 and 























5.3.6. Effect of KN-93 treatment on pCaMKII levels within plaques of 20wk ApoE-/- 
mice 
Although in Chapter 4 there was no effect of KN-93 treatment on plaque size or pCaMKII 
levels within plaques, as mentioned in the 2nd and 3rd hypothesis of this chapter I anticipated 
that CaMKII inhibition would have a marked effect on plaque progression. Therefore, I also 
anticipated that pCaMKII would be the active form of CaMKII at this earlier stage in disease 
progression, so I examined levels of pCaMKII as a measure of CaMKII activity in these 
earlier plaques. 
 
pCaMKII immunoreactivity was observed in plaques from both male (Fig. 5-21A) and female 
(Fig. 5-20A) ApoE-/- vessels. pCaMKII-DAB staining  was localized to the nuclei of lipid-rich 
cells  and was noticeably absent from nuclei of smooth muscle cells of the medial layer. 
Cytoplasmic staining was observed in some hyperplasic smooth muscle cells in female 
arteries (Fig. 5-20A).  
 
Once quantified, there was no effect of KN-93 treatment on expression of pCaMKII in 
plaques from female ApoE-/- mice (Fig. 5-20B). 
 
Interestingly in male ApoE-/- mice expression of pCaMKII in KN-93 treated group was 28% 















Figure 5-20 pCaMKII expression within plaques of 20WK female ApoE-/- mice.  
(A) Representative images showing positive DAB staining (brown) of pCaMKII expression 
within plaques in KN-92 and KN-93 treated female ApoE-/- innominate arteries. Sections 
were counterstained with Mayer’s haematoxylin. L denotes vessel lumen. Straight arrows 
indicate cells lining the lumen. Curved arrows point to lipid-rich regions. Image 40x 
magnification. Inset shows full image of vessel section, 10x magnification. Scale bar- 100µm. 
(B) Mean DAB staining intensity of pCaMKII in plaques from the innominate artery of 
female KN-92 and KN-93 treated ApoE-/- mice. Data comparison was made unpaired t-test, 

































Figure 5-21 pCaMKII expression within plaques of 20WK male ApoE-/- mice.  
(A) Representative images showing positive DAB staining (brown) of pCaMKII expression 
within plaques in KN-92 and KN-93 treated male ApoE-/- innominate arteries. Sections were 
counterstained with Mayer’s haematoxylin. L denotes vessel lumen. Straight arrows indicate 
cells lining the lumen. Curved arrows point to lipid-rich regions. Image 40x magnification. 
Inset shows full image of vessel section, 10x magnification. Scale bar- 100µm. (B) Mean 
DAB staining intensity of pCaMKII in plaques from the innominate artery of male KN-92 























The experiments carried out in this chapter set out to first establish whether plaques were 
consistently present in the innominate artery of 20wk ApoE-/- mice at the end of the 6 week 
treatment schedule. Additionally, whether treatment with the CaMKII inhibitor KN-93 
impeded this progression by decreasing plaque size and calcification.  
 
The first major finding from this chapter was the observation in the KN-92 control group of 
the sex-related difference in plaque formation in ApoE-/- mice. There is a sex-related 
difference in humans in the development of ASCVD (Go et al., 2013; Mikkola et al., 2013), 
so male mice were included in this study in order to ensure similar anti-atherogenic effects of 
CaMKII inhibition, investigated in aims 2 and 3. Based on the human data and previous 
reports on ApoE-/- mice at this 25-week time-point (Nakashima et al., 1994; Reddick et al., 
1994; Lhoták et al., 2016) the expectation was that disease progression would be similar or 
greater in male mice. This observation of decreased presence of plaques in male KN-92 
control group relative to female KN-92 control was particularly surprising and partially 
supports the first hypothesis. This finding is supported by data from others groups using the 
ApoE-/- mice. Marek et al. (2017) in a study looking at the effect of a matrix receptor deletion 
on plaque development observed in their control ApoE-/- group that female mice developed 
larger and more severe plaques than males. Caligiuri et al. (1999) specifically looked into the 
sex-related difference in plaques in male and female ApoE-/- mice over time. They observed 
larger plaque areas in young 16wk female mice relative to age-matched males, but the 
difference was abrogated in older 48wk mice.  
 
Plaque calcification only occurs in more progressed plaques as reported in literature 
(Nakashima et al., 1994; Reddick et al., 1994) and confirmed in Chapters 3 and 4. So with the 
observed low occurrence of plaques in male ApoE-/- mice, a decrease in calcification in the 
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male ApoE-/- mice was anticipated. Yet the complete absence of calcification in the male 
ApoE-/- mice was surprising. This finding differs from the report by Reddick et al. (1994). 
Those researchers observed calcification in 1 out of 2 ApoE-/- mice at 24-28 weeks of age. It 
was noted in their report that the mice were female, which is in support of the finding in the 
present chapter, where calcification was only noted in the female group.  
 
Plaque calcification in male ApoE-/- mice has only previously been reported in older (Marek 
et al., 2017) or diabetic (Tse et al., 1999) and on a high fat diet (HFD) (Wang et al., 2012) 
ApoE-/- mice. McRobb et al. (2017) showed an almost equal occurrence of calcification in the 
innominate artery of male and female ApoE-/- mice (80% and 89% respectively); the mice at 
the end of that study however were 41-42 weeks old, an age range in which plaques are 
described as being advanced (Nakashima et al., 1994; Reddick et al., 1994; Caligiuri et al., 
1999; Lhoták et al., 2016). To my knowledge there has been no study illustrating when 
calcium mineral deposition starts occurring in plaques of standard-chow fed male ApoE-/- 
mice. 
 
Similarly in female ApoE-/- mice there is no known report investigating the first observation 
of calcium mineral deposition. The two main studies characterising plaque progression in the 
ApoE-/- mouse model, state ages of the mice in which calcification is observed. However, they 
do not state occurrence per sex. The observation that one out of five female mice in the KN-
92 control group had calcification does support my hypothesis and is corroborated by the 
study by Reddick et al. (1994). The limitation of that report is that only 2 mice within that age 
range were studied. That study showed that at 24-28 weeks, 50% of female ApoE-/- mice 
showed signs of plaque calcification. However the conclusion from this chapter, having a 
greater sample size of 5, is that within the same age-range only 20% of female ApoE-/- mice 
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have calcification. This highlights a disparity in the field in the interpretation and reporting of 
preclinical atherosclerosis studies, this will be discussed in the following Chapter. 
 
Some groups have suggested sex-related differences in immune-regulation mechanisms in the 
ApoE-/- mice. Caligiuri et al. (1999) observed an increased proliferative capacity, in response 
to LDL, in spleen cells from the younger 16wk female mice in which greater plaques were 
observed. Prostaglandin I2 (PGI2) and thromboxane A2 (TXA2) are mediators of the innate 
immune system, though with contrasting roles in progression of plaques (Kobayashi et al., 
2004). Smith et al. (2010) observed in female ApoE-/- mice a 15-fold increase in the pro-
atherogenic TXA2 and 50% decrease in the anti-atherogenic PGI2 relative to age-matched 
males. These sex-related differences in the development and progression of plaques in the 
ApoE-/- mice are in direct contrast to observational and epidemiological studies in humans. 
How this immune disparity relates to contrasting observations in humans is yet to be 
established. 
 
The increased occurrence of observed plaques and trend towards increased plaque area in the 
KN-93 treated male mice was surprising and disconcerting. It does further highlight the sex-
related difference in the sequence of events resulting in plaque progression and possibly 
suggests differential roles of CaMKII at different stages. CaMKII has been shown in 
peritoneal macrographs to regulate prostaglandin E2 production (Zhou et al., 2014). If 
prostaglandins are considered anti-atherogenic and male ApoE-/- mice have a greater 
expression relative to female mice (Smith et al., 2010) then inhibition of CaMKII in a male 
ApoE-/- mouse would accelerate atherogenesis. A further study would be to determine 
whether there is an association with CaMKII activity and the levels of prostaglandins present 
in the ApoE-/- mice; and whether the prostaglandin to thromboxane ratio in male ApoE-/- mice 
is reversed in humans. 
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Interestingly, although this fundamental difference between the sexes in plaque progression 
exists in the ApoE-/- mice, KN-93 treatment resulted in similar modulation trends of OCN 
expression within plaques (Figs. 5-15B and 5-16B). In both sexes there was a trend towards 
an increase in OCN expression in plaques from the KN-93 treated group. A differential effect 
of KN-93 treatment on RUNX2 expression within plaques was noted. In female vessels KN-
93 treatment produced a trend towards a decrease in RUNX2 expression while in males the 
trend was towards an increase. The expression of these osteogenic markers in the absence of 
calcification was expected, as markers have been shown to precede the calcification event 
(Tyson et al., 2003). Hence the expectation that alteration in these markers would be 
indicative of alterations in calcification. Like in this study, OCN expression in non-diseased 
arteries from individuals with atherosclerosis has been documented previously elsewhere 
(Dhore et al., 2001). There is a possibility that once the disease is present there is a systemic 
initiation of vascular ossification, whether that is the case here is beyond the scope of the 
study.  
 
Interpretation of this data is difficult because the purpose of the KN-93 treatment (addressing 
the 2nd and 3rd aims of this study) was to inhibit CaMKII and observe the effect on these 
parameters. As discussed in Chapter 4, KN-93 acts by binding to the calcium/calmodulin 
(Ca2+/CaM) site on the enzyme, thereby competing with the complex and preventing 
activation of the kinase. There is a limitation that if the Ca2+/CaM complex is already bound 
and the kinase activated, KN-93 will have no inhibitory effect. Based on the lack of effect of 
KN-93 treatment on pCaMKII levels within plaques in the female mice in this study (Fig. 5-
19), that appears to be the case. 
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When CaMKII is activated it uses ATP as a substrate for the autophosphorylation event, 
which is measured in IHC experiments by probing for pCaMKII. Hence the levels of 
pCaMKII give an indication of activated CaMKII. Nonetheless, it is important to bear in mind 
that once activated by Ca2+/CaM other post-translational modifications discussed in Chapter 
1, such as oxidation and S-nitrosylation, can occur without phosphorylation of CaMKII. It is 
therefore possible that measurements of pCaMKII do not fully reflect the activation state of 
the kinase or the effects of KN-93 in my experiments. One possibility for future studies is to 
measure these other post-translational modifications. A more prudent approach may be to use 
a more global inhibitor of CaMKII that precludes direct and autonomous activation of the 
kinase such as AC3-I peptide expression or even vascular-specific genetic deletion of 
CaMKII.  
 
The rationale for the experiments carried out in this chapter was to address the observations 
made in Chapter 4, in which no discernable plaque was present in some of the 25wk old KN-
93 treated female ApoE-/- mice and therefore establish whether CaMKII inhibition with KN-
93 could potentially cause a regression of atherosclerotic plaques in this model. Referring to 
my listed objectives above, I must conclude that my data supports the 1st hypothesis in female 
but not male mice. Moreover, my findings do not support the 2nd hypothesis in both sexes and 




CHAPTER 6: FINAL DISCUSSION 
This thesis focused on the effect of E2 treatment in plaque advancement and elucidating the 
potential mechanisms behind E2-induced effects. Specifically the investigation addressed the 
role of CaMKII in the pathogenesis of atherosclerosis. I utilized the ApoE-/- mouse model of 
atherosclerosis that spontaneously develops plaques while on standard-chow diet (Nakashima 
et al., 1994; Reddick et al., 1994), at different stages of plaque advancement.  
 
The initial studies in this thesis determined the effect of exogenous E2 on different stages of 
plaque progression and whether this was associated with changes in CaMKII expression or 
activity (Chapter 3). E2 treatment increased calcification in ApoE-/- mice with intermediate 
plaques; this was associated with decreased CaMKII expression and no change in pCaMKII. 
ApoE-/- effects on CaMKII expression and phosphorylation were assessed to increase 
understanding of this model of atherosclerosis in context of CaMKII (Chapter 3). There was 
no effect of ApoE-/- on CaMKII expression or phosphorylation in western blot and IHC 
experiments. Finally CaMKII-mediated effects on plaque progression were investigated and 
potential mechanisms utilized by the kinase to exert these effects were explored (Chapter 4, 
5). Inhibition of CaMKII with KN-93 decreased calcification in intermediate plaques with no 
effect on plaque size and no significant effect on pCaMKII and OCN expression. CaMKII 
inhibition in female ApoE-/- mice showed a trend to decreased calcification in early plaques 
and in male ApoE-/- mice showed a trend to increased plaque formation with no effect on 
RUNX2, OCN and pCaMKII expression. 
 
These main findings from this work will be discussed in this final chapter and suitability of 
the mouse model used will be explored. Implications of this work in the understanding of the 




This study showed for the first time in the innominate artery of female ApoE-/- mice with 
intermediate plaques the E2-induced accelerated progression of plaques through increased 
calcification. This major finding provides a potential mechanism through which discontinued 
hormone replacement therapy (HRT) trials may have increased incidence of major adverse 
cardiovascular events (MACE). It is known that most MACE occurs due to vulnerable, high-
risk plaques (Davies, 1992; van der Wal & Becker, 1999), in regions of high fibrous cap 
stress (Brown et al., 2016). Calcification is indicative of severe ASCVD (Stary, 2000; Budoff 
et al., 2010; Coylewright et al., 2011) and is associated with MACE (Virmani et al., 2003; 
Brown et al., 2016). It has long since been established that the proteins expressed in calcified 
vessels are the same proteins, involved in bone formation (Boström et al., 1993; Dhore et al., 
2001; Bobryshev et al., 2008; Persy & D'Haese, 2009). The adverse cardiovascular effects 
reported in the discontinued trials on HRT were associated with a decrease in osteoporotic 
fractures and increased bone mass (Cauley et al., 2003). These benefits on bone health 
quickly regress upon termination of HRT use (Heiss et al., 2008; NAMS, 2012). In vitro 
studies have elucidated a variety of mechanisms through which E2 promotes bone 
mineralization; this has been extensively reviewed by Khosla et al. (2012). E2 is known to 
promote osteoblast differentiation (Okazaki et al., 2002; Matsumoto et al., 2013), maintain 
osteocyte survival (Joshua et al., 2014) and prevent bone resorption by inducing osteoclast 
apoptosis (Nakamura et al., 2007). Therefore a possibility exists in which E2, having the same 
role in osteoblast-like calcifying vascular cells (CVCs) and bone-osteoblasts, leads to 
pathological vascular calcium mineralization and physiological bone formation. Together 




However, clinical evidence shows that a major symptom of menopause is osteoporosis 
(Martinez Perez et al., 2013), and as discussed in Chapter 1, increased prevalence of ASCVD, 
in the same patients (London, 2013). Further studies have shown a correlation between low 
bone mineral density and increased atherosclerosis (Shaffer et al., 2007; Wang et al., 2015), 
which is age-independent (Ye et al., 2016), specifically the correlation between osteoporosis 
and arterial calcification (Kiel et al., 2001).  If the factors involved in vascular calcification, 
are the same regulators of bone formation, and E2 administration induces mineralization in 
both vessels (Chapter 3; McRobb et al. (2017)) and bone, why does the loss of E2 have 
seemingly opposite effects? Systemic deletion of one of these bone-associated proteins, 
osteoprotegerin (OPG) in mice, resulted in aortic calcification and osteoporosis (Bucay et al., 
1998). Murine models of atherosclerosis have shown increased plaque calcification and 
osteoporosis following ovariectomization, which was reverted in E2 replacement (Osako et 
al., 2010). These reports altogether raise more questions than answers.  
 
The calcifying cells within plaques are described as osteoblast-like due to their expression of 
a range of key bone-associated factors such as OCN, OPG, RUNX2, (Dhore et al., 2001) bone 
morphogenic protein (Boström et al., 1993) and matrix vesicles (Bobryshev et al., 2008). 
These cells once induced express alkaline phosphatase, a marker of osteoblast differentiation 
(Stein & Lian, 1993). However, some reports have suggested that these osteoblast-like CVCs 
are not true osteoblasts and therefore function differently (Parhami et al., 1997; Burnett & 
Vasikaran, 2002; Alves et al., 2014; Laroche et al., 2017). Parhami et al. (1997) showed in 
vitro that oxidized lipids and lipoprotein products, present in atherosclerotic plaques, are able 
to induce osteoblastic differentiation of CVCs. These same products, however, inhibited the 
differentiation of bone-derived preosteoblasts (Parhami et al., 1997). Other groups have seen 
similar oxidative stress-induction of osteoblast differentiation in CVCs (Byon et al., 2008) 
and an inhibition in bone-osteoblasts (Maziere et al., 2010; McCauley, 2010; Nishikawa et 
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al., 2010). More recently, Alves et al. (2014) through genomic analyses have shown the lack 
of overlap in the transcriptional programs of osteoblast-like CVCs and bone-derived 
osteoblasts. The osteoblast-like CVCs modulate genes for bone formation but still retained 
certain vascular-specific markers (Alves et al., 2014). In bone formation, osteoblasts are 
involved with mineral deposition and osteoclasts are involved in bone re-absorption. Byon et 
al. (2011) showed that in calcified aortic root plaques there was an increase in osteoclast-like 
cells. Yet RANKL, a regulator of bone-derived osteoclast formation, was not required for 
oxidative stress-induced VSMC calcification (Byon et al., 2011). These studies illustrate that, 
although these osteoblast-like and osteoclast-like cells are key regulators of vascular calcium 
mineralization, due to different cell origin i.e. bone and vasculature, they respond differently 
to stimuli. The observed lack of effect of KN-93 on OCN expression with decreased 
calcification (Chapter 4) does support this notion. OCN is a protein secreted by osteoblasts 
with calcium binding γ-carboxyglutamic acid (Gla) residues. It is the most abundant non-
collagen protein found in mineralized bone matrix (Hauschka et al., 1989). Thus, the 
paradoxical increased prevalence of arterial calcification and osteoporosis in menopause 
could be due to differential alterations in the tissue-specific local environment, as a result of 
loss of E2. The effect of exogenous E2 administration on bone mass in the group of ApoE-/- 
mice, in which increased plaque calcification was observed (Chapter 3), was not investigated 
and goes beyond the scope of the thesis. It does however present a future topic that could be 
pursed.  
 
CaMKII inhibition decreased calcification in the innominate artery of female ApoE-/- mice 
with intermediate plaques (Chapter 4). This compliments the results in Chapter 3, which 
demonstrated the down regulation of CaMKII in E2-induced increase in plaque calcification. 
Disease-induced decrease in CaMKII expression has been documented in other tissues. In 
skeletal muscle, sepsis-induced muscle wasting was associated with decreases in both 
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CaMKII expression and activity (Aversa et al., 2013). In hippocampal synapses, flurazepam 
withdrawal was associated with decreased CaMKII expression with no change in pCaMKII 
(Earl et al., 2012). However most models of cardiovascular disease or injury report increased 
CaMKII activity and expression (Hoch et al., 1999; House & Singer, 2008; Sossalla et al., 
2010), which results in the pathological aetiology. In models of heart failure (Ai et al., 2005; 
Sossalla et al., 2010) and in patients with ischaemic cardiomyopathy (Sossalla et al., 2010), 
CaMKII expression is increased and usually associated with increased activity. It seems in the 
context of atherosclerosis the location of induced changes in CaMKII expression and activity 
is more relevant than overall protein levels or activity.  
 
Maione et al. (2017) recently reported differential cell-specific expression of CaMKII in 
atherosclerotic plaques. The group observed decreased expression of CaMKII in unstable 
plaques relative to stable plaques, which was associated with the down-regulation of VSMCs 
and up-regulation of macrophages (Maione et al., 2017) in these unstable plaques. This study 
is in agreement with my data from Chapter 3, in which an E2-induced increase in 
calcification, known to increase plaque burden (Sangiorgi et al., 1998; Brown et al., 2016), is 
associated with a decrease in CaMKII expression. Maione et al. (2017) also support data from 
Chapter 4 in which there was an observed difference in the expression pattern of total 
CaMKII and pCaMKII. Within the plaque region pCaMKII was mainly present in the nuclei 
of certain cells and absent from the cytoplasm and lipid-rich regions; this was also observed 
in plaques from Chapter 3, though more apparent in Chapter 4. In addition to the conclusion 
drawn by Maione et al. (2017), in that the cell-specific activation of CaMKII determines the 
type or stability of the plaque, there is the added possibility that the isoform-variant of 
CaMKII activated within those cells may govern the progression of the plaque. CaMKII exists 
as four isoforms, two of which (γ and δ) are expressed in the vasculature. Within those 
isoforms are splice variants with specific intracellular organization tags. Of the known splice 
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variants CaMKIIδB is currently the only identified variant with a nuclear localization 
sequence (Srinivasan et al., 1994). It is known that these isoforms are not exclusively 
compartmentalized in the heart (Mishra et al., 2011) but rather mobilize between the nucleus 
and cytosol, whether a similar situation exists in cells of the vasculature is known. Doran et 
al. (2017) have documented the macrophage-specific role of CaMKIIγ in insufficient 
efferocytosis in HFD LDLR-/- mice. Whether the different isoforms within the same cell 
results in different morphological plaque features is worth investigating. There is a possibility 
that phosphorylated-CaMKIIδB-variant is being detected within the plaques in this thesis. 
 
It is probable that the observed down-regulation of CaMKII is the initiation of a 
compensatory mechanism due to kinase over-activity. Although E2 treatment had no effect on 
pCaMKII levels within intermediate plaques, as discussed in Chapter 3, the highly oxidative 
and nitrile-rich environment in atherosclerotic plaques presents the possibility of kinase over-
activity through ox- or nitro-CaMKII. Data from Chapter 4 showed that systemic inhibition of 
CaMKII with KN-93 treatment decreased calcification of intermediate plaques. This finding 
is supported by the report from Shin et al. (2011), showing the inhibition of drug-induced 
osteoblast differentiation following KN-93 treatment of mesenchymal cells. Like E2, CaMKII 
can regulate bone-derived osteoblast differentiation (Zayzafoon, 2006; Choi et al., 2013) and 
osteoclastogenesis (Yao et al., 2012). Constitutively active CaMKII was shown to result in 
the premature maturation of chondrocytes (Taschner et al., 2008). In Chapter 4 KN-93 
treatment had no effect on pCaMKII levels suggesting that pCaMKII may not be the form of 
CaMKII responsible for plaque calcification. As discussed in Chapters 4 and 5, KN-93 acts by 
competing for the Ca2+/CaM binding site. Binding of Ca2+/CaM activates the kinase, which 
enables access to sites of constitutively active modifications (Maier & Bers, 2002) by 
oxidation (Erickson et al., 2008) and S-nitrosylation (Coultrap & Bayer, 2014; Erickson et al., 
2015). These modifications can occur without the kinase undergoing phosphorylation. So the 
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levels of ox-CaMKII or nitro-CaMKII may be increased in E2-treated intermediate arteries 
(Chapter 3) or be decreased in KN-93 treated intermediate arteries (Chapter 4). 
Limitations 
The transgenic ApoE-/- model of atherosclerosis has proven to be beneficial in enabling the 
study of plaque progression. In addition to determining the biological and mechanical 
properties of plaques, the model has enabled understanding of the effects of pharmacological 
and endogenous agents to these properties. However, like most preclinical models, this 
presents some limitations in the translation of data from this thesis and in discerning clinical 
relevance of the results. As discussed in Chapter 1, murine physiology differs significantly 
from humans and therefore in the context of pathologies, the course of events will vary. 
Plaque rupture in humans that result in MACE usually show evidence of thrombosis. The 
ApoE-/- mouse does present a model in which rupture, evidenced by intra-plaque haemorrhage 
(Williams et al., 2002) has been observed in the innominate artery (Rosenfeld et al., 2002a; 
Williams et al., 2002). However, this still differs from observation in humans as no 
thrombosis has ever been reported in the ApoE-/- or any murine model of atherosclerosis 
(Rosenfeld et al., 2000; Bond & Jackson, 2011; Getz & Reardon, 2016). Plaque development 
in the ApoE-/- mouse is initiated from hyperlipidaemia caused by insufficient clearance of 
chylomicron remnants and lipoproteins (Ishibashi et al., 1994b). In addition to this lipid 
metabolism role ApoE has additional roles in macrophages and the vasculature, in humans 
and in mice. Considering that atherosclerosis is also an immune disease, the disease 
morphology and sequence of progression captured in the ApoE-/- mice and may not be a 
perfect representation of human atherosclerosis. In human plaques, there is an increased 
expression of ApoE (O'Brien et al., 1994), due to the ApoE present on 
monocytes/macrophages and the attempt of these cells to promote cholesterol efflux (Bellosta 
et al., 1995). The deletion of this function in the ApoE-/- mice model could account for the 
reason behind differential morphology in advanced plaques relative to human plaques. 
 197	
Reports from Maione et al. (2017) and Doran et al. (2017) confirm the ApoE-/- model and 
data obtained in this thesis because CaMKII is also expressed in human plaques. A 
noteworthy follow-up study from Chapter 3 would be to investigate the morphology and 
localization of CaMKII in plaques from postmenopausal women with or without E2 
treatment. It would be interesting to see if a similar association of increased plaque 
calcification reported in women treated with E2 and whether the associated decrease in 
CaMKII expression within those plaques are detected.  
 
The finding of increased female to male plaque occurrence in this study (Chapter 5) is in clear 
contrast to observations in humans, in that younger women have decreased prevalence of 
ASCVD relative to age-matched men (Go et al., 2013). The lack of ApoE-/- on murine 
macrophages could cause a shift in immune function. The sex-related difference in immune-
regulated mechanisms reported by Smith et al. (2010) (discussed in Chapter 5) highlight a 
need in the ApoE-/- mice to investigate how the immune-regulated system is affected by the 
ApoE-/- status.  
 
In review of the literature a challenge faced was in understanding the mode of reporting and 
interpretation of data from previous preclinical studies. This I think is a limitation to the field 
of preclinical atherosclerotic research and has recently been discussed by Daugherty et al. 
(2017). My experience in trying to interpret data observed, particularly from Chapter 4, was 
an awareness of the gaps in the literature in the holistic characterization of the ApoE-/- model. 
To elaborate, Nakashima et al. (1994) and Reddick et al. (1994) carried out the only two 
studies, to my knowledge, which characterized plaque formation in standard-chow fed ApoE-/- 
mice. A number of studies interchangeably report features of progressing plaques, rightly 
based on the ages of the mice, but from different predilection sites e.g. aortic root, aorta arch 
or innominate artery (Bourassa et al., 1996; Elhage et al., 1997; Huber et al., 1999; Smith et 
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al., 2010). Yet Nakashima et al. (1994) point out that at these different predilection sites, 
plaques at different stages were observed within the same mouse. This means that, although 
plaques in the aortic root of 25-week old ApoE-/- mice are at the intermediate stage, the 
plaques in the innominate artery may still be at the early stage. For example, the appearance 
of early foam cells probably in the aortic root at ~12weeks in standard-chow fed ApoE-/- mice 
may occur at ~16weeks in the innominate artery. This would explain the absence of plaques 
in some mice in Chapter 5. Additionally, although there may be a difference in the age of site-
directed initial xanthoma formation, progression might be accelerated at the innominate artery 
relative to the aortic root due to the smaller surface area coverage required for plaque growth. 
This possibility is confirmed in combining data obtained in Chapter 3 and the report by 
McRobb et al. (2017). The group observed no effect of E2 in the innominate artery of the 
same mice in which there was an E2-induced increase in plaque calcification in the aortic 
root. The age of mice in that study (McRobb et al., 2017) correlated with age of mice with 
advanced plaques (Chapter 3, Rosenfeld et al. (2000)) 
 
Additionally, the occurrence of key morphological features per sex of mice has not been 
documented. Reddick et al. (1994) pointed out the occurrence of certain morphological 
features within plaques in the aortic root for most age groups, though these observations 
included both sexes. Meir and Leitersdorf (2004), in a review, highlighted the strong 
correlation in terms of plaque size between aortic root and the innominate artery. This was 
only documented in female ApoE-/- mice at 26, 40, and 60 weeks.  The early studies on ApoE-
/- mice (Nakashima et al., 1994; Reddick et al., 1994) were pivotal in providing a pathological 
analysis of plaque development in standard-chow fed mice (Daugherty et al., 2017). 
Differences in plaque progression between male and female ApoE-/- mice (Chapter 5, 
Caligiuri et al. (1999) and Smith et al. (2010)), highlight a need for a detailed stage-by-stage 
characterization of plaque development and progression in different predilection sites of male 
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and female ApoE-/- mice. The initial studies in this thesis examined progression of 
intermediate and advanced plaques. This is why the innominate artery was chosen as site of 
investigation, due to previous reports highlighting the innominate artery as the site for study 
of advanced plaques (Rosenfeld et al., 2000; Williams et al., 2002; Schwartz et al., 2007). 
Use of the innominate artery was maintained throughout the project for consistency and the 
terminology used for description of disease stage was relative to the age of mice at the start of 
previous studies within the thesis. My data suggest that initial xanthoma formation in male 
ApoE-/- mice within the innominate artery occurs much later than in female ApoE-/- mice 
(Chapter 5). It would be interesting to determine the reason for this delay and also whether the 
male ApoE-/- mice have a longer life expectancy as a result. There could simply be a physical 
difference in athero-susceptibility of the male innominate artery relative to the same artery in 
female ApoE-/- mice. It would be informative to determine whether the similar KN-93 
induced increase in observed-plaques in the male ApoE-/- innominate artery (Chapter 5) was 
observed in the aortic root of the same mice.  
 
Finally, atherosclerotic plaques are not homogenous in nature. There is a nidus in which the 
plaque forms and expands, through and along the vessel wall. This was evident in looking 
through cross-sections of the innominate artery in all groups of mice in this study. In some 
mice, plaque was greatest in the end closest to the aortic arch, and in others plaque was 
greatest towards the middle of the artery or close to the carotid bifurcation. To maintain 
consistency, sections for calculation of plaque area were included starting from the aortic arch 
end (Chapter 2). For the IHC analyses, the ideal situation would be to select sections based on 
the same criteria or any other anatomical landmark. This was attempted for all chapters, 
however in Chapters 3 and 4 this was not always possible as sections with large or calcified 
plaques tended to fold or lift off the slide during the IHC protocol. So, to try to maintain 
numbers per group, IHC protocols were repeated using subsequent sections within the mouse 
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selected. This is evident from the lower sample numbers in all IHC experiments relative to 
plaque area analyses. It is unlikely that this would have significantly skewed the results, but 
rather highlighted the relevance of protein expression within plaques. 
 
Future Studies 
To further corroborate the study by Maione et al. (2017) and increase understanding in the 
field, it would be particularly useful to determine what cells within the plaques are staining 
positive for pCaMKII in the E2-treated study and in both KN-93 treated studies. Particularly 
between chapters 4 and 5 it would be very informative to determine how these pCaMKII-
expressing cells change as plaque progresses from early (Chapter 5) to intermediate (Chapter 
4) stage. Then, in the context of inhibition with KN-93, determine if there is a shift in the 
cells, which are still expressing pCaMKII. CaMKII is expressed and active in osteoblasts 
(Shin et al., 2011; Choi et al., 2013), proliferating and migrating VSMCs (Pauly et al., 1995; 
House et al., 2007; Mercure et al., 2008) and cholesterol-loaded macrophages (Timmins et 
al., 2009). Assessing the expression profile of pCaMKII within these cell-types in different-
treatment conditions would provide insight, not only relating the changes in cell-composition 
to plaque morphology, but also the functional contribution of pCaMKII to the process.    
 
With this probable switching of cells within the plaque, there is the added possibility that 
these new cells, which are responsible for the calcium mineral deposition in the E2-treated 
mice, may have lower levels of CaMKII relative to the non-calcifying cells. By this I mean 
the physical change in cell-type e.g. less VMSCs, with potentially inherently greater levels of 
CaMKII vs. more macrophages. Furthermore, if these CVCs are differentiated osteoblast-like 
VSMCs, this phenotypic switch may cause a reduction in the CaMKII expression. This would 
result in the decrease in the total levels of CaMKII within those plaques from E2-treated mice 
(Chapter 3). The assessment of the phenotypic modulation of VSMCs is generally based on 
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the changes in protein and gene expression profile. In differentiating cells, there is an up-
regulation of osteoblast-type and bone associated genes and gene products (Steitz et al., 
2001). This is usually coupled with the decrease or loss of certain contractile proteins (Zhang 
et al., 2017). The status of CaMKII expression and phosphorylation in osteoblast-like VSMCs 
has not been determined, particularly in the context of E2 treatment. Whether CaMKII 
inhibition directly in human VSMCs promotes or attenuates osteoblast-like differentiation is 
unknown, experiments to address this topic are detailed in Appendix III.  
 
Some groups consider the involvement of calcification in plaque rupture to be dependent on 
the location and size of the calcium deposits (Hutcheson et al., 2014). This has subsequently 
been shown in plaques from human patients (Vengrenyuk et al., 2006; Maldonado et al., 
2012), in that these regions of micro-calcifications are in a way “hot-spots” for rupture and 
adverse events. Data presented in this thesis assessed the overall presence and extent of 
calcification. An immediate future study would be to determine whether, with the data already 
gathered, evidence of these micro-calcifications could potentially be assessed to establish 
whether there are E2-induced or CaMKII-inhibited effects on frequency of micro-
calcifications.     
 
Data from this thesis did show the involvement of CaMKII in plaque progression with and 
without E2 treatment in intermediate arteries, there still remain some unanswered questions. 
An appropriate future study would be to investigate in more detail the morphology of plaques 
treated with KN-93. The results indicated, in all chapters, changes in plaque composition with 
no effect on plaque size, the detection of calcification was the only assessment of plaque 
composition, due to its implications in increasing plaque burden (Sangiorgi et al., 1998; 
Brown et al., 2016). A more detailed stain for example the Movat-pentachrome or Carstairs 
stain could be applied to vessel sections in this study, as it would give an indication to other 
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composition changes occurring within the plaques to support the current findings. For 
example decreased collagen content in E2-treated plaques and increased in KN-93 treated 
plaques would support the mineralization data and destabilization theory (Hutcheson et al., 
2016; Miller, 2016). There were observational reports within plaques of chondrocyte-like 
cells staining positive for pCaMKII (Chapters 3 and 4). IHC staining with chondrocyte 
marker would confirm the identity of the cells, and highlight modulations as a result of the 
different treatments. 
 
Predilection sites for plaque development along the vessel tend to be in regions of turbulent 
flow. These potentially athero-susceptible regions are thought to be due to the flow-mediated 
phenotype of the endothelium (Topper & Gimbrone, 1999; Gimbrone & Garcia-Cardena, 
2013). Cai et al. (2004) showed the increase in CaMKII phosphorylation and peroxide 
production in bovine aortic endothelial cells exposed to turbulent shear stress, yet laminar 
shear stress inhibited CaMKII phosphorylation. An interesting subject to explore is the 
expression and activation profile of CaMKII along the innominate artery of WT mice, and 
ApoE-/- mice at different stages of plaque growth.  
 
The increased occurrence in observed plaques in KN-93 treated male ApoE-/- mice in Chapter 
5, which contrasts to the observed effects on calcification in female ApoE-/- mice (Chapter 4), 
highlight the need for more preclinical studies. Inhibition of CaMKII is strongly being 
considered in cardiology as a therapeutic target for cardiac arrhythmias (Maier, 2014). There 
is an extensive amount of data illustrating these benefits in the heart (see review by Rokita 
and Anderson (2012)). Based on my data I would presently recommend use of a cardiac-
specific inhibitory agent. A clinical strategy such as inhibiting CaMKII in atherosclerotic 
individuals may prove to be beneficial in women at a certain age (Chapter 4), but in younger 
men may exacerbate plaque growth (Chapter 5). Use of double-knockout ApoE-/- and 
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CaMKII-deficient (ApoE-/-CaMKII-/-) male and female mice would provide more insight on 
the role of CaMKII in plaque progression. 
 
Comparison of the expected stages of plaque development, using the timeline in this thesis 
(Chapter 2), in the ApoE-/-CaMKII-/- mice with the CaMKII-/- mice and ApoE-/- mice, would 
be informative on the roles both proteins play in murine vascular physiology. It would also 
separate atherosclerotic changes observed with vascular changes that occur with age. Data 
collected from the ‘non-diseased VSMC region’ of all mice in this study, coupled with the 
comparison with WT mice confirm a lack of effect of ApoE-deletion on all protein targets 
investigated (Chapter 3). This data also show the plaque specific role of CaMKII (Chapters 3-
5), but it does highlight the question of when does CaMKII get involved? Data from this 
thesis show in female ApoE-/- mice from 20-25 weeks plaque calcification begins with 20% 
occurrence (Chapter 5), with CaMKII inhibition it remains at 0%. From 25-30 weeks plaque 
calcification occurs with 50% occurrence, but if CaMKII is inhibited it is maintained at 25% 
(Chapter 4). These decreases occur with no observed change in expression or phosphorylation 
of CaMKII within the plaques or in ‘non-diseased VSMC’ regions. From the findings in this 
thesis and from studies by Maione et al. (2017) and Doran et al. (2017), I hypothesize that 
CaMKII is involved in atherosclerotic disease once the plaque is formed and the local 
oxidative inflammatory environment set. I also hypothesize that the progression of plaques, 
by calcification, occurs through ox-CaMKII or nitro-CaMKII. Based on the data from male 
ApoE-/- mice, I hypothesize in male mice, CaMKII may be preventing the initial plaque 
formation, and confirmation of this hypothesis would be increased plaques in male ApoE-/-




In summary, the observed increase in E2-induced plaque calcification in intermediate but not 
advanced plaques is the first preclinical model to confirm in ovary-intact animals the timing 
hypothesis of E2-treatment. Using the VCD/ApoE-/- model (discussed in Chapter 3) would 
provide insight to the effect of E2 treatment on pre-intermediate early plaques (like in Chapter 
5). This would confirm the mechanism through which E2 may be exacerbating ASCVD. 
There is currently an on-going clinical trial investigating this timing hypothesis in women 
with early vs. late HRT after menopause (Hodis et al., 2015). Comparing the calcium mineral 
deposition in the arteries of these women before and after the trial would confirm the data 
presented in this thesis. It is known that vascular health declines with age and in the 
postmenopausal situation, with or without HRT, this is coupled with age-related progression 
of atherosclerotic plaques. How this correlates with changes in the endogenous activity and 
expression of CaMKII in unknown. My data suggest that in women with intermediate 
plaques, defined by the presence of but not extensive amount of calcium deposits, E2 
treatment will exacerbate the mineralization of those plaques in a CaMKII-mediated manner. 
Yet, it is necessary to further understand and establish whether there are age-related changes 
in CaMKII that may alter vascular function.  
 
The findings in this thesis provide novel insights to the role of CaMKII in plaque 
advancement in the ApoE-/- mice. Specifically this thesis proposed a novel mechanism 
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Negative Control (IHC experiments) 
  
 
Figure A-1 Representative images of negative control IHC sections of the innominate 
artery of ApoE-/- mice. Sections were incubated in TBS-T instead of primary antibody 
during IHC protocol. Section in left panel was counterstained with Gill’s haematoxylin. 




Chapter 4 protein expression in ‘non-diseased VSMC’ region vs. plaque region 
 
 
Figure A-2 Protein expression in non-diseased VSMC regions compared with plaque 
regions. Absolute levels of CaMKII (A), pCaMKII (B) and OCN (C) expression in non-
diseased VSMC region compared to plaque regions for each group of treated mice. Data are 



























































Experimental plan for CaMKII status in differentiating VSMCs. 
Studies show that differentiation of VSMCs grown in osteogenic media into osteoblast-like or 
macrophage-like cells require incubation for 2 to 3 weeks with media changes every 2 to 3 
days (Byon et al., 2011; Goettsch et al., 2011; Liberman et al., 2011). The cells grown in each 
well would be harvested for analyses specified in the schematic table. Each experiment 
consists of 6 plates for harvesting on Days: 0, 1, 2, 3, 7 and 14. Additional days can be added 
or removed depending on the first preliminary experiment in osteogenic media, showing 
when differentiation begins. 
 














Experiment 1 (Prelim): Establish timeline for differentiation of HCASMCs using β-
glycerophosphate and ascorbic acid.  
 
Experiment 2 (Baseline): Establish effect of experimental timeline on CaMKII expression and 
activation (normal media). 
 
Experiment 3 (Baseline calc.): Establish effect of osteogenic media at different harvesting 
time-points on CaMKII expression and activation. 
 
Experiment 4: Effect of CaMKII inhibition with KN-93 on differentiation of HCASMCs-
calcium mineral deposition (extra set for KN-92). 
 
Experiment 5: Effect of CaMKII inhibition with KN-93 on differentiation of HCASMCs- 
expression of osteogenic markers (extra set for KN-92). 
 
